WW International (WW) 10-K 28 Feb 25 2024 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 28, 2024	Feb. 03, 2025	Jun. 28, 2024
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 28, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Trading Symbol	WW
Entity Registrant Name	WW INTERNATIONAL, INC.
Entity Central Index Key	0000105319
Current Fiscal Year End Date	--12-28
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	true
Entity Common Stock, Shares Outstanding		80,127,091
Entity Public Float			$ 92,644,603
Entity File Number	001-16769
Entity Incorporation, State or Country Code	VA
Entity Tax Identification Number	11-6040273
Entity Address, Address Line One	675 Avenue of the Americas
Entity Address, Address Line Two	6th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10010
City Area Code	212
Local Phone Number	589-2700
Title of 12(b) Security	Common Stock, no par value
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Annual Report	true
Document Transition Report	false
Document Financial Statement Error Correction [Flag]	false
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	New York, New York
Auditor Firm ID	238
Auditor Opinion	Opinions on the Financial Statements and Internal Control over Financial Reporting We have audited the accompanying consolidated balance sheets of WW International, Inc. and its subsidiaries (the “Company”) as of December 28, 2024 and December 30, 2023, and the related consolidated statements of operations, of comprehensive loss, of changes in total deficit and of cash flows for each of the three years in the period ended December 28, 2024, including the related notes and financial statement schedule listed in the accompanying index (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of December 28, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 28, 2024 and December 30, 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 28, 2024 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 28, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.
Documents Incorporated by Reference	Portions of the registrant’s definitive Proxy Statement for its 2025 annual meeting of shareholders are incorporated herein by reference in Part III, Items 10-14. Such Proxy Statement will be filed with the SEC no later than 120 days after the registrant’s fiscal year ended December 28, 2024.

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 28, 2024	Dec. 30, 2023
CURRENT ASSETS
Cash and cash equivalents	$ 53,024	$ 109,366
Receivables (net of allowances: December 28, 2024 - $3,166 and December 30, 2023 - $1,041)	14,428	14,938
Prepaid income taxes	11,676	25,370
Prepaid marketing and advertising	4,969	10,149
Prepaid expenses and other current assets	18,551	19,651
TOTAL CURRENT ASSETS	102,648	179,474
Property and equipment, net	15,798	19,741
Operating lease assets	42,047	52,272
Franchise rights acquired	71,131	386,526
Goodwill	239,583	243,441
Other intangible assets, net	44,631	63,208
Deferred income taxes	16,686	19,683
Other noncurrent assets	17,752	17,685
TOTAL ASSETS	550,276	982,030
CURRENT LIABILITIES
Portion of operating lease liabilities due within one year	8,168	9,613
Accounts payable	17,803	18,507
Salaries and wages payable	53,143	79,096
Accrued marketing and advertising	12,805	18,215
Accrued interest	11,322	5,346
Deferred acquisition payable	15,503	16,500
Other accrued liabilities	20,593	22,610
Income taxes payable	2,339	1,609
Deferred revenue	31,655	33,966
TOTAL CURRENT LIABILITIES	173,331	205,462
Long-term debt, net	1,430,643	1,426,464
Long-term operating lease liabilities	44,322	53,461
Deferred income taxes	14,762	41,994
Other noncurrent liabilities	1,590	15,743
TOTAL LIABILITIES	1,664,648	1,743,124
Commitments and contingencies (Note 16)
TOTAL DEFICIT
Common stock, $0 par value; 1,000,000 shares authorized; 130,048 shares issued at December 28, 2024 and 130,048 shares issued at December 30, 2023	0	0
Treasury stock, at cost, 49,997 shares at December 28, 2024 and 50,859 shares at December 30, 2023	(3,024,710)	(3,064,628)
Retained earnings	1,936,170	2,314,834
Accumulated other comprehensive loss	(25,832)	(11,300)
TOTAL DEFICIT	(1,114,372)	(761,094)
TOTAL LIABILITIES AND TOTAL DEFICIT	$ 550,276	$ 982,030

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 28, 2024	Dec. 30, 2023
Statement of Financial Position [Abstract]
Receivables, allowances	$ 3,166	$ 1,041
Common stock, par value	$ 0	$ 0
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	130,048,000	130,048,000
Treasury stock, shares	49,997,000	50,859,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Revenues, net	$ 785,921	$ 889,551	$ 1,039,835
Cost of revenues	252,818	360,248	418,456
Gross profit	533,103	529,303	621,379
Marketing expenses	236,467	238,387	244,783
Selling, general and administrative expenses	217,825	264,950	263,840
Franchise rights acquired and goodwill impairments	315,033	3,633	396,727
Operating (loss) income	(236,222)	22,333	(283,971)
Interest expense	108,954	95,893	81,141
Other (income) expense, net	(1)	72	1,691
Loss before income taxes	(345,175)	(73,632)	(366,803)
Provision for (benefit from) income taxes	526	38,623	(109,935)
Net loss	$ (345,701)	$ (112,255)	$ (256,868)
Net loss per share
Basic	$ (4.34)	$ (1.46)	$ (3.65)
Diluted	$ (4.34)	$ (1.46)	$ (3.65)
Weighted average common shares outstanding
Basic	79,578	76,677	70,321
Diluted	79,578	76,677	70,321
Subscription
Revenues, net	$ 776,993	$ 822,755	$ 919,055
Cost of revenues	250,954	301,062	321,528
Other
Revenues, net	8,928	66,796	120,780
Cost of revenues	$ 1,864	$ 59,186	$ 96,928

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (345,701)	$ (112,255)	$ (256,868)
Other comprehensive (loss) gain:
Foreign currency translation (loss) gain	(9,096)	2,880	(11,222)
Income tax (expense) benefit on foreign currency translation (loss) gain	(2,720)	(703)	2,790
Foreign currency translation (loss) gain, net of taxes	(11,816)	2,177	(8,432)
(Loss) gain on derivatives	(3,473)	(10,673)	28,768
Income tax benefit (expense) on (loss) gain on derivatives	757	2,666	(7,202)
(Loss) gain on derivatives, net of taxes	(2,716)	(8,007)	21,566
Total other comprehensive (loss) gain	(14,532)	(5,830)	13,134
Comprehensive loss	$ (360,233)	$ (118,085)	$ (243,734)

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN TOTAL DEFICIT - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Treasury Stock	Accumulated Other Comprehensive Loss	Retained Earnings
Beginning Balance at Jan. 01, 2022	$ (452,904)	$ 0	$ (3,120,149)	$ (18,604)	$ 2,685,849
Beginning balance (in shares) at Jan. 01, 2022		122,052	51,988
Comprehensive (loss) income	(243,734)			13,134	(256,868)
Issuance of treasury stock under stock plans	(2,099)		$ 22,845		(24,944)
Issuance of treasury stock under stock plans (in shares)			(492)
Compensation expense on share-based awards	12,957				12,957
Ending Balance at Dec. 31, 2022	(685,780)	$ 0	$ (3,097,304)	(5,470)	2,416,994
Ending balance (in shares) at Dec. 31, 2022		122,052	51,496
Comprehensive (loss) income	(118,085)			(5,830)	(112,255)
Issuance of treasury stock under stock plans	(1,475)		$ 32,676		(34,151)
Issuance of treasury stock under stock plans (in shares)			(637)
Compensation expense on share-based awards	11,303				11,303
Issuance of common stock	32,943				32,943
Issuance of common stock (in shares)		7,996
Ending Balance at Dec. 30, 2023	(761,094)	$ 0	$ (3,064,628)	(11,300)	2,314,834
Ending balance (in shares) at Dec. 30, 2023		130,048	50,859
Comprehensive (loss) income	(360,233)			(14,532)	(345,701)
Issuance of treasury stock under stock plans	(809)		$ 39,918		(40,727)
Issuance of treasury stock under stock plans (in shares)			(862)
Compensation expense on share-based awards	7,764				7,764
Ending Balance at Dec. 28, 2024	$ (1,114,372)	$ 0	$ (3,024,710)	$ (25,832)	$ 1,936,170
Ending balance (in shares) at Dec. 28, 2024		130,048	49,997

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Operating activities:
Net loss	$ (345,701)	$ (112,255)	$ (256,868)
Adjustments to reconcile net loss to cash (used for) provided by operating activities:
Depreciation and amortization	37,784	52,471	43,801
Amortization of deferred financing costs and debt discount	5,018	5,018	5,018
Impairment of franchise rights acquired and goodwill	315,033	3,633	396,727
Impairment of intangible and long-lived assets	481	1,112	3,455
Share-based compensation expense	7,764	15,185	12,957
Deferred tax (benefit) provision	(26,578)	19,821	(145,829)
Allowance for doubtful accounts	2,062	1,306	(460)
Reserve for inventory obsolescence	72	7,350	6,796
Foreign currency exchange rate (gain) loss	(2,276)	263	2,374
Changes in cash due to:
Receivables	1,599	17,112	(7,558)
Inventories	91	14,018	3,733
Prepaid expenses	18,703	(4,133)	8,878
Accounts payable	(508)	(54)	(2,691)
Accrued liabilities	(14,998)	(11,625)	20,925
Deferred revenue	(1,780)	1,273	(11,733)
Other long term assets and liabilities, net	(14,624)	(3,598)	(2,291)
Income taxes	1,018	(211)	(588)
Cash (used for) provided by operating activities	(16,840)	6,686	76,646
Investing activities:
Capital expenditures	(718)	(2,485)	(2,065)
Capitalized software and website development expenditures	(15,692)	(33,816)	(36,187)
Cash paid for acquisitions, net of cash acquired		(38,362)	(4,350)
Other items, net	(5)	(33)	(42)
Cash used for investing activities	(16,415)	(74,696)	(42,644)
Financing activities:
Taxes paid related to net share settlement of equity awards	(839)	(2,241)	(2,197)
Proceeds from stock options exercised		718
Cash paid for acquisitions	(16,500)	(1,178)	(2,413)
Other items, net	(4)	(48)	(112)
Cash used for financing activities	(17,343)	(2,749)	(4,722)
Effect of exchange rate changes on cash and cash equivalents and restricted cash	(2,248)	1,799	(4,748)
Net (decrease) increase in cash and cash equivalents and restricted cash	(52,846)	(68,960)	24,532
Cash and cash equivalents and restricted cash, beginning of period	109,366	178,326	153,794
Cash and cash equivalents and restricted cash, end of period	$ 56,520	$ 109,366	$ 178,326

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ (345,701)	$ (112,255)	$ (256,868)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 28, 2024
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	From time to time, our directors and officers may engage in open-market transactions with respect to their Company equity holdings for diversification or other personal reasons. All such transactions by directors and officers must comply with the Company’s Amended and Restated Securities Trading Policy, which requires that such transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in the Company’s securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information. No contracts, instructions or written plans for the purchase or sale of Company securities were adopted or terminated by our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) during the quarter ended December 28, 2024 , that were intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). No “non-Rule 10b5–1 trading arrangements” (as defined by Item 408(c) of Regulation S-K) or other Rule 10b5-1 trading arrangements were entered into or terminated , nor were any such arrangements modified , by our directors or officers during such period.
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Non-Rule10b5-1 Arrangement Modified	false

Cybersecurity Risk Management,

Cybersecurity Risk Management, Strategy and Governance	12 Months Ended
	Dec. 28, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Item 1C. Cybersecurity In the ordinary course of business, we provide proprietary content and we collect, store and use confidential information (including, but not limited to, personal customer information and data) in connection with providing our products and engaging our employees and contractors. We have developed systems and processes designed to protect such content and information and we maintain cybersecurity insurance coverage. Our Board of Directors (the “Board”) and management recognize the critical importance of protecting the confidentiality and integrity of such information and data and maintaining the trust and confidence of our members, business partners, employees, contractors and shareholders, as well as complying with applicable regulatory requirements and contractual obligations. The Board and its committees actively oversee the Company’s risk management program. Cybersecurity threats and related risks are an important component of the Company’s overall approach to enterprise risk management (“ERM”). We annually examine our cybersecurity program with third parties, evaluating its effectiveness in part by considering industry standards and established frameworks, such as the National Institute of Standards and Technology (NIST), as guidelines. Cybersecurity risk management is a Company-wide initiative. In general, the Company seeks to address cybersecurity risks through a comprehensive, multi-disciplinary approach that is focused on preserving the confidentiality, security, and availability of the information that the Company collects and stores by identifying, preventing, and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur. Risk Management and Strategy As one of the elements of the Company’s overall ERM program, the Company’s cybersecurity program includes the following key areas: • Governance: As discussed in more detail under the heading “Governance,” the Board’s oversight of cybersecurity risk management is supported by the Audit Committee of the Board (the “Audit Committee”), which is regularly updated on cybersecurity matters by the Company’s Chief Information Security Officer (“CISO”), other members of management, and relevant representatives from management’s committees and the Company’s Internal Audit function. • Collaborative Approach: The Company has implemented a comprehensive, multi-disciplinary approach to identifying, preventing and mitigating cybersecurity threats and incidents, while also implementing controls and procedures that provide for the prompt escalation of certain cybersecurity incidents so that decisions regarding the public disclosure and reporting of such incidents can be made by management in a timely manner. • Technical Safeguards: The Company deploys technical safeguards that are designed to protect the Company’s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments by internal and third-party experts, and cybersecurity threat intelligence. • Incident Response and Recovery Planning: The Company has established and maintains comprehensive incident response and recovery plans pursuant to the NIST framework that fully address the Company’s response to a cybersecurity incident, and such plans are evaluated on a regular basis. • Third-Party Risk Management: The Company has implemented a risk-based evaluation process to identify and oversee cybersecurity risks presented by third parties, including vendors, service providers and other external users of the Company’s systems, as well as the systems of third parties that could adversely impact our business in the event of a cybersecurity incident affecting those third-party systems. • Education and Awareness: The Company provides regular, mandatory training and education for personnel regarding cybersecurity threats as a means to equip the Company’s personnel with effective tools to address cybersecurity threats, and to communicate the Company’s evolving information security policies, standards, processes and practices. The Company engages in the regular evaluations of the Company’s policies, standards, processes, and practices that are designed to address cybersecurity threats and incidents. These efforts include a wide range of activities, including tabletop exercises and vulnerability testing, focused on evaluating the effectiveness of our cybersecurity measures and planning. The Company regularly engages third parties to perform assessments on certain of our cybersecurity measures, including audits and penetration testing. For example, we annually engage qualified third-party auditors to independently assess and attest to and/or provide certifications of compliance with the HIPAA Security and Privacy Rule, SOC2 Type 2, the Payment Card Industry Data Security Standard (PCI-DSS), UK CyberEssentials, and HITRUST. The results of such assessments, audits and reviews are presented to the Audit Committee and members of the Board, as appropriate, and the Company adjusts its cybersecurity policies, standards, processes, and practices as necessary based on such assessments, audits and reviews. Governance The Board, in coordination with the Audit Committee, oversees the Company’s ERM process. The Audit Committee oversees our cybersecurity program, as well as the steps management has taken to monitor and control cybersecurity threats and related risks. This oversight includes receiving reports on the regular assessments of the Company’s disclosure controls and procedures to ensure that current practices account for material cybersecurity risks facing the Company. The Audit Committee receives presentations on the cybersecurity program and related risks on at least a quarterly basis. These presentations address a wide range of topics including recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological trends, and information security considerations arising with respect to the Company’s peers and third parties. The Audit Committee, and the full Board as necessary, also receive prompt and timely information regarding any cybersecurity incident that meets recognized established reporting thresholds, as well as ongoing updates regarding any such incident until it has been addressed. The Audit Committee routinely meets with our Chief Legal and Regulatory Officer (“CLRO”) and CISO as well as outside experts as appropriate to assess cybersecurity risks and to evaluate the status of the Company’s cybersecurity efforts, which include a broad range of tools and training initiatives that work together to protect the data and systems used in our businesses. Our cybersecurity management team includes our CISO, Data Privacy Officer, CLRO, Chief Financial Officer, and Head of Internal Audit . The CISO, in coordination with the team, works collaboratively across the Company to implement a program designed to protect the Company’s information systems from cybersecurity threats and to promptly respond to any cybersecurity incidents in accordance with the Company’s incident response and recovery plans. The cybersecurity management team meets regularly to review cybersecurity and data privacy strategy, receive updates, and consider the Company’s current risk posture. The team meetings also build leadership consensus on cybersecurity risk management and tolerance. In the event they become aware of a cybersecurity threat or incident, employees are expected to follow established lines of communication to notify the relevant members of the cybersecurity management team and allow the relevant team members to coordinate the evaluation and response to such threats and incidents as necessary. To facilitate the Company’s cybersecurity risk management program, multidisciplinary teams throughout the Company are deployed to address cybersecurity threats and to respond to cybersecurity incidents. Through ongoing communications with these teams, the CISO and the rest of the cybersecurity management team monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time and report such threats and incidents to other members of senior management and the Audit Committee when appropriate. Such plans also dictate notification responses to Company management based on the severity of the incident. The CISO has worked in the information security field for over 15 years and holds an undergraduate degree in computer systems management and master’s degrees in both cybersecurity and technology management. He has also attained multiple cybersecurity-related professional certifications and licenses, including Certified Information Systems Security Professional, and is an adjunct professor of cybersecurity at New York University and Fordham University. While we have experienced cybersecurity incidents in the past, we are not aware of any cybersecurity incidents that have materially affected or are reasonably likely to materially affect the Company, including its business strategy, results of operations, financial condition, cash flows or reputation. However, cybersecurity threats and/or incidents could have a material effect on the Company. While we maintain cybersecurity insurance, the costs related to cybersecurity threats or disruptions may not be fully insured. For additional information regarding the cybersecurity risks we face, see “Item 1A. Risk Factors— Risks Related to Technology, Security and Intellectual Property” of this Annual Report on Form 10-K.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]	While we have experienced cybersecurity incidents in the past, we are not aware of any cybersecurity incidents that have materially affected or are reasonably likely to materially affect the Company, including its business strategy, results of operations, financial condition, cash flows or reputation. However, cybersecurity threats and/or incidents could have a material effect on the Company. While we maintain cybersecurity insurance, the costs related to cybersecurity threats or disruptions may not be fully insured. For additional information regarding the cybersecurity risks we face, see “Item 1A. Risk Factors— Risks Related to Technology, Security and Intellectual Property” of this Annual Report on Form 10-K.
Cybersecurity Risk Board of Directors Oversight [Text Block]	The Board, in coordination with the Audit Committee, oversees the Company’s ERM process. The Audit Committee oversees our cybersecurity program, as well as the steps management has taken to monitor and control cybersecurity threats and related risks. This oversight includes receiving reports on the regular assessments of the Company’s disclosure controls and procedures to ensure that current practices account for material cybersecurity risks facing the Company. The Audit Committee receives presentations on the cybersecurity program and related risks on at least a quarterly basis. These presentations address a wide range of topics including recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological trends, and information security considerations arising with respect to the Company’s peers and third parties. The Audit Committee, and the full Board as necessary, also receive prompt and timely information regarding any cybersecurity incident that meets recognized established reporting thresholds, as well as ongoing updates regarding any such incident until it has been addressed. The Audit Committee routinely meets with our Chief Legal and Regulatory Officer (“CLRO”) and CISO as well as outside experts as appropriate to assess cybersecurity risks and to evaluate the status of the Company’s cybersecurity efforts, which include a broad range of tools and training initiatives that work together to protect the data and systems used in our businesses. Our cybersecurity management team includes our CISO, Data Privacy Officer, CLRO, Chief Financial Officer, and Head of Internal Audit . The CISO, in coordination with the team, works collaboratively across the Company to implement a program designed to protect the Company’s information systems from cybersecurity threats and to promptly respond to any cybersecurity incidents in accordance with the Company’s incident response and recovery plans. The cybersecurity management team meets regularly to review cybersecurity and data privacy strategy, receive updates, and consider the Company’s current risk posture. The team meetings also build leadership consensus on cybersecurity risk management and tolerance. In the event they become aware of a cybersecurity threat or incident, employees are expected to follow established lines of communication to notify the relevant members of the cybersecurity management team and allow the relevant team members to coordinate the evaluation and response to such threats and incidents as necessary. To facilitate the Company’s cybersecurity risk management program, multidisciplinary teams throughout the Company are deployed to address cybersecurity threats and to respond to cybersecurity incidents. Through ongoing communications with these teams, the CISO and the rest of the cybersecurity management team monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time and report such threats and incidents to other members of senior management and the Audit Committee when appropriate. Such plans also dictate notification responses to Company management based on the severity of the incident. The CISO has worked in the information security field for over 15 years and holds an undergraduate degree in computer systems management and master’s degrees in both cybersecurity and technology management. He has also attained multiple cybersecurity-related professional certifications and licenses, including Certified Information Systems Security Professional, and is an adjunct professor of cybersecurity at New York University and Fordham University. While we have experienced cybersecurity incidents in the past, we are not aware of any cybersecurity incidents that have materially affected or are reasonably likely to materially affect the Company, including its business strategy, results of operations, financial condition, cash flows or reputation. However, cybersecurity threats and/or incidents could have a material effect on the Company. While we maintain cybersecurity insurance, the costs related to cybersecurity threats or disruptions may not be fully insured. For additional information regarding the cybersecurity risks we face, see “Item 1A. Risk Factors— Risks Related to Technology, Security and Intellectual Property” of this Annual Report on Form 10-K.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Board, in coordination with the Audit Committee, oversees the Company’s ERM process. The Audit Committee oversees our cybersecurity program, as well as the steps management has taken to monitor and control cybersecurity threats and related risks.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	This oversight includes receiving reports on the regular assessments of the Company’s disclosure controls and procedures to ensure that current practices account for material cybersecurity risks facing the Company.
Cybersecurity Risk Role of Management [Text Block]	Our cybersecurity management team includes our CISO, Data Privacy Officer, CLRO, Chief Financial Officer, and Head of Internal Audit . The CISO, in coordination with the team, works collaboratively across the Company to implement a program designed to protect the Company’s information systems from cybersecurity threats and to promptly respond to any cybersecurity incidents in accordance with the Company’s incident response and recovery plans. The cybersecurity management team meets regularly to review cybersecurity and data privacy strategy, receive updates, and consider the Company’s current risk posture. The team meetings also build leadership consensus on cybersecurity risk management and tolerance. In the event they become aware of a cybersecurity threat or incident, employees are expected to follow established lines of communication to notify the relevant members of the cybersecurity management team and allow the relevant team members to coordinate the evaluation and response to such threats and incidents as necessary. To facilitate the Company’s cybersecurity risk management program, multidisciplinary teams throughout the Company are deployed to address cybersecurity threats and to respond to cybersecurity incidents. Through ongoing communications with these teams, the CISO and the rest of the cybersecurity management team monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time and report such threats and incidents to other members of senior management and the Audit Committee when appropriate. Such plans also dictate notification responses to Company management based on the severity of the incident. The CISO has worked in the information security field for over 15 years and holds an undergraduate degree in computer systems management and master’s degrees in both cybersecurity and technology management. He has also attained multiple cybersecurity-related professional certifications and licenses, including Certified Information Systems Security Professional, and is an adjunct professor of cybersecurity at New York University and Fordham University.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our cybersecurity management team includes our CISO, Data Privacy Officer, CLRO, Chief Financial Officer, and Head of Internal Audit . The CISO, in coordination with the team, works collaboratively across the Company to implement a program designed to protect the Company’s information systems from cybersecurity threats and to promptly respond to any cybersecurity incidents in accordance with the Company’s incident response and recovery plans.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	The CISO has worked in the information security field for over 15 years and holds an undergraduate degree in computer systems management and master’s degrees in both cybersecurity and technology management. He has also attained multiple cybersecurity-related professional certifications and licenses, including Certified Information Systems Security Professional, and is an adjunct professor of cybersecurity at New York University and Fordham University.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	The cybersecurity management team meets regularly to review cybersecurity and data privacy strategy, receive updates, and consider the Company’s current risk posture. The team meetings also build leadership consensus on cybersecurity risk management and tolerance. In the event they become aware of a cybersecurity threat or incident, employees are expected to follow established lines of communication to notify the relevant members of the cybersecurity management team and allow the relevant team members to coordinate the evaluation and response to such threats and incidents as necessary. To facilitate the Company’s cybersecurity risk management program, multidisciplinary teams throughout the Company are deployed to address cybersecurity threats and to respond to cybersecurity incidents. Through ongoing communications with these teams, the CISO and the rest of the cybersecurity management team monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time and report such threats and incidents to other members of senior management and the Audit Committee when appropriate. Such plans also dictate notification responses to Company management based on the severity of the incident.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 28, 2024
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation The accompanying consolidated financial statements include the accounts of WW International, Inc., all of its subsidiaries and the variable interest entities of which WW International, Inc. is the primary beneficiary (as discussed below). The terms “Company” and “WW” as used throughout these notes are used to indicate WW International, Inc. and all of its operations consolidated for purposes of its financial statements. The Company’s “Digital” business refers to providing subscriptions to the Company’s digital product offerings, which formerly included Digital 360 (as applicable). The Company’s “Workshops + Digital” business refers to providing subscriptions for unlimited access to the Company’s workshops combined with the Company’s digital subscription product offerings (including to former Digital 360 members (as applicable)). The Company’s “Clinical” business refers to providing subscriptions to the Company’s clinical product offerings provided by WeightWatchers Clinic (formerly referred to as Sequence) combined with the Company’s digital subscription product offerings and unlimited access to the Company’s workshops. In the second quarter of fiscal 2022, the Company ceased offering its Digital 360 product. More than a majority of associated members were transitioned from the Company’s Digital business to its Workshops + Digital business during the second quarter of fiscal 2022, with a de minimis number transitioning during the beginning of the third quarter of fiscal 2022. The cessation of this product offering and these transitions of former Digital 360 members at the then-current pricing for such product impacted the number of End of Period Subscribers in each business as well as the associated Paid Weeks and Revenues for each business. The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“GAAP”) and include all of the Company’s majority-owned subsidiaries. All entities acquired, and any entity of which a majority interest was acquired, are included in the consolidated financial statements from the date of acquisition. All intercompany accounts and transactions have been eliminated in consolidation. As previously disclosed, effective the first day of fiscal 2024 (i.e., December 31, 2023), as a result of the continued evolution of the Company’s centralized organizational structure in fiscal 2023, and management’s 2024 strategic planning process, the Company’s reportable segments changed to one segment for the purpose of making operational and resource decisions and assessing financial performance. Segment data for the fiscal years ended December 30, 2023 and December 31, 2022 has been updated to reflect this reportable segment structure. See Note 17 for disclosures related to segments. In the fourth quarter of fiscal 2024, the Company identified and recorded an out-of-period adjustment related to an income tax error. The impact of correcting this error, which was immaterial to all current and prior period financial statements and corrected in the fourth quarter of fiscal 2024, resulted in an income tax benefit of approximately $ 1,963 , with a corresponding increase to other comprehensive loss, for the fiscal year ended December 28, 2024. In the second quarter of fiscal 2024, the Company identified and recorded an out-of-period adjustment related to an income tax error. The impact of correcting this error, which was immaterial to all current and prior period financial statements and corrected in the second quarter of fiscal 2024, resulted in an income tax expense of approximately $ 2,748 , with a corresponding decrease to net income, for the fiscal year ended December 28, 2024. On April 10, 2023, the Company completed its previously announced acquisition of Weekend Health, Inc., doing business as Sequence (“Sequence”). The accompanying consolidated financial statements include the results of operations of Sequence (now operating as WeightWatchers Clinic) from the date of acquisition. See Note 6 for additional information on the Company’s acquisitions. Prior period amounts have been reclassified to conform with the current period presentation. Liquidity The Company has experienced significant disruption and competitive pressures, including shifts in consumer behavior in the weight loss category, a rapid proliferation of GLP-1 and other medications available as weight-loss options, and significantly increased competition from new entrants. These factors have negatively impacted the Company’s Behavioral business. While the Clinical business is growing, it has not yet been able to offset the declines in the Behavioral business, resulting in decreased revenue overall and decreased cash flows from operations. The Company’s management has continued to execute certain cost-savings initiatives, including the Company’s previously disclosed 2024 restructuring plan, to proactively manage the Company’s liquidity. If the cost-saving initiatives do not provide the expected net benefit, the Company’s liquidity, results of operations and financial position may be materially adversely impacted. The Company has recurring net losses. During the fiscal year ended December 28, 2024, the Company recorded an operating loss of $ 236,222 and a net loss of $ 345,701 . Operating loss included $ 315,033 of franchise rights acquired impairments that were non-cash. The Company’s annual revenues decreased from $ 889,551 for the fiscal year ended December 30, 2023 to $ 785,921 for the fiscal year ended December 28, 2024, in which the closure of the consumer products business resulted in a revenue decline of $ 54,968 versus the prior year. Cash used for operating activities for the fiscal year ended December 28, 2024 was $ 16,840 , which included $ 96,844 of interest payments and $ 30,716 of severance payments. The Company has a total deficit of $ 1,114,372 at December 28, 2024. In addition, the Company has $ 1,430,643 of long-term debt, net at December 28, 2024 and incurred $ 108,954 in interest expense for the fiscal year ended December 28, 2024. The Company’s principal sources of liquidity are cash and cash equivalents, cash flows from operations and proceeds from the January 2025 borrowings under its Revolving Credit Facility (as defined below). The Company’s primary cash needs for the twelve months following the issuance date of these financial statements (“issuance date”) are funding its operations and global strategic initiatives, meeting debt service requirements and other financing commitments. The Company believes that future cash flows from operations, unrestricted cash on hand of $ 53,024 at December 28, 2024 (of which $ 22,024 is maintained at foreign subsidiaries), proceeds from the January 2025 borrowings under its Revolving Credit Facility and the continued impact of its cost-savings initiatives will provide it with sufficient liquidity to meet its obligations for at least the next twelve months from the issuance date. The Company’s Revolving Credit Facility matures on April 13, 2026. This facility provides a source of liquidity for the Company. On January 2, 2025 and January 31, 2025, the Company increased its outstanding debt by borrowing $ 50,000 and $ 121,341 , respectively, under its Revolving Credit Facility currently at an interest rate of approximately 7.3 %. As a result of these drawdowns and outstanding letters of credit, the Company has no availability for future borrowings under its Revolving Credit Facility . All outstanding borrowings under the Revolving Credit Facility on April 13, 2025 and thereafter will be reflected as a current liability. If the aggregate principal amount of extensions of credit outstanding under the Revolving Credit Facility, inclusive of outstanding letters of credit, as of any fiscal quarter end exceeds 35 %, or $ 61,250 , of the amount of the aggregate commitments under the Revolving Credit Facility, the Company is required to be in compliance with a Consolidated First Lien Leverage Ratio of 5.25 :1.00 through and including the first fiscal quarter of 2025 and 5.00 :1.00 thereafter. The Company’s Consolidated First Lien Leverage Ratio as of December 28, 2024 was 8.36 :1.00. Accordingly, in order to avoid an Event of Default under the Revolving Credit Facility, absent the Company and its lenders agreeing to a change in the existing terms and conditions, the Company will need to repay Revolving Credit Facility borrowings in excess of $ 61,250 by March 29, 2025, the end of the Company's first fiscal quarter of 2025. At December 28, 2024, the Company also had outstanding $ 1,445,000 of total debt, consisting of borrowings under the Term Loan Facility (as defined below) of $ 945,000 that mature on April 13, 2028 and $ 500,000 in aggregate principal amount of Senior Secured Notes (as defined below) that matures on April 15, 2029. The debt facilities pursuant to which such long-term debt was issued contain cross-default and/or cross-acceleration provisions that could result in an acceleration of such indebtedness in the event of an Event of Default under the Revolving Credit Facility. The Company has the intent and ability to remain in compliance with its obligations under its debt agreements for at least the next twelve months following the issuance date. The Company continues to actively evaluate its capital structure and intends to engage with its lenders to explore transactions to strengthen its balance sheet by reducing its leverage and interest expense and extending its existing debt maturities. As of the issuance date, the Company believes it has sufficient liquidity to meet its obligations, including compliance with covenants under its long-term debt and Revolving Credit Facility obligations, through at least twelve months from the issuance date. However, beyond the period of twelve months from the issuance date, if the Company does not successfully enter into a transaction(s) to strengthen its balance sheet and increase its financial flexibility, the Company’s liquidity, results of operations, cash flows and financial condition may be materially adversely impacted.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 28, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Fiscal Year The Company’s fiscal year ends on the Saturday closest to December 31st and consists of either 52 or 53-week periods. Fiscal 2024, fiscal 2023 and fiscal 2022 each contained 52 weeks. Use of Estimates The preparation of financial statements, in conformity with GAAP, requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and judgments, including those related to the im pairment analyses for goodwill and other indefinite-lived intangible assets, revenue, share-based compensation, income taxes, tax contingencies and litigation. The Company bases its estimates on historical experience and on various other factors and assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. While all available information has been considered, actual amounts could differ from these estimates. These estimates and assumptions may change as new events occur and additional information is obtained, and such future changes may have an adverse impact on the Company's results of operations, financial position and liquidity. Variable Interest Entity The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex and involve judgment and the use of estimates and assumptions based on available information. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, such entity is consolidated in the Company’s consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. The Company performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Through WeightWatchers Clinic, the Company operates certain clinical telehealth groups which are deemed to be Friendly-Physician Entities (“FPEs”) and due to legal requirements, the physician-owners must retain 100 % of the equity interest. The Company’s agreements with FPEs generally consist of both an Administrative Services Agreement, which provides for various administrative and management services to be provided by the Company to the FPE, and Share Transfer Agreement (“STA”) with the physician-owners of the FPEs, which provides for the transition of ownership interest of the FPEs under certain conditions. The Company has the right to receive income as an ongoing management fee, which effectively absorbs all of the residual interests, and can also provide financial support through loans to the FPEs. The Company has exclusive responsibility for the provision of all nonmedical services including technology and intellectual property required for the day-to-day operation and management of each of the FPEs. In addition, the STA provides that the Company has the right to designate a person(s) to purchase the equity interest of the FPE for a nominal amount in the event of a succession event at the Company’s discretion. Based on the provisions of these agreements, the Company determined that the FPEs are VIEs due to their equity holder having insufficient capital at risk, and the Company has a variable interest in the FPEs. The contractual arrangements described above allow the Company to direct the activities that most significantly affect the economic performance of the FPEs. Accordingly, the Company is the primary beneficiary of the FPEs and consolidates the FPEs under the VIE model. Furthermore, as a direct result of nominal initial equity contributions by the physicians, the financial support the Company can provide to the FPEs (e.g., loans) and the provisions of the contractual arrangements and nominee shareholder succession arrangements described above, the interests held by noncontrolling interest holders lack economic substance and do not provide them with the ability to participate in the residual profits or losses generated by the FPEs. Therefore, all income and expenses recognized by the FPEs are consolidated by the Company. The Company does not hold interests in any VIEs for which the Company is not deemed to be the primary beneficiary. Translation of Foreign Currencies For all foreign operations, the functional currency is the local currency. Assets and liabilities of these operations are translated into U.S. dollars using the exchange rate in effect at the end of each reporting period. Income statement accounts are translated at the average rate of exchange prevailing during each reporting period. Translation adjustments arising from the use of differing exchange rates from period to period are included in accumulated other comprehensive loss. Foreign currency gains and losses arising from the translation of intercompany receivables and intercompany payables with the Company’s international subsidiaries are recorded as a component of other expense , net, unless the receivable or payable is considered long-term in nature, in which case the foreign currency gains and losses are recorded as a component of accumulated other comprehensive loss. Cash and Cash Equivalents Cash and cash equivalents are defined as highly liquid investments with original maturities of three months or less. Cash balances may, at times, exceed insurable amounts. The Company believes it mitigates this risk by investing in or through major financial institutions. Cash includes balances due from third-party credit card companies. Receivables Receivables include amounts that are billed and currently due from customers. The amounts due are stated at their net estimated realizable value. The Company maintains an allowance for credit losses to provide for the estimated amount of receivables that will not be collected, including balances from customers under recur bill commitment plans. The assessment of the likelihood of customer defaults is based on various factors, including length of time the receivables are past due and historical experience, all of which are subject to change. The Company’ s credit write offs were $ 15,080 and $ 1,241 for the fiscal years ended December 28, 2024 and December 30, 2023 , respectively. Inventories Inventories, which consist of finished goods, are stated at the lower of cost or net realizable value on a first-in, first-out basis, net of reserves for obsolescence and shrinkage. Property and Equipment Property and equipment are recorded at cost. For financial reporting purposes, equipment is depreciated on the straight-line method over the estimated useful lives of the assets ( 3 to 10 years ). Leasehold improvements are amortized on the straight-line method over the shorter of the term of the lease o r the useful life of the related assets. Expenditures for new facilities and improvements that substantially extend the useful life of an asset are capitalized. Ordinary repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related depreciation are removed from the accounts and any related gains or losses are included in income. Leases A lease is defined as an arrangement that contractually specifies the right to use and control an identified asset for a specific period of time in exchange for consideration. Operating leases are included in operating lease assets, portion of operating lease liabilities due within one year, and long-term operating lease liabilities in the Company’s consolidated balance sheets. Finance leases are included in property and equipment, net, other accrued liabilities, and other long-term liabilities in the Company’s consolidated balance sheets. Lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term, using the Company’s incremental borrowing rate commensurate with the lease term, since the Company’s lessors do not provide an implicit rate, nor is one readily available. The incremental borrowing rate is calculated based on the Company’s credit yield curve and adjusted for collateralization, credit quality and economic environment impact, all where applicable. The lease asset includes scheduled lease payments and excludes lease incentives, such as free rent periods and tenant improvement allowances. The Company has certain leases that may include an option to renew and when it is reasonably probable to exercise such option, the Company will include the renewal option terms in determining the lease asset and lease liability. The Company does not have any renewal options that would have a material impact on the terms of the leases and that are also reasonably expected to be exercised as of December 28, 2024. A lease may contain both fixed and variable payments. Variable lease payments that are linked to an index or rate are measured based on the current index or rate at the implementation of the lease accounting standard, or lease commencement date for new leases, with the impact of future changes in the index or rate being recorded as a period expense. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components and has elected not to separate non-lease components from lease components and instead to account for each separate lease component and non-lease component as a single lease component. The Company has elected the short-term lease exception accounting policy, whereby the recognition requirements of the updated guidance is not applied and lease expense is recorded on a straight-line basis with respect to leases with an initial term of 12 months or less. Impairment of Long-Lived Assets The Company reviews long-lived assets, including amortizable intangible assets, for impairment whenever events or changes in business circumstances indicate that the carrying value of the assets may not be fully recoverable. In fiscal 2024, fiscal 2023 and fiscal 2022, the Company recorded impairment charg es of $ 142 , $ 900 and $ 714 , respectively, related to internal-use computer software and website development costs that were not expected to provide substantive service potential. In fiscal 2024, fiscal 2023 and fiscal 2022, the Company recorded impairment charges of $ 339 , $ 212 and $ 61 , respectively, related to property and equipment that were expected to be disposed of before the end of their estimated useful lives. In fiscal 2022, the Company recorded lease asset impairment charges of $ 2,680 in the aggregate. See No te 4 for further information on the Company’s leases. Franchise Rights Acquired Finite-lived franchise rights acquired are amortized over the remaining contractual period, which is generally less than one year . Indefinite-lived franchise rights acquired are tested for potential impairment on at least an annual basis or more often if events so require. In performing the impairment analysis for indefinite-lived franchise rights acquired, the fair value for franchise rights acquired is estimated using a discounted cash flow approach referred to as the hypothetical start-up approach for franchise rights related to the Company’s Workshops + Digital business and a relief from royalty methodology for franchise rights related to the Company’s Digital business. The aggregate estimated fair value for these franchise rights is then compared to the carrying value of the unit of account for these rights. The Company has determined the appropriate unit of account for purposes of assessing impairment to be the combination of the rights in both the Workshops + Digital business and the Digital business in the country in which the applicable acquisition occurred. The net book value of franchise rights acquired for the United States unit of account as of the December 28, 2024 balance sheet date was $ 68,627 , which represented 100.0 % of total franchise rights acquired as of December 28, 2024 . The net book values of franchise rights acquired for the United States, Australia, United Kingdom and New Zealand units of account as of the December 30, 2023 balance sheet date were $ 374,353 , $ 4,232 , $ 2,806 and $ 2,420 , respectively, which represented 97.6 %, 1.1 %, 0.7 % and 0.6 %, respectively, of total franchise rights acquired as of December 30, 2023. In its hypothetical start-up approa ch analyses for fiscal 2024, the Company assumed that the year of maturity was reached after 7 years. Subsequent to the year of maturity, the Company estimated future cash flows for the Workshops + Digital business in each country based on assumptions regarding revenue growth and operating income margins. In the Company’s relief from royalty approach analyses for fiscal 2024, the cash flows associated with the Digital business in each country were based on the expected Digital re venue for such country and the application of a royalty rate based on current market terms. The cash flows for the Workshops + Digital and the Digital businesses were discounted utilizing rates which were calculated using the weighted average cost of capital, which included the cost of equity and the cost of debt. Goodwill In performing the impairment analysis for goodwill, the fair value for the Company’s reporting units is estimated using a discounted cash flow approach. This approach involves projecting future cash flows attributable to the reporting unit and discounting those estimated cash flows using an appropriate discount rate. The estimated fair value is then compared to the carrying value of the reporting unit. The Company has determined the appropriate reporting units for purposes of assessing goodwill impairment to be the Behavioral and Clinical business lines. See Note 7 for further information on the Company’s change in goodwill reporting units. The net book values of goodwill for the Behavioral and Clinical reporting units as of the December 28, 2024 balance sheet date were $ 149,841 and $ 89,742 , respectively, which represented 62.5 % and 37.5 %, respectively, of total goodwill as of December 28, 2024. In performing the impairment analysis for goodwill, for all of the Company’s reporting units, the Company estimated future cash flows by utilizing the historical debt-free cash flows (cash flows provided by operations less capital expenditures) attributable to each of the Behavioral and Clinical reporting units and then applied expected future operating income growth rates for the respective reporting unit. The Company utilized operating income as the basis for measuring its potential growth because it believes it is the best indicator of the performance of its business. The Company then discounted the estimated future cash flows utilizing a discount rate which was calculated using the weighted average cost of capital, which included the cost of equity and the cost of debt. Indefinite-Lived Franchise Rights Acquired and Goodwill Impairment Tests The Company reviews indefinite-lived franchise rights acquired and goodwill for potential impairment on at least an annual basis or more often if events so require. The Company performed its annual fair value impairment testing as of May 5, 2024 and May 7, 2023, each the first day of fiscal May, on its indefinite-lived franchise rights acquired and goodwill. In addition, based on triggering events, the Company performed interim impairment tests as of March 30, 2024 and September 28, 2024 on its indefinite-lived franchise rights acquired and goodwill for the first and third quarters of fiscal 2024, respectively. See Note 7 for further information regarding the results of the franchise rights acquired and goodwill annual impairment tests, and the franchise rights acquired and goodwill interim impairment tests for the first and third quarters of fiscal 2024. Other Intangible Assets Other finite-lived intangible assets are amortized using the straight-line method over their estimated useful lives o f 3 to 20 years . The Company expenses all software costs incurred during the preliminary project stage and capitalizes all internal and external direct costs of materials and services consumed in developing software once the development has reached the application development stage. Application development stage costs generally include software configuration, coding, installation to hardware and testing. These costs are amortized over their estimated useful lives of 3 to 5 years for software and website development costs. All costs incurred for upgrades, maintenance and enhancements, including the cost of website content, which do not result in additional functionality, are expensed as incurred. Revenue Recognition Revenues are recognized when control of the promised services or goods is transferred to the Company’s customers in an amount that reflects the consideration it expects to be entitled to in exchange for those services or goods. The Company earns revenue from subscriptions for its Digital and Clinical products and by conducting workshops, for which it charges a fee, predominantly through commitment plans, as well as prepayment plans. The Company also earns revenue by collecting royalties related to licensing agreements, collecting royalties from franchisees, and publishing. Prior to fiscal 2024, the Company also earned revenue by selling consumer products. Commitment plan revenues and prepaid workshop fees are recorded to revenue on a straight-line basis as control is transferred since these performance obligations are satisfied over time. “Digital Subscription Revenues,” consisting of the fees associated with subscriptions for the Company’s Digital offerings, are recognized on a straight-line basis as control is transferred since these performance obligations are satisfied over time. One-time Digital sign-up fees are considered immaterial in the context of the contract and the related revenue is amortized into revenue over the commitment period. “Workshops + Digital Subscription Revenues”, consisting of the fees associated with subscriptions for the Company’s Workshops + Digital offerings, are recognized on a straight-line basis as control is transferred since these performance obligations are satisfied over time. In the Workshops + Digital business, the Company generally charges non-refundable registration and starter fees in exchange for access to the Company’s digital subscription products, an introductory information session and materials it provides to new members. Revenue from these registration and starter fees is considered immaterial in the context of the contract and is amortized into revenue over the commitment period. “Clinical Subscription Revenues” consist of revenues earned from initial consultations that are conducted to determine if a prospective member is eligible to be a Clinical subscriber and from fees associated with subscriptions for the Company’s Clinical offerings, predominantly through monthly commitment plans and prepayment plans. One-time initial consultation fees are recorded as revenue at the point in time control is transferred, which is when the initial consultation takes place. Commitment plan revenues and prepaid subscription fees are recognized on a straight-line basis as control is transferred since these performance obligations are satisfied over time. Revenue from royalties is recognized at the point in time control is transferred, which is when royalties are earned. Revenue from consumer product sales was recognized at the point in time control was transferred, which was when products were shipped to customers and partners and title and risk of loss passed to them. For revenue transactions that involve multiple performance obligations, the amount of revenue recognized is determined using the relative fair value approach, which is generally based on each performance obligation’s stand-alone selling price. Discounts to customers, including free registration offers, are recorded as a deduction from gross revenue in the period such revenue was recognized. The Company grants refunds in aggregate amounts that historically have not been material. Because the period of payment of the refund generally approximates the period revenue was originally recognized, refunds are recorded as a reduction of revenue over the same period. The Company does not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. The Company expenses sales commissions when incurred (amortization period would have been one year or less) and these expenses are recorded within selling, general and administrative expenses. The Company treats shipping and handling fees as fulfillment costs and not as a separate performance obligation, and as a result, any fees received from customers are included in the transaction price allocated to the performance obligation of providing goods with a corresponding amount accrued within cost of product sales and other for amounts paid to applicable carriers. Sales tax, value-added tax and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue. Advertising Costs Advertising costs consist primarily of broadcast and digital media. All costs related to advertising are expensed in the period incurred, except for media production-related costs, which are expensed the first time the advertising takes place. Total advertising expenses for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 were $ 234,316 , $ 235,227 and $ 238,978 , respectively. Income Taxes Deferred income tax assets and liabilities result primarily from temporary differences between the financial statement and tax bases of assets and liabilities, using enacted tax rates in effect for the year in which differences are expected to reverse. If it is more-likely-than-not that some portion of a deferred tax asset will not be realized, a valuation allowance is recognized. The Company considers historic levels of income, estimates of future taxable income and feasible tax planning strategies in assessing the need for a tax valuation allowance. The Company recognizes a benefit for uncertain tax positions when a tax position taken or expected to be taken in a tax return is more-likely-than-not to be sustained upon examination by taxing authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company recognizes accrued interest and penalties associated with uncertain tax positions as part of the provision for income taxes on its consolidated statements of operations. In addition, assets and liabilities acquired in purchase business combinations are assigned their fair values and deferred taxes are provided for lower or higher tax bases. Derivative Instruments and Hedging The Company is exposed to certain risks related to its ongoing business operations, primarily interest rate risk and foreign currency risk. Interest rate swaps were historically entered into to hedge a portion of the cash flow exposure associated with the Company’s variable-rate borrowings. At December 28, 2024, the Company did not have any interest rate swaps in effect. The Company does not use any derivative instruments for trading or speculative purposes. The Company recognized the fair value of all derivative instruments as either assets or liabilities on the balance sheet. The Company designated and accounted for interest rate swaps as cash flow hedges of its variable-rate borrowings. For derivative instruments that were designated and qualified as cash flow hedges, the effective portion of the gain or loss on the derivative was reported as a component of accumulated other comprehensive loss and reclassified into earnings in the periods during which the hedged transactions affected earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness were recognized in current earnings. The fair value of the Company’s interest rate swaps was reported as a component of accumulated other comprehensive loss on its balance sheet. See Note 18 for a further discussion regarding the fair value of the Company’s interest rate swaps. The net effect of the interest payable and receivable under the Company’s effective interest rate swap was included in interest expense on its consolidated statements of operations. Deferred Financing Costs Deferred financing costs consist of fees paid by the Company as part of the establishment, exchange and/or modification of the Company’s long-term debt. Amortization expense for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 was $ 5,018 , $ 5,018 and $ 5,018 , respectively.

Accounting Standards Adopted in

Accounting Standards Adopted in Current Year	12 Months Ended
	Dec. 28, 2024
Accounting Changes and Error Corrections [Abstract]
Accounting Standards Adopted in Current Year and Recently Issued Accounting Pronouncements	3. Accounting Standards Adopted in Current Year In November 2023, the Financial Accounting Standards Board (the “FASB”) issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures” , to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, ASU 2023-07 enhances interim disclosure requirements, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment and contains other disclosure requirements. The effective date of the new guidance for public companies is for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. In the fourth quarter of fiscal 2024, the Company adopted ASU 2023-07 and applied the new guidance retrospectively to all prior periods presented in the financial statements. The adoption of this guidance did no t have a material impact on the Company’s consolidated financial statements. 21. Recently Issued Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” , to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. ASU 2023-09 also improves the effectiveness and comparability of income tax disclosures by (1) adding disclosures of pretax income (or loss) and income tax expense (or benefit) and (2) removing disclosures that no longer are considered cost beneficial or relevant. The effective date of the new guidance for public companies is for annual periods beginning after December 15, 2024. Early adoption is permitted. The new guidance should be applied prospectively, although retrospective application is permitted. The Company is currently evaluating the impact that ASU 2023-09 will have on its consolidated financial statements and related disclosures, including the adoption date and transition method. In November 2024, the FASB issued ASU 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures”, which requires the disaggregation of certain expenses in the notes to the financial statements to provide enhanced transparency into the expense captions presented on the face of the income statement. Additionally, in January 2025, the FASB issued ASU 2025-01 to clarify the effective date of ASU 2024-03. Under ASU 2024-03, a public entity would be required to disclose information about purchases of inventory, employee compensation, depreciation, intangible asset amortization, and depletion for each income statement line item that contains those expenses, as well as a qualitative description of amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. ASU 2024-03 also requires disclosure of the total amount of selling expenses and, in annual periods, an entity’s definition of selling expenses. This guidance is effective for fiscal years beginning after December 15, 2026 and interim periods within annual reporting periods beginning after December 15, 2027, and may be applied either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that ASU 2024-03 will have on its consolidated financial statements and related disclosures, including the adoption date and transition method. The Company has determined that other recently issued accounting pronouncements are not expected to have a material impact on its consolidated financial statements.

Leases

Leases	12 Months Ended
	Dec. 28, 2024
Leases [Abstract]
Leases	4. Leases At December 28, 2024 and December 30, 2023, the Company’s lease assets and lease liabilities, primarily for its studios and corporate offices, were as follows: December 28, 2024 December 30, 2023 Assets: Operating leases $ 42,047 $ 52,272 Finance leases — 5 Total lease assets $ 42,047 $ 52,277 Liabilities: Current Operating leases $ 8,168 $ 9,613 Finance leases — 4 Noncurrent Operating leases 44,322 53,461 Finance leases — — Total lease liabilities $ 52,490 $ 63,078 For the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022, the components of the Company’s lease expense were as follows: Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 Operating lease cost: Fixed lease cost $ 15,444 $ 21,259 $ 33,227 Lease termination cost 34 12,718 2,726 Variable lease cost 23 62 27 Total operating lease cost $ 15,501 $ 34,039 $ 35,980 Finance lease cost: Amortization of leased assets $ 4 $ 48 $ 112 Interest on lease liabilities 0 1 6 Total finance lease cost $ 4 $ 49 $ 118 Total lease cost $ 15,505 $ 34,088 $ 36,098 As previously disclosed, in conjunction with the continued rationalization of its real estate portfolio, the Company entered into subleases with commencement dates in the first quarter of fiscal 2023 , which resulted in lease asset impairment charges of $ 2,680 in the aggregate that were recognized in general and administrative expenses in the Company's consolidated statements of operations for the fiscal year ended December 31, 2022. The Company reco rded $ 4,217 and $ 3,375 of sublease income for the fiscal years ended December 28, 2024 and December 30, 2023, respectively, as an offset to general and administrative expenses. At December 28, 2024 and December 30, 2023, the Company’s weighted average remaining lease term and weighted average discount rates were as follows: December 28, 2024 December 30, 2023 Weighted Average Remaining Lease Term (years) Operating leases 6.84 7.31 Finance leases — 0.48 Weighted Average Discount Rate Operating leases 7.68 7.54 Finance leases — 4.10 The Company’s leases have remaining lease terms of 0 to 8 years with a weighted average lease term of 6.84 years as of December 28, 2024. At December 28, 2024, the maturity of the Company’s operating lease liabilities in each of the next five fiscal years and thereafter are as follows: Operating Fiscal 2025 $ 11,977 Fiscal 2026 10,088 Fiscal 2027 9,307 Fiscal 2028 9,073 Fiscal 2029 8,963 Thereafter 17,852 Total lease payments $ 67,260 Less imputed interest 14,770 Present value of lease liabilities $ 52,490 Supplemental cash flow information related to leases for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 were as follows: Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 15,786 $ 22,013 $ 31,580 Operating cash flows from finance leases $ 0 $ 1 $ 6 Financing cash flows from finance leases $ 4 $ 48 $ 112 Lease assets obtained (modified) in exchange for new (modified) operating lease liabilities $ 968 $ ( 7,086 ) $ 13,297 Lease assets obtained in exchange for new finance lease liabilities $ — $ — $ 49

Revenue

Revenue	12 Months Ended
	Dec. 28, 2024
Revenue from Contract with Customer [Abstract]
Revenue	5. Revenue The following table presents the Company’s revenues disaggregated by revenue source: Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 Digital Subscription Revenues $ 512,853 $ 571,074 $ 662,668 Workshops + Digital Subscription Revenues 186,139 221,139 256,387 Clinical Subscription Revenues 78,001 30,542 — Subscription Revenues, net $ 776,993 $ 822,755 $ 919,055 Other Revenues, net 8,928 66,796 120,780 Revenues, net $ 785,921 $ 889,551 $ 1,039,835 Information about Contract Balances For Subscription Revenues, the Company can collect payment in advance of providing services. Any amounts collected in advance of services being provided are recorded in deferred revenue. In the case where amounts are not collected, but the service has been provided and the revenue has been recognized, the amounts are recorded in accounts receivable. The opening and ending balances of the Company’s deferred revenues were as follows: Deferred Deferred Revenue Revenue-Long Term Balance as of December 31, 2022 $ 32,156 $ 360 Net increase (decrease) during the period 1,810 ( 195 ) Balance as of December 30, 2023 $ 33,966 $ 165 Net increase (decrease) during the period ( 2,311 ) ( 72 ) Balance as of December 28, 2024 $ 31,655 $ 93 Revenue recognized from amounts included in current deferred revenue as of December 30, 2023 wa s $ 33,753 for the fiscal year ended December 28, 2024 . Revenue recognized from amounts included in current deferred revenue as of December 31, 2022 was $ 32,156 for the fiscal year ended December 30, 2023 . The Company’s long-term deferred revenue, which is included in other liabilities on its consolidated balance sheets, represents revenue that will not be recognized during the next 12 months and is generally related to upfront payments received as an inducement for entering into certain sales-based royalty agreements with third-party licensees. This revenue is amortized on a straight-line basis over the term of the applicable agreement.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 28, 2024
Business Combinations [Abstract]
Acquisitions	6. Acquisitions Acquisition of Sequence On April 10, 2023 (the “Closing Date”), the Company completed its previously announced acquisition of Weekend Health, Inc., doing business as Sequence, a Delaware corporation (“Sequence”), subject to the terms and conditions set forth in the Agreement and Plan of Merger, dated as of March 4, 2023, by and among the Company, Well Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company, Sequence, and Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as the Equityholders’ Representative (as defined therein) for Sequence (the “Merger Agreement”), pursuant to which Sequence continued as a wholly-owned subsidiary of the Company (the “Acquisition”). Sequence provided a technology powered care platform and mobile web application through its subscription based service, which included a comprehensive weight management program, pharmacotherapy treatment, nutrition plans, health insurance coordination services, and access to clinicians, dietitians, fitness coaches and care coordinators. As consideration for the Acquisition, the Company agreed to pay an aggregate amount equal to $ 132,000 , subject to the adjustments set forth in the Merger Agreement (the “Merger Consideration”). Subject to the terms and conditions of the Merger Agreement, the Merger Consideration has been paid, or is payable, as f ollows: (i) approximately $ 64,217 in cash (inclusive of approximately $ 25,800 of cash on the balance sheet of Sequence) and approximately $ 34,702 in the form of approximately 7,996 newly issued shares of Company common stock (valued at $ 4.34 per share), in each case, paid on or promptly following the Closing Date, (ii) $ 16,000 in cash paid on April 10, 2024, and (iii) $ 16,000 in cash to be paid on April 10, 2025, in each case, subject to the adjustments and deductions set forth in the Merger Agreement. The following table show s the purchase price allocation for Sequence to the acquired identifiable assets, liabilities assumed and goodwill: Total consideration: Cash paid at closing $ 64,217 Cash paid on April 10, 2024 16,000 Cash to be paid on April 10, 2025 (1) 12,420 Total cash payments $ 92,637 Less stock-based compensation expense attributable to post combination vesting ( 3,882 ) Common shares issued 7,996 Stock price as of April 10, 2023 (2) $ 4.12 Total stock issuance purchase price (2) 32,943 Aggregated merger consideration $ 121,698 Assets acquired: Cash $ 25,776 Prepaid expenses and other current assets 2,220 Property, plant and equipment 34 Intangible assets 7,222 Total assets acquired 35,252 Liabilities assumed: Accounts payable $ 70 Accrued liabilities 14 Deferred revenue 1,300 Deferred tax liability 1,912 Total liabilities assumed 3,296 Net assets acquired 31,956 Total goodwill $ 89,742 (1) Reflects $ 16,000 of cash payable on April 10, 2025 as Merger Consideration discounted using the Company's weighted average cost of debt. (2) Represents the fair value of the shares transferred to the sellers as Merger Consideration, based on the number of shares to be issued, 7,996 , multiplied by the closing price of the Company's shares on April 10, 2023 of $ 4.12 per share. The Acquisition has been accounted for under the purchase method of accounting. The Acquisition resulted in goodwill related to, among other things, expected synergies in operations. The goodwill will not be deductible for tax purposes. The results of operations of Sequence (now operating as WeightWatchers Clinic) have been included in the consolidated operating results of the Company from the Closing Date. The Company incurred transaction-related costs of $ 8,605 for t he fiscal year ended December 30, 2023. These costs were associated with legal and professional services and were recognized as operating expenses on the consolidated statements of operations. Acquisitions of Franchisees On February 18, 2022, the Company acquired the entire issued share capital of its Republic of Ireland franchisee, Denross Limited, and its Northern Ireland franchisee, Checkweight Limited, as follows: (a) The Company acquired the entire issued share capital of Denross Limited for a purchase price of $ 4,500 . Payment was in the form of cash paid on December 21, 2021 ($ 650 ), cash paid on February 18, 2022 ($ 3,100 ) and cash in reserves ($ 750 ) , of which $ 375 was paid on February 17, 2023 and $ 375 was paid on February 20, 2024 . The total purchase price was allocated to goodwill ($ 4,645 ), deferred tax asset ($ 496 ) fully offset by a tax valuation allowance ($ 496 ), assumed liabilities ($ 166 ), customer relationship value ($ 14 ), cash ($ 4 ) and other receivables ($ 3 ). The goodwill will not be deductible for tax purposes; and (b) The Company acquired the entire issued share capital of Checkweight Limited for a purchase price of $ 1,500 . Payment was in the form of cash ($ 1,250 ) and cash in reserves ($ 250 ) , of which $ 125 was paid on February 17, 2023 and $ 125 was paid on February 20, 2024 . The total purchase price was allocated to goodwill ($ 1,291 ), franchise rights acquired ($ 240 ), assumed liabilities ($ 56 ), customer relationship value ($ 17 ), deferred tax asset ($ 5 ) fully offset by a tax valuation allowance ($ 5 ), cash ($ 4 ) and other receivables ($ 4 ). The goodwill will not be deductible for tax purposes. These acquisitions have been accounted for under the purchase method of accounting and, accordingly, earnings of the acquired franchises have been included in the consolidated operating results of the Company since the date of acquisition. The goodwill and franchise rights acquired for these acquisitions, as applicable, have been subsequently impaired since the date of acquisition. See Note 7 for additional information on the Company’s impairment charges.

Franchise Rights Acquired, Good

Franchise Rights Acquired, Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 28, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Franchise Rights Acquired, Goodwill and Other Intangible Assets	7. Franchise Rights Acquired, Goodwill and Other Intangible Assets Franchise rights acquired are due to acquisitions of the Company’s franchised territories as well as the acquisition of franchise promotion agreements and other factors associated with the acquired franchise territories. For the fiscal year ended December 28, 2024, the change in the carrying value of franchise rights acquired was due to the impairments of the United States, Australia, United Kingdom and New Zealand units of account as discussed below and the effect of exchange rate changes. Goodwill primarily relates to the acquisition of the Company by The Kraft Heinz Company (successor to H.J. Heinz Company) in 1978, and the Compa ny’s acquisitions of WW.com, LLC (formerly known as WW.com, Inc. and WeightWatchers.com, Inc.) in 2005, Sequence in 2023 and the Company’s franchised territories. See Note 6 for additional information on the Company’s acquisitions. For the fiscal year ended December 28, 2024, the change in the carrying value of goodwill was due to the effect of exchange rate changes as follows: Balance as of December 31, 2022 $ 155,998 Goodwill acquired during the period 89,742 Goodwill impairment ( 3,586 ) Effect of exchange rate changes 1,287 Balance as of December 30, 2023 $ 243,441 Effect of exchange rate changes ( 3,858 ) Balance as of December 28, 2024 $ 239,583 Accumulated goodwill impairment loss was $ 25,111 at both December 28, 2024 and December 30, 2023. Change in Goodwill Reporting Units As discussed in Note 1, effective the first day of fiscal 2024 (i.e., December 31, 2023), as a result of the continued evolution of the Company’s centralized organizational structure in fiscal 2023, and management’s 2024 strategic planning process, the Company’s reportable segments changed to one segment for the purpose of making operational and resource decisions and assessing financial performance. In connection with the Company’s change to one reportable segment, the Company’s operating segments also changed to one segment. As a result of this change to the Company’s operating segments, the Company reassessed its reporting units for the evaluation of goodwill during the first quarter of fiscal 2024. In accordance with the Financial Accounting Standards Board’s Accounting Standards Codification 350, Intangibles—Goodwill and Other (“ASC 350”), the Company determines its reporting units based upon whether discrete financial information is available, if management regularly reviews the operating results of the component, the nature of the products offered to customers and the market characteristics of each reporting unit. A reporting unit is considered to be an operating segment or one level below an operating segment also known as a component. Prior to the change in operating segments, the Company’s reporting units for the evaluation of goodwill were determined by country. Component level financial information is reviewed by management across two business lines: Behavioral and Clinical. The Company’s “Behavioral” business line consists of the Company’s Workshops + Digital business and Digital business. Accordingly, these were determined to be the Company's new reporting units as of the first day of fiscal 2024. This change in reporting units qualified as a triggering event and required goodwill to be tested for impairment. As required by ASC 350, the Company tested goodwill for impairment immediately before and after the change in reporting units. As a result of these impairment analyses, it was determined that goodwill was not impaired before or after the change in reporting units. Third Quarter Fiscal 2024 Indefinite-Lived Franchise Rights Acquired and Goodwill Interim Impairment Tests During the quarter ended September 28, 2024, the Company identified various qualitative and quantitative factors which collectively indicated a triggering event had occurred. These factors included the continued decline in the Company’s stock price and market capitalization, and actual business performance. As a result of this triggering event, the Company performed interim impairment tests for all of its franchise rights acquired units of account and goodwill reporting units in the third quarter of fiscal 2024. In performing the interim franchise rights acquired impairment test as of September 28, 2024, the Company determined that the carrying values of its United States and United Kingdom franchise rights acquired with indefinite-lived units of account exceeded their respective fair values. Accordingly, the Company recorded impairment charges for its United States and United Kingdom units of account of $ 54,295 and $ 2,750 (which comprised the remaining balance of franchise rights acquired for the United Kingdom unit of account), respectively, in the third quarter of fiscal 2024. These impairments were driven primarily by the weighted average cost of capital used in this interim impairment test, reflecting market factors, including higher interest rates and the trading values of the Company’s equity and debt, and, to a lesser extent, business performance. In performing the interim goodwill impairment test as of September 28, 2024 , the Company determined that the carrying values of its goodwill reporting units did not exceed their respective fair values and, therefore, no impairment existed. Based on the results of the interim franchise rights acquired impairment test as of September 28, 2024 performed for the Company’s United States unit of account, which held 100.0 % of the Company’s indefinite-lived franchise rights acquired as of the December 28, 2024 balance sheet date, the estimated fair value of this unit of account was equal to its respective carrying value. Accordingly, a change in the underlying assumptions for the United States unit of account may change the results of the impairment assessment and, as such, could result in further impairment of the franchise rights acquired related to the United States, for which the net book value was $ 68,627 as of December 28, 2024. Based on the results of the interim goodwill impairment test as of September 28, 2024 performed for the Company’s Behavioral re porting unit, which held 62.5 % of the Company’s goodwill as of the December 28, 2024 balance sheet date, there was significant headroom in the goodwill impairment test for this unit with the difference between the fair value and the carrying value exceeding 100 % and, therefore, no impairment existed. Based on the results of the interim goodwill impairment test as of September 28, 2024 performed for the Company’s Clinical reporting unit, which held 37.5 % of the Company’s goodwill as of the December 28, 2024 balance sheet date, the estimated fair value of this reporting unit was at least 20 % higher than the respective unit's carrying value and, therefore, no impairment existed. Indefinite-Lived Franchise Rights Acquired and Goodwill Annual Impairment Tests The Company performed its annual fair value impairment testing on its indefinite-lived franchise rights acquired and goodwill for fiscal 2024, fiscal 2023 and fiscal 2022 on May 5, 2024, May 7, 2023 and May 8, 2022, respectively. In performing the annual impairment analyses as of May 5, 2024 and May 7, 2023, the Company determined that the carrying values of its franchise rights acquired with indefinite-lived units of account and goodwill reporting units did not exceed their respective fair values and, therefore, no impairment existed. In performing the annual impairment analysis as of May 8, 2022, the Company determined that (i) the carrying values of its Canada and New Zealand franchise rights acquired with indefinite-lived units of account exceeded their respective fair values and, as a result, the Company recorded impairment charges for its Canada and New Zealand units of account of $ 24,485 and $ 834 , respectively, in the second quarter of fiscal 2022; and (ii) the carrying values of all of its other franchise rights acquired with indefinite-lived units of account did not exceed their respective fair values and, therefore, no impairment existed with respect thereto. In performing the annual impairment analysis as of May 8, 2022, the Company determined that the carrying values of its goodwill reporting units did not exceed their respective fair values and, therefore, no impairment existed. Based on the results of the Company’s May 5, 2024 annual franchise rights acquired impairment test performed for its United States and United Kingdom units of account, each unit of account had an estimated fair value at least 5 % higher than the respective unit's carrying value and, therefore, no impairment existed. Based on the results of the Company’s May 5, 2024 annual goodwill impairment test performed for all of its reporting units, each unit had an estimated fair value at least 30 % higher than the respective unit’s carrying value and, therefore, no impairment existed. First Quarter Fiscal 2024 Indefinite-Lived Franchise Rights Acquired and Goodwill Interim Impairment Tests During the quarter ended March 30, 2024, the Company identified various qualitative and quantitative factors which collectively indicated a triggering event had occurred. These factors included the continued decline in the Company’s stock price and market capitalization, and actual business performance. As a result of this triggering event, the Company performed interim impairment tests for all of its franchise rights acquired units of account and goodwill reporting units in the first quarter of fiscal 2024. In performing the interim franchise rights acquired impairment test as of March 30, 2024, the Company determined that the carrying values of its United States, Australia, New Zealand and United Kingdom franchise rights acquired with indefinite-lived units of account exceeded their respective fair values. Accordingly, the Company recorded impairment charges for its United States, Australia, New Zealand and United Kingdom units of account of $ 251,431 , $ 4,074 (which comprised the remaining balance of franchise rights acquired for the Australia unit of account), $ 2,328 (which comprised the remaining balance of franchise rights acquired for the New Zealand unit of account) and $ 155 , respectively, in the first quarter of fiscal 2024. These impairments were driven primarily by the weighted average cost of capital used in this interim impairment test, reflecting market factors, including higher interest rates and the trading values of the Company’s equity and debt, and, to a lesser extent, business performance. Based on the results of the interim goodwill impairment test as of March 30, 2024 performed for all of the Company’s reporting units, each unit had an estimated fair value at least 25 % higher than the respective unit’s carrying value and, therefore, no impairment existed. Republic of Ireland and Northern Ireland Goodwill Impairments During the fourth quarter of fiscal 2023, the Company had a shift in future strategic priorities and as a result, a triggering event occurred which required the Company to impair the remaining goodwill balances for the Republic of Ireland and Northern Ireland reporting units, resulting in goodwill impairment charges of $ 2,383 and $ 1,203 , respectively. With respect to its Republic of Ireland reporting unit, during the fourth quarter of fiscal 2022, the Company made a strategic decision to delay the launch of the Digital business in that country. As a result of this decision, a triggering event occurred which required the Company to perform an interim goodwill impairment analysis. In performing its discounted cash flow analysis, the Company determined that the carrying value of this reporting unit exceeded its fair value and, as a result, recorded an impairment charge of $ 2,023 . The preponderance of this impairment was driven by a decrease in projected revenues and an increased weighted average cost of capital used in this interim impairment test as compared to the weighted average cost of capital used in the May 8, 2022 annual impairment test of its goodwill, reflecting market factors including higher interest rates and the trading values of the Company's equity and debt. Fourth Quarter Fiscal 2022 Indefinite-Lived Franchise Rights Acquired Interim Impairment Test During the quarter ended December 31, 2022, the Company identified various qualitative and quantitative factors which collectively indicated a triggering event had occurred. These factors included (i) actual business performance as compared to the assumptions used in its third quarter fiscal 2022 interim impairment test for the United States, Canada and New Zealand units of account and as compared to the assumptions used in its annual impairment test in the second quarter of fiscal 2022 for the United Kingdom and Australia units of account; and (ii) the further decline in the Company’s market capitalization and market factors, including the increase in interest rates. As a result of this triggering event, the Company performed an interim impairment test for all of its franchise rights acquired units of account in the fourth quarter of fiscal 2022. In performing the interim franchise rights acquired impairment test as of December 31, 2022, the Company determined that the carrying values of its United States, Canada, United Kingdom and Australia franchise rights acquired with indefinite-lived units of account exceeded their respective fair values. Accordingly, the Company recorded impairment charges for its United States, Canada, United Kingdom and Australia units of account of $ 25,739 , $ 19,657 (which comprised the remaining balance of franchise rights acquired for this unit of account), $ 8,275 and $ 1,872 , respectively, in the fourth quarter of fiscal 2022. These impairments were driven by the increased weighted average cost of capital used in this interim impairment test as compared to the weighted average cost of capital used in the third quarter fiscal 2022 interim impairment test for the United States and Canada units of account and as compared the weighted average cost of capital used in the May 8, 2022 annual impairment test for the United Kingdom and Australia units of account, reflecting market factors including higher interest rates and the trading values of the Company's equity and debt. Additionally, these impairments were driven by the decline in the assumptions used in the hypothetical start-up approach and relief from royalty approach analyses as compared to the assumptions used in the third quarter fiscal 2022 interim impairment test for the United States and Canada units of account and as compared the assumptions used in the May 8, 2022 annual impairment test for the United Kingdom and Australia units of account. The carrying value of its New Zealand franchise rights acquired with indefinite-lived unit of account did not exceed its respective fair value and, therefore, no impairment existed with respect thereto. Third Quarter Fiscal 2022 Indefinite-Lived Franchise Rights Acquired Interim Impairment Test During the quarter ended October 1, 2022, the Company identified various qualitative and quantitative factors which collectively, when combined with the difference or lack thereof between the estimated fair value of the applicable unit of account and its carrying value for the United States, Canada and New Zealand units of account, indicated a triggering event had occurred within these units of account. These factors included actual business performance as compared to the assumptions used in its annual impairment test, the continued decline in the Company’s market capitalization and market factors, including the increase in interest rates. As a result of this triggering event, the Company performed an interim impairment test of these units of account. In performing the interim franchise rights acquired impairment test as of October 1, 2022, the Company determined that the carrying values of its United States, Canada and New Zealand franchise rights acquired with indefinite-lived units of account exceeded their respective fair values. Accordingly, the Company recorded impairment charges for its United States, Canada and New Zealand units of account of $ 298,291 , $ 13,312 and $ 1,138 , respectively, in the third quarter of fiscal 2022. The preponderance of these impairments was driven by the increased weighted average cost of capital used in this interim impairment test as compared to the weighted average cost of capital used in the May 8, 2022 annual impairment test of its indefinite-lived franchise rights acquired, reflecting market factors including higher interest rates and the trading values of the Company's equity and debt. Kurbo Goodwill Impairment On August 10, 2018, the Company acquired substantially all of the assets of Kurbo Health, Inc., a family-based healthy lifestyle coaching program, for a net purchase price of $ 3,063 , of which $ 1,101 was allocated to goodwill. The goodwill was deductible annually for tax purposes. The Company determined in the second quarter of fiscal 2022 to exit the business of its wholly-owned subsidiary Kurbo, Inc. (“Kurbo”) in the third quarter of fiscal 2022 as part of its strategic plan. As a result of this determination, the Company recorded an impairment charge of $ 1,101 in the second quarter of fiscal 2022, which comprised the entire goodwill balance for Kurbo. Finite-lived Intangible Assets The carrying values of finite-lived intangible assets as of December 28, 2024 and December 30, 2023 were as follows: December 28, 2024 December 30, 2023 Gross Gross Carrying Accumulated Carrying Accumulated Amount Amortization Amount Amortization Capitalized software and website development costs $ 255,822 $ 218,103 $ 251,410 $ 195,696 Trademarks 12,192 12,103 12,188 12,024 Other 13,537 6,714 13,991 6,661 Trademarks and other intangible assets $ 281,551 $ 236,920 $ 277,589 $ 214,381 Franchise rights acquired 7,820 5,316 8,029 5,314 Total finite-lived intangible assets $ 289,371 $ 242,236 $ 285,618 $ 219,695 During the fourth quarter of fiscal 2023, the Company had a shift in future strategic priorities and as a result, a triggering event occurred which required the Company to impair the remaining franchise rights acquired balance for the Northern Ireland unit of account, resulting in a franchise rights acquired impairment charge of $ 47 . Aggregate amortization expense for finite-lived intangible assets was recorded in the amounts of $ 33,596 , $ 42,449 and $ 33,676 for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022, respectively. Estimated amortization expense of existing finite-lived intangible assets for the next five fiscal years and thereafter is as follows: Fiscal 2025 $ 22,025 Fiscal 2026 $ 13,143 Fiscal 2027 $ 4,776 Fiscal 2028 $ 727 Fiscal 2029 $ 704 Thereafter $ 5,760

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 28, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment	8. Property and Equipment The carrying values of property and equipment as of December 28, 2024 and December 30, 2023 were as follows: December 28, 2024 December 30, 2023 Equipment $ 24,561 $ 31,264 Leasehold improvements 40,802 42,039 $ 65,363 $ 73,303 Less: Accumulated depreciation and amortization ( 49,565 ) ( 53,562 ) $ 15,798 $ 19,741 Depreciation and amortization expense of property and equipment for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 was $ 4,188 , $ 10,022 and $ 10,125 , respectively.

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 28, 2024
Debt Disclosure [Abstract]
Long-Term Debt	9. Long-Term Debt The components of the Company’s long-term debt were as follows: December 28, 2024 December 30, 2023 Principal Unamortized Unamortized Effective (1) Principal Unamortized Unamortized Effective (1) Revolving Credit Facility due $ — $ — $ — 0.00 % $ — $ — $ — 0.00 % Term Loan Facility due 945,000 3,604 7,468 9.37 % 945,000 4,712 9,766 9.21 % Senior Secured Notes due 500,000 3,285 — 4.69 % 500,000 4,058 — 4.70 % Total $ 1,445,000 $ 6,889 $ 7,468 7.74 % $ 1,445,000 $ 8,770 $ 9,766 7.64 % Less: Current portion — — Unamortized deferred 6,889 8,770 Unamortized debt discount 7,468 9,766 Total long-term debt $ 1,430,643 $ 1,426,464 (1) Includes amortization of deferred financing costs and debt discount. In the second quarter of fiscal 2021, in connection with its refinancing of its then-existing credit facilities, the Company incurred approximately $ 1,000,000 in an aggregate principal amount of borrowings under its new credit facilities (as amended from time to time, the “Credit Facilities”) and issued $ 500,000 in aggregate principal amount of 4.500 % Senior Secured Notes due 2029 (the “Senior Secured Notes”), each as described in further detail below. Credit Facilities The Credit Facilities were issued under a credit agreement, dated April 13, 2021 (as amended from time to time, the “Credit Agreement”), among the Company, as borrower, the lenders party thereto, and Bank of America, N.A. (“Bank of America”), as administrative agent and an issuing bank. The Credit Facilities consist of (1) $ 1,000,000 in aggregate principal amount of senior secured tranche B term loans due in 2028 (the “Term Loan Facility”) and (2) $ 175,000 in an aggregate principal amount of commitments under a senior secured revolving credit facility (which includes borrowing capacity available for letters of credit) due in 2026 (the “Revolving Credit Facility”). As of December 28, 2024, the Company had $ 945,000 in an aggregate principal amount of loans outstanding under the Credit Facilities, w ith $ 173,841 of availability and $ 1,159 in iss ued but undrawn letters of credit outstanding under the Revolving Credit Facility subject to its terms and conditions as discussed below. There were no outsta nding borrowings under the Revolving Credit Facility as of December 28, 2024. All obligations under the Credit Agreement are guaranteed by, subject to certain exceptions, each of the Company’s current and future wholly-owned material domestic restricted subsidiaries. All obligations under the Credit Agreement, and the guarantees of those obligations, are secured by substantially all of the assets of the Company and each guarantor, subject to customary exceptions, including: • a pledge of 100 % of the equity interests directly held by the Company and each guarantor in any wholly-owned material subsidiary of the Company or any guarantor (which pledge, in the case of any non-U.S. subsidiary of a U.S. subsidiary, will not include more than 65 % of the voting stock of such first-tier non-U.S. subsidiary), subject to certain exceptions; and • a security interest in substantially all other tangible and intangible assets of the Company and each guarantor, subject to certain exceptions. The Credit Facilities require the Company to prepay outstanding term loans, subject to certain exceptions, with: • 50 % (which percentage will be reduced to 25 % and 0 % if the Company attains certain first lien secured net leverage ratios) of the Company’s annual excess cash flow; • 100 % of the net cash proceeds of certain non-ordinary course asset sales by the Company and its restricted subsidiaries (including casualty and condemnation events, subject to de minimis thresholds), and subject to the right to reinvest 100 % of such proceeds, subject to certain qualifications; and • 100 % of the net proceeds of any issuance or incurrence of debt by the Company or any of its restricted subsidiaries, other than certain debt permitted under the Credit Agreement. The foregoing mandatory prepayments will be used to reduce the installments of principal on the Term Loan Facility. The Company may voluntarily repay outstanding loans under the Credit Facilities at any time without penalty, except for customary “breakage” costs with respect to Term SOFR loans under the Credit Facilities. In June 2023, in connection with the planned phase-out of LIBOR, the Company amended its Credit Facilities to replace LIBOR with Term SOFR as the benchmark rate under the Credit Agreement, which is calculated to include a credit spread adjustment of 0.11448 %, 0.26161 %, 0.42826 %, or 0.71513 % for 1, 3, 6, or 12 months period, respectively, in addition to the Term SOFR Screen Rate (as defined in the Credit Agreement) and the margin (which was not amended). Borrowings under the Term Loan Facility bear interest at a rate per annum equal to, at the Company’s option, either (1) an applicable margin plus a base rate determined by reference to the highest of (a) 0.50 % per annum plus the Federal Funds Effective Rate as determined by the Federal Reserve Bank of New York, (b) the prime rate of Bank of America and (c) the Term SOFR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month adjusted for certain additional costs, plus 1.00 %; provided that such rate is not lower than a floor of 1.50 % or (2) an applicable margin plus a Term SOFR rate determined by reference to the cost of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs, provided that Term SOFR is not lower than a floor of 0.50 %. Borrowings under the Revolving Credit Facility bear interest at a rate per annum equal to an applicable margin based upon a leverage-based pricing grid, plus, at the Company’s option, either (1) a base rate determined by reference to the highest of (a) 0.50 % per annum plus the Federal Funds Effective Rate as determined by the Federal Reserve Bank of New York, (b) the prime rate of Bank of America and (c) the Term SOFR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month adjusted for certain additional costs, plus 1.00 %; provided that such rate is not lower than a floor of 1.00 % or (2) a Term SOFR rate determined by reference to the cost of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs, provided such rate is not lower than a floor of zero . As of December 28, 2024, the applicable margins for the Term SOFR rate borrowings under the Term Loan Facility and the Revolving Credit Facility were 3.50 % and 2.75 %, resp ectively. On a quarterly basis, the Company pays a commitment fee to the lenders under the Revolving Credit Facility in respect of unutilized commitments thereunder, which commitment fee fluctuates depending upon the Company’s Consolidated First Lien Leverage Ratio (as defined in the Credit Agreement). The Credit Agreement contains other customary terms, including (1) representations, warranties and affirmative covenants, (2) negative covenants, including limitations on indebtedness, liens, mergers, acquisitions, asset sales, investments, distributions, prepayments of subordinated debt, amendments of material agreements governing subordinated indebtedness, changes to lines of business and transactions with affiliates, in each case subject to baskets, thresholds and other exceptions, and (3) customary events of default. The availability of certain baskets and the ability to enter into certain transactions are also subject to compliance with certain financial ratios. In addition, if the aggregate principal amount of extensions of credit (inclusive of outstanding letters of credit) under the Revolving Credit Facility as of any fiscal quarter end exceeds 35 %, or $ 61,250 , of the aggregate revolving commitments, the Company is required to be in compliance with a Con solidated First Lien Leverage Ratio of 5.25 :1.00 through and including the first fiscal quarter of 2025 and 5.00 :1.00 thereafter. The Company’s Consolidated First Lien Leverage Ratio as of December 28, 2024 was 8.36 :1.00. If the Company has more than $ 61,250 outstanding under the Revolving Credit Facility and is not in compliance with the specified leverage ratio at the required time, it would be in default under the Revolving Credit Facility. Senior Secured Notes The Senior Secured Notes were issued pursuant to an Indenture, dated as of April 13, 2021 (as amended, supplemented or modified from time to time, the “Indenture”), among the Company, the guarantors named therein and The Bank of New York Mellon, as trustee and notes collateral agent. The Indenture contains customary terms, events of default and covenants for an issuer of non-investment grade debt securities. These covenants include limitations on indebtedness, liens, mergers, acquisitions, asset sales, investments, distributions, prepayments of subordinated debt and transactions with affiliates, in each case subject to baskets, thresholds and other exceptions. The Senior Secured Notes accrue interest at a rate per annum equal to 4.500 % and will mature on April 15, 2 029 . Interest on the Senior Secured Notes is payable semi-annually on April 15 and October 15 of each year. Commencing April 15, 2024 , the Company may on any one or more occasions redeem some or all of the Senior Secured Notes at a purchase price equal to 102.250 % of the principal amount of the Senior Secured Notes, plus accrued and unpaid interest, if any, to, but not including, the redemption date, such optional redemption price decreasing to 101.125 % on or after April 15, 2025 and to 100.000 % on or after April 15, 2026 . If a change of control occurs, the Company must offer to purchase for cash the Senior Secured Notes at a purchase price equal to 101 % of the principal amount of the Senior Secured Notes, plus accrued and unpaid interest, if any, to, but not including, the purchase date. Following the sale of certain assets and subject to certain conditions, the Company must offer to purchase for cash the Senior Secured Notes at a purchase price equal to 100 % of the principal amount of the Senior Secured Notes, plus accrued and unpaid interest, if any, to, but not including, the purchase date. The Senior Secured Notes are guaranteed on a senior secured basis by the Company’s subsidiaries that guarantee the Credit Facilities. The Senior Secured Notes and the note guarantees are secured by a first-priority lien on all the collateral that secures the Credit Facilities, subject to a shared lien of equal priority with the Company’s and each guarantor’s obligations under the Credit Facilities and subject to certain thresholds, exceptions and permitted liens. Outstanding Debt At December 28, 2024, the Company had $ 1,445,000 outstanding under the Credit Facilities and the Senior Secured Notes, consisting of borrowings under the Term Loan Facility of $ 945,000 , $ 0 drawn down on the Revolving Credit Facility and $ 500,000 in aggregate principal amount of Senior Secured Notes issued and outstanding. At December 28, 2024 and December 30, 2023, the Company’s debt consisted of both fixed and variable-rate instruments. The Company has historically entered into interest rate swaps to hedge a portion of the cash flow exposure associated with the Company’s variable-rate borrowings. At December 28, 2024, the Company did not have any interest rate swaps in effect. See Note 19 for further information on the Company’s use of interest rate swaps. The weighted average interest rate (which includes amortization of deferred financing costs and debt discount) on the Company’s outstanding debt, exclusive of the impact of any applicable interest rate swaps, was approxim ately 7.75 % and 7.64 % per annum at December 28, 2024 and December 30, 2023 , respectively, based on interest rates on these dates. The weighted average interest rate (which includes amortization of deferred financing costs and debt discount) on the Company’s outstanding debt, including the impact of any applicable interest rate swaps, was approximately 7.47 % and 6.53 % per annum at December 28, 2024 and December 30, 2023, respectively, based on interest rates on these dates. Maturities At December 28, 2024, the aggregate amounts of the Company’s existing long-term debt maturing in each of the next five fiscal years and thereafter are as follows: Fiscal 2025 — Fiscal 2026 — Fiscal 2027 10,000 Fiscal 2028 935,000 Fiscal 2029 500,000 Thereafter — $ 1,445,000

Treasury Stock

Treasury Stock	12 Months Ended
	Dec. 28, 2024
Class of Stock Disclosures [Abstract]
Treasury Stock	10. Treasury Stock On October 9, 2003, the Company’s Board of Directors authorized, and the Company announced, a program to repurchase up to $ 250,000 of the Company’s outstanding common stock. On each of June 13, 2005, May 25, 2006 and October 21, 2010, the Company’s Board of Directors authorized, and the Company announced, the addition of $ 250,000 to the program. The repurchase program allows for shares to be purchased from time to time in the open market or through privately negotiated transactions. The repurchase program currently has no expiration date. During the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 , the Company repurchased no shares of its common stock under this program. As of the end of fiscal 2024, $ 208,933 remained available to purchase shares of the Company’s common stock under the repurchase program.

Per Share Data

Per Share Data	12 Months Ended
	Dec. 28, 2024
Earnings Per Share [Abstract]
Per Share Data	11. Per Share Data Basic net loss per share is calculated utilizing the weighted average number of common shares outstanding during the periods presented. Diluted net loss per share is calculated utilizing the weighted average number of common shares outstanding during the periods presented adjusted for the effect of dilutive common stock equivalents. The following table sets forth the computation of basic and dilut ed net loss per share: Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 Numerator: Net loss $ ( 345,701 ) $ ( 112,255 ) $ ( 256,868 ) Denominator: Weighted average shares of common stock outstanding 79,578 76,677 70,321 Effect of dilutive common stock equivalents — — — Weighted average diluted common shares outstanding 79,578 76,677 70,321 Net loss per share Basic $ ( 4.34 ) $ ( 1.46 ) $ ( 3.65 ) Diluted $ ( 4.34 ) $ ( 1.46 ) $ ( 3.65 ) The number of anti-dilutive common stock equivalents excluded from the calculation of the weighted average number of common shares for diluted net loss per s hare was 9,572 , 9,113 and 8,540 for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 , respectively.

Stock Plans

Stock Plans	12 Months Ended
	Dec. 28, 2024
Share-Based Payment Arrangement [Abstract]
Stock Plans	12. Stock Plans Incentive Compensation Plans On May 6, 2008, the Company’s shareholders approved the 2008 Stock Incentive Plan (the “2008 Plan”). On May 6, 2014, the Company’s shareholders approved the 2014 Stock Incentive Plan (as amended and restated, the “2014 Plan”, and together with the 2008 Plan, the “Stock Plans”), which replaced the 2008 Plan for all equity-based awards granted on or after May 6, 2014. The 2014 Plan is designed to promote the long-term financial interests and growth of the Company by attracting, motivating and retaining employees with the ability to contribute to the success of the business and to align compensation for the Company’s employees over a multi-year period directly with the interests of the shareholders of the Company. The Company’s long-term equity incentive compensation program has historically included time-vesting non-qualified stock option and/or restricted stock unit (“RSUs”) (including performance-based stock unit with both time- and performance-vesting criteria (“PSUs”)) awards. From time to time, the Company has granted fully-vested shares of its common stock to individuals in connection with special circumstances. The Company’s Board of Directors or a committee thereof administers the 2014 Plan. Under the 2014 Plan, grants may take the following forms at the Company’s Board of Directors’ Compensation and Benefits Committee’s (the “Compensation Committee”) discretion: non-qualified stock options, incentive stock options, stock appreciation rights, RSUs, restricted stock and other stock-based awards. As of December 28, 2024, the maximum number of shares of common stock available for grant under the 2014 Plan was 12,500 , subj ect to increase and adjustment as set forth in the 2014 Plan. Under the 2014 Plan, the Company also grants fully-vested shares of its common stock to certain members of its Board of Directors. While these shares are fully vested, the directors are restricted from selling these shares while they are still serving on the Company’s Board of Directors subject to limited exceptions. During the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022, the Company granted to members of the Company’s Board of Directors an a ggregate of 53 , 70 and 77 fully-vested shares, respectively, and recognized compensation expense of $ 181 , $ 404 an d $ 624 , respectively. Commencing during the fiscal year ended December 31, 2022, the above-referenced members of the Company’s Board of Directors could elect to defer receipt of such grants of fully vested shares of the Company’s common stock with respect to their service on the Company’s Board of Directors. Certain members of the Company’s Board of Directors made such an election such that for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022, the Company granted to those members of its Board of Directors an aggregate of 89 , 54 and 27 deferred stock units, respectively, and recognized compensation expense of $ 809 , $ 373 and $ 174 , respect ively. These deferred stock units will be settled on the date of separation from service from the Company's Board of Directors of the applicable member of the Company’s Board of Directors or earlier based on his or her election or upon a change in control of the Company. During the fiscal years ended December 28, 2024 and December 30, 2023, an aggregate of 0 and 23 deferred stock units were settled, respectively. The Company issues common stock for share-based compensation awards from treasury stock. The total compensation cost that has been charged against income for share-based compensation awards was $ 7,583 , $ 10,715 and $ 12,333 for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022, respectively. The total income tax benefit recognized in the Company’s consolidated statements of operations for all share-based compensation awards was $ 1,197 , $ 1,850 and $ 2,603 for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 , respectively. The tax benefits realized from options exercised and RSUs and PSUs vested totaled $ 658 , $ 1,287 and $ 1,017 for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 , respectively. No compensation costs were capitalized. As of December 28, 2024 , there was $ 6,569 of total unrecognized compensation cost related to stock options and RSUs granted under the Stock Plans. That cost is expected to be recognized over a weighted average period of approximately 1.2 ye ars. Additionally, during the fiscal year ended December 30, 2023, the Company charged $ 3,882 of compensation costs against income for share-based compensation expense attributable to post combination vesting in relation to the Sequence acquisition. See Note 6 for additional information on the Company’s acquisitions. Such amounts have been included as a component of selling, general and administrative expenses. Stock Option Awards with Time-Vesting Criteria Stock options with time-vesting criteria (“Time-Vesting Options”) are exercisable based on the terms and conditions outlined in the applicable award agreement. Time-Vesting Options outstanding at December 28, 2024, December 30, 2023 and December 31, 2022 vest over a perio d of three to four years and the expiration term is seven to ten years . Time-Vesting Options outstanding at December 28, 2024, December 30, 2023 and December 31, 2022 have an exercise price between $ 5.25 and $ 50.00 per shar e. The fair value of each of these option awards is estimated on the date of grant using the Black-Scholes option pricing model with the weighted average assumptions noted in the following table. Expected volatility is based on the historical volatility of the Company’s common stock. The expected term takes into consideration option exercise history. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of grant which most closely corresponds to the expected term of the Time-Vesting Options. The dividend yield is based on the Company’s historic average dividend yield. The Company did not grant any Time-Vesting Options for the fiscal years ended December 28, 2024 and December 30, 2023. December 31, 2022 Dividend yield 0.0 % Volatility 57.0 % - 57.1 % Risk-free interest rate 2.36 % - 2.86 % Expected term (years) 6.0 - 7.0 Option Activity A summary of all option activity for the fiscal year ended December 28, 2024 is presented below. Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Shares Price Life (Yrs.) Value Outstanding at December 30, 2023 6,951 $ 34.57 Granted — $ — Exercised — $ — Cancelled ( 1,919 ) $ 38.40 Outstanding at December 28, 2024 5,032 $ 33.12 1.9 $ — Exercisable at December 28, 2024 5,002 $ 33.27 1.9 $ — T he weighted average grant date fair value of all options granted was $ 3.96 for the fiscal year ended December 31, 2022. The total intrinsic value of all options exercised was $ 0 , $ 248 and $ 0 for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022, respectively. Cash received from Time-Vesting Options exercised during the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 wa s $ 0 , $ 718 and $ 0 , respectively. Restricted Stock Unit Awards with Time-Vesting Criteria RSUs are exercisable based on the terms outlined in the applicable award agreement. The RSUs generally vest over a period of one to three ye ars . The fair value of RSUs is determined using the closing market price of the Company’s common stock on the date of grant. A summary of RSU activity under t he Stock Plans for the fiscal year ended December 28, 2024 is presented below. Weighted Average Grant Date Fair Shares Value Outstanding at December 30, 2023 2,657 $ 7.75 Granted 4,810 $ 1.32 Vested ( 1,318 ) $ 6.59 Forfeited ( 2,061 ) $ 4.76 Outstanding at December 28, 2024 4,088 $ 2.06 The weighted average grant date fair value of RSUs granted was $ 1.32 , $ 7.43 and $ 6.69 for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022, respectively. The total fair value of RSUs vested during the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 was $ 8,692 , $ 7,943 and $ 14,576 , respectively. Performance-Based Stock Unit Awards with Time- and Performance-Vesting Criteria In fiscal 2024, the Company granted 598 PSUs having both time- and performance-vesting criteria. The time-vesting criteria for these PSUs will be satisfied upon continued employment (with limited exceptions) on the third anniversary of the grant date. The performance-vesting criteria for these PSUs will be based on a relative total shareholder return performance goal, measuring the Company’s stock price performance against the performance of the Russell 2000 Index from the start of fiscal 2024 through the end of fiscal 2026. The Company estimated the fair value of the PSUs granted in fiscal 2024 to be $ 1.86 . The Company estimated this fair value using a Monte Carlo simulation that used various assumptions that included expected volatility of 97.8 %, a risk-free rate of 4.59 %, an expected term of 3.0 years and a dividend yield of 0.00 %. Expected volatility was based on the historical volatility of the Company’s stock. The risk-free interest rate was based on the U.S. Treasury yield curve in effect on the date of grant which most closely corresponds to the performance measurement period. The expected term represents the three-year performance measurement period. Compensation expense is recognized ratably over the three-year required service period. In fiscal 2023, the Company granted 239 PSUs having both time- and performance-vesting criteria. The time-vesting criteria for these PSUs will be satisfied upon continued employment (with limited exceptions) on the third anniversary of the grant date. The performance-vesting criteria for these PSUs will be based on a relative total shareholder return performance goal, measuring the Company’s stock price performance against the performance of the Russell 2000 Index from the start of fiscal 2023 through the end of fiscal 2025. The Company estimated the fair value of the PSUs granted in fiscal 2023 to be $ 13.80 . The Company estimated this fair value using a Monte Carlo simulation that used various assumptions that included expected volatility of 86.2 %, a risk-free rate of 3.79 %, an expected term of 3.0 years and a dividend yield of 0.00 %. Expected volatility was based on the historical volatility of the Company’s stock. The risk-free interest rate was based on the U.S. Treasury yield curve in effect on the date of grant which most closely corresponds to the performance measurement period. The expected term represents the three-year performance measurement period. Compensation expense is recognized ratably over the three-year required service period. In fiscal 2019, the Company granted 280 PSUs having both time- and performance-vesting criteria. The time-vesting criteria for these PSUs was satisfied upon continued employment (with limited exceptions) on the third anniversary of the grant date. The performance-vesting criteria for these PSUs was not satisfied and 0 PSUs became vested in fiscal 2022 upon the satisfaction of the time-vesting criteria. The Company accrued compensation expense in an amount equal to the outcome upon vesting. A summary of PSU activity for the fiscal year ended December 28, 2024 is presented below. Weighted Average Grant Date Fair Shares Value Outstanding at December 30, 2023 215 $ 13.80 Granted 598 $ 1.86 Vested — $ — Forfeited ( 655 ) $ 5.78 Outstanding at December 28, 2024 158 $ 1.86 The weighted average grant date fair value of PSUs granted was $ 1.86 and $ 13.80 during the fiscal years ended December 28, 2024 and December 30, 2023, respectively. There were no PSUs vested during the fiscal years ended December 28, 2024 and December 30, 2023. There were no PSUs granted or vested during the fiscal year ended December 31, 2022.

Taxes

Taxes	12 Months Ended
	Dec. 28, 2024
Income Tax Disclosure [Abstract]
Taxes	13. Taxes Income Taxes The components of the Company’s consolidated loss before income taxes consist of the following: Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 Domestic $ ( 358,108 ) $ ( 222,260 ) $ ( 376,710 ) Foreign 12,933 148,628 9,907 $ ( 345,175 ) $ ( 73,632 ) $ ( 366,803 ) The following table summarizes the Company’s consolidated provision for (benefit from) U.S. federal, state and foreign income taxes: Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 Current: U.S. federal $ 6,369 $ 1,330 $ 12,426 State 1,519 1,947 3,446 Foreign 19,216 15,525 20,022 $ 27,104 $ 18,802 $ 35,894 Deferred: U.S. federal $ ( 6,856 ) $ ( 12,419 ) $ ( 110,611 ) State ( 8,420 ) 4,263 ( 23,213 ) Foreign ( 11,302 ) 27,977 ( 12,005 ) $ ( 26,578 ) $ 19,821 $ ( 145,829 ) Total provision for (benefit from) income taxes $ 526 $ 38,623 $ ( 109,935 ) The effective tax rates for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 were ( 0.2 %) , ( 52.5 %) and 30.0 %, respectively. The Company’s effective tax rate for the fiscal year ended December 28, 2024 was impacted by the following items: (i) a $ 87,624 tax expense due to a valuation allowance and (ii) a $ 5,342 tax expense related to share-based awards. These expenses were partially offset by (i) a $ 15,689 tax benefit related to state tax and (ii) a $ 3,976 tax benefit related to foreign-derived intangible income (“FDII”). The Company’s effective tax rate for the fiscal year ended December 30, 2023 was impacted by the following items: (i) a $ 53,626 tax expense due to a valuation allowance and (ii) a $ 12,172 tax expense related to income earned in foreign jurisdictions at rates higher than the U.S. These expenses were partially offset by (i) a $ 9,441 tax benefit related to state tax and (ii) a $ 2,637 tax benefit related to FDII. The Company’s effective tax rate for the fiscal year ended December 31, 2022 was impacted by the following items: (i) a $ 45,748 tax benefit from a legal entity restructuring in connection with the Organizational Realignment (as defined below), which resulted in a reversal of certain deferred tax liabilities, and (ii) a $ 4,450 tax benefit related to FDII. These benefits were partially offset by (i) a $ 27,108 tax expense from a valuation allowance established to offset certain deferred tax assets due to the uncertainty of realizing future tax benefits from its interest expense carryforwards, (ii) a $ 2,245 tax expense related to income earned in foreign jurisdictions at rates higher than the U.S., and (iii) a $ 1,732 tax expense related to share-based awards. Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 U.S. federal statutory tax rate 21.0 % 21.0 % 21.0 % State income taxes (net of federal benefit) 4.6 % 12.8 % 3.8 % Research and development credit 0.4 % 3.0 % 0.4 % Tax windfall/shortfall on share-based awards ( 1.5 %) ( 0.9 %) ( 0.5 %) Tax rate changes 0.0 % ( 0.1 %) 0.3 % Executive compensation limitation ( 0.4 %) ( 1.4 %) ( 0.2 %) FDII 1.2 % 3.6 % 1.2 % Change in valuation allowance ( 25.4 %) ( 72.8 %) ( 7.1 %) Impact of foreign operations ( 0.3 %) ( 16.5 %) ( 1.6 %) Reversal of certain deferred tax liabilities 0.0 % 0.0 % 12.5 % Nondeductible costs 0.0 % ( 1.3 %) 0.0 % Other 0.2 % 0.1 % 0.2 % Total effective tax rate ( 0.2 %) ( 52.5 %) 30.0 % The deferred tax assets and liabilities recorded on the Company’s consolidated balance sheets are as follows: December 28, 2024 December 30, 2023 Interest expense disallowance $ 101,563 $ 76,350 Operating lease liabilities 13,672 16,174 Operating loss carryforwards 11,703 12,446 Provision for estimated expenses 2,916 3,657 Salaries and wages 8,904 13,489 Share-based compensation 9,553 14,920 Other comprehensive income 6,995 3,833 Capitalized research and development expenses 34,767 — Other 12,045 4,287 Less: valuation allowance ( 178,451 ) ( 89,801 ) Total deferred tax assets $ 23,667 $ 55,355 Goodwill and intangible assets $ ( 663 ) $ ( 47,323 ) Operating lease assets ( 10,941 ) ( 13,285 ) Depreciation ( 9,000 ) ( 12,749 ) Termination fee — ( 3,408 ) Prepaid expenses ( 1,289 ) ( 900 ) Total deferred tax liabilities $ ( 21,893 ) $ ( 77,665 ) Net deferred tax assets (liabilities) $ 1,774 $ ( 22,310 ) As of December 28, 2024 and December 30, 2023 , the Company had primarily foreign and state net operating loss carryforwards of approximately $ 110,471 and $ 107,415 , respectively, some of which have an unlimited carryforward period, while others expire in various years beginning in fiscal 2025. The Company maintains a full valuation allowance on its state and certain foreign net operating loss carryforwards as it is deemed more likely than not that such losses will not be realized. In fiscal 2022, the Company established a $ 27,108 valuation allowance on its business interest expense carryforwards. In fiscal 2023, the Company increased the valuation allowance on its business interest expense carryforwards by $ 20,268 and established a $ 30,331 valuation allowance on its remaining U.S. deferred tax assets. As of December 28, 2024, the Company recorded an additional $ 88,650 valuation allowance on its U.S. deferred tax assets . The Company does not assert its $ 114,545 of undistributed foreign earnings as of December 28, 2024 are permanently reinvested. The Company has considered whether there would be any potential future costs of not asserting indefinite reinvestment and does not expect such costs to be significant. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 Balance at beginning of year $ 613 $ 611 $ 1,055 Increases related to tax positions taken in current year — — 145 Increases related to tax positions taken in prior years — 9 8 Reductions related to tax positions taken in prior years — ( 9 ) ( 95 ) Reductions related to settlements with tax authorities — — ( 273 ) Reductions related to lapse of statutes of limitations ( 99 ) — ( 206 ) Effects of foreign currency translation ( 6 ) 2 ( 23 ) Balance at end of year $ 508 $ 613 $ 611 At December 28, 2024 , the total amount of unrecognized tax benefits that, if recognized, would affect the Company’s effective tax rate is $ 424 . The Company files income tax returns in the U.S. federal jurisdiction, and various state and foreign jurisdictions. At December 28, 2024, with few exceptions, the Company was no longer subject to U.S. federal, state or local income tax examinations by tax authorities for fiscal years prior to fiscal 2020, or non-U.S. income tax examinations by tax authorities for fiscal years prior to fiscal 2017. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. The Company had $ 33 and $ 83 of accrued interest and penalties at December 28, 2024 and December 30, 2023 , respectively. The Company recognized $( 50 ), $ 0 and $( 60 ) of income tax expense in interest and penalties during the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 , respectively. It is reasonably possible that within the next twelve months the Company’s unrecognized tax benefits could change due to the resolution of open tax matters, which would reduce unrecognized tax benefits by $ 120 . Non-Income Tax Matters The Internal Revenue Service (the “IRS”) notified the Company of certain penalties assessed related to the annual disclosure and reporting requirements of the Affordable Care Act. The Company appealed this determination, and in the third quarter of fiscal 2024, the penalties were fully abated and the federal tax lien maintained by the IRS during the appeals process was lifted.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 28, 2024
Retirement Benefits [Abstract]
Employee Benefit Plans	14. Employee Benefit Plans The Company sponsors the WW Savings Plan (the “Savings Plan”) for salaried and certain hourly U.S. employees of the Company. The Savings Plan is a defined contribution plan that provides for employer matching contributions of 50 % of the employee’s tax deferred contributions up to 6 % of an employee’s eligible compensation for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022. Expense related to these contributions for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 was $ 2,462 , $ 3,227 and $ 2,564 , respectively. The Company received a favorable determination letter from the IRS that qualifies the Savings Plan under Section 401(a) of the Internal Revenue Code. Pursuant to the Savings Plan, the Company also made profit sharing contributions for all full-time salaried U.S. employees who were eligible to participate in the Savings Plan (except for certain personnel above a determined compensation level). The profit sharing contribution was a guaranteed monthly employer contribution on behalf of each participant based on the participant’s age and a percentage of the participant’s eligible compensation. The Savings Plan also had a discretionary supplemental profit sharing employer contribution component that was determined annually by the Compensation Committee. Effective as of March 6, 2022, the Company suspended profit sharing contributions. Expense related to these contributions for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 was $ 0 , $ 0 and $ 179 , respectively. For certain U.S. personnel above a determined compensation level, the Company sponsors the Second Amended and Restated Weight Watchers Executive Profit Sharing Plan (“EPSP”). Under the IRS definition, the EPSP is considered a Nonqualified Deferred Compensation Plan. There is a promise of payment by the Company made on the employees’ behalf instead of an individual account with a cash balance. The EPSP provided for a guaranteed employer contribution on behalf of each participant based on the participant’s age and a percentage of the participant’s eligible compensation. The EPSP also had a discretionary supplemental employer contribution component that was determined annually by the Compensation Committee. Effective as of March 6, 2022, the Company suspended EPSP contributions. Although the Company suspended EPSP contributions, EPSP balances continue to accrue interest. The EPSP is valued at the end of each fiscal month, based on an annualized interest rate of prime plus 2 %, with an annualized cap of 15 %. Expense related to this commitment for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 was $ 631 , $ 1,005 and $ 929 , respectively.

Cash Flow Information

Cash Flow Information	12 Months Ended
	Dec. 28, 2024
Supplemental Cash Flow Elements [Abstract]
Cash Flow Information	15. Cash Flow Information Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 Net cash paid during the year for: Interest $ 96,844 $ 91,614 $ 76,216 Income taxes (1) $ 11,499 $ 30,908 $ 25,815 Noncash investing and financing activities were as follows: Fair value of net assets acquired in connection with acquisitions $ — $ 7,256 $ 240 Capital expenditures and capitalized software included in accounts payable and accrued expenses $ 75 $ 802 $ 1,466 Common stock issued in connection with acquisition of Sequence $ — $ 32,943 $ — (1) Fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 include tax refunds received of $ 15,421 , $ 7,054 and $ 5,109 , respectively. See Note 4 for disclosures on supplemental cash flow information related to leases. The following table presents the Company’s cash and cash equivalents and restricted cash by balance sheet location at December 28, 2024 and December 30, 2023: December 28, 2024 December 30, 2023 Cash and cash equivalents $ 53,024 $ 109,366 Restricted cash included in “Prepaid expenses and other current assets” 3,003 — Restricted cash included in “Other noncurrent assets” 493 — Total cash and cash equivalents and restricted cash $ 56,520 $ 109,366 The Company’s restricted cash as of December 28, 2024 consists solely of cash held in an escrow account in connection with a foreign entity’s restructuring payments.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 28, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Litigation Matters Due to the nature of the Company’s activities, it is, at times, subject to pending and threatened legal actions that arise out of the ordinary course of business. In the opinion of management, the disposition of any such matters is not expected, individually or in the aggregate, to have a material adverse effect on the Company’s results of operations, financial condition or cash flows. However, the results of legal actions cannot be predicted with certainty. Therefore, it is possible that the Company’s results of operations, financial condition or cash flows could be materially adversely affected in any particular period by the unfavorable resolution of one or more legal actions. Commitments Minimum commitments under non-cancelable purchase obligations at December 28, 2024 were $ 13,726 , of which $ 9,483 is due in fiscal 2025, $ 1,981 is due in fiscal 2026, $ 1,696 is due in fiscal 2027, and the remaining $ 566 is due in fiscal 2028. See Note 4 for di sclosures related to minimum commitments under lease obligations for the Company’s studios and corporate offices.

Segment and Geographic Data

Segment and Geographic Data	12 Months Ended
	Dec. 28, 2024
Segment Reporting [Abstract]
Segment and Geographic Data	17. Segment and Geographic Data As previously disclosed, effective the first day of fiscal 2024 (i.e., December 31, 2023), as a result of the continued evolution of the Company’s centralized organizational structure in fiscal 2023, and management’s 2024 strategic planning process, the Company’s reportable segments changed to one segment for the purpose of making operational and resource decisions and assessing financial performance. The Company operates as one operating segment. The Company's chief operating decision maker ( “CODM”) is its chief executive officer, who reviews financial information presented on a consolidated basis. The CODM uses consolidated operating income and net income to assess financial performance and allocate resources. Significant expenses within operating income, as well as within net income, include cost of revenues, marketing expenses, and selling, general and administrative expenses, which are each separately presented on the Company’s Consolidated Statements of Operations. Other segment items within net income include interest expense, other (income) expense, net, and provision for (benefit from) income taxes. The following tables present information about the Company’s revenue and other information by geographic area. There were no material amounts of sales or transfers among geographic areas and no material amounts of U.S. export sales. Revenues, net for the Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 United States $ 541,973 $ 604,441 $ 682,428 Germany 82,649 97,085 116,452 Other 161,299 188,025 240,955 $ 785,921 $ 889,551 $ 1,039,835 Long-Lived Assets (1) December 28, 2024 December 30, 2023 United States $ 15,037 $ 18,171 Germany 257 418 Other 504 1,152 $ 15,798 $ 19,741 (1) Amounts include finance lease assets Operating Lease Assets December 28, 2024 December 30, 2023 United States $ 39,939 $ 48,870 Germany 130 446 Other 1,978 2,956 $ 42,047 $ 52,272

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 28, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	18. Fair Value Measur ements Accounting guidance on fair value measurements for certain financial assets and liabilities requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. When measuring fair value, the Company is required to maximize the use of observable inputs and minimize the use of unobservable inputs. Fair Value of Financial Instruments The Company’s significant financial instruments include long-term debt agreements as of December 28, 2024 . The Company’s significant financial instruments included long-term debt and interest rate swap agreements as of December 30, 2023. Since there were no outstanding borrowings under the Revolving Credit Facility as of December 28, 2024 and December 30, 2023 , the fair value approximated a carrying value of $ 0 at both December 28, 2024 and December 30, 2023. The fair value of the Company’s Credit Facilities is determined by utilizing average bid prices on or near the end of each fiscal quarter (Level 2 input). As of December 28, 2024 and December 30, 2023, the fair value of the Company’s long-term debt was approximately $ 320,174 and $ 996,429 , respectively, as compared to the carrying value (net of deferred financing costs and debt discount) of $ 1,430,643 and $ 1,426,464 , respectively. Derivative Financial Instruments The fair values for the Company’s derivative financial instruments were determined using observable current market information such as the prevailing Term SOFR interest rate and Term SOFR yield curve rates and included consideration of counterparty credit risk. See Note 19 for disclosures related to the Company’s use of derivative financial instruments. The following table presents the aggregate fair value of the Company’s derivative financial instruments: Fair Value Measurements Using: Total Quoted Prices in Significant Other Significant Interest rate swaps current asset at December 28, 2024 $ — $ — $ — $ — Interest rate swaps current asset at December 30, 2023 $ 3,555 $ — $ 3,555 $ — The Company did no t have any transfers into or out of Levels 1 and 2 and did no t maintain any assets or liabilities classified as Level 3 during the fiscal years ended December 28, 2024 and December 30, 2023 .

Derivative Instruments and Hedg

Derivative Instruments and Hedging	12 Months Ended
	Dec. 28, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging	19. Derivative Instruments and Hedging In June 2023, the Company amended the terms of its then-effective interest rate swap agreements to implement a forward-looking interest rate based on Term SOFR in place of LIBOR. Since the interest rate swap agreements were affected by reference rate reform, the Company applied the expedients and exceptions provided to preserve the past presentation of its derivatives without de-designating the existing hedging relationships. All amendments to interest rate swap agreements were executed with the existing counterparties and did not change the notional amounts, maturity dates, or other critical terms of the hedging relationships. As of December 28, 2024, due to the termination of the interest rate swaps on March 31, 2024 as discussed below, the Company did no t have any interest rate swaps in effect. As of December 30, 2023 , the Company had in effect interest rate swaps with an aggregate notional amount totaling $ 500,000 . On June 11, 2018, in order to hedge a portion of its variable rate debt, the Company entered into a forward-starting interest rate swap (the “2018 swap”) with an effective date of April 2, 2020 and a termination date of March 31, 2024 . The initial notional amount of this swap was $ 500,000 . During the term of this swap, the notional amount decreased from $ 500,000 effective April 2, 2020 to $ 250,000 on March 31, 2021 . Following the transition from LIBOR to Term SOFR, this interest rate swap effectively fixed the variable interest rate on the notional amount of this swap at 3.1513 %. On June 7, 2019, in order to hedge a portion of its variable rate debt, the Company entered into a forward-starting interest rate swap (the “2019 swap”, and together with the 2018 swap, the “ interest rate swaps”) with an effective date of April 2, 2020 and a termination date of March 31, 2024 . The notional amount of this swap was $ 250,000 . Following the transition from LIBOR to Term SOFR, this interest rate swap effectively fixed the variable interest rate on the notional amount of this swap at 1.9645 %. The interest rate swaps qualified for hedge accounting and, therefore, changes in the fair value of the interest rate swaps were recorded in accumulated other comprehensive loss. As of December 28, 2024, there was no cumulative unrealized gain for qualifying hedges reported as a component of accumulated other comprehensive loss. As of December 30, 2023, the cumulative unrealized gain for qualifying hedges was reported as a component of accumulated other comprehensive loss in the amount of $ 2,716 ($ 3,474 before taxes). The following table presents the aggregate fair value of the Company’s derivative financial instruments by balance sheet classification and location: Fair Value Balance Sheet Classification Balance Sheet December 28, 2024 December 30, 2023 Assets: Interest rate swaps Current asset Prepaid expenses and other current assets $ — $ 3,555 Total assets $ — $ 3,555

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	12 Months Ended
	Dec. 28, 2024
Equity [Abstract]
Accumulated Other Comprehensive Loss	20. Accumulated Other Comprehensive Loss Amounts reclassified out of accumulated other comprehensive loss were as follows: Changes in Accumulated Other Comprehensive Loss by Component (1) Fiscal Year Ended December 28, 2024 Qualifying Loss on Total Beginning balance at December 30, 2023 $ 2,716 $ ( 14,016 ) $ ( 11,300 ) Other comprehensive loss before reclassifications, net of tax ( 66 ) ( 11,816 ) ( 11,882 ) Amounts reclassified from accumulated other comprehensive loss, net of tax (2) ( 2,650 ) — ( 2,650 ) Net current period other comprehensive loss $ ( 2,716 ) $ ( 11,816 ) $ ( 14,532 ) Ending balance at December 28, 2024 $ — $ ( 25,832 ) $ ( 25,832 ) (1) Amounts in parentheses indicate debits (2) See separate table below for details about these reclassifications Fiscal Year Ended December 30, 2023 Gain on Loss on Total Beginning balance at December 31, 2022 $ 10,723 $ ( 16,193 ) $ ( 5,470 ) Other comprehensive income before reclassifications, net of tax 1,731 2,177 3,908 Amounts reclassified from accumulated other comprehensive loss, net of tax (2) ( 9,738 ) — ( 9,738 ) Net current period other comprehensive (loss) income $ ( 8,007 ) $ 2,177 $ ( 5,830 ) Ending balance at December 30, 2023 $ 2,716 $ ( 14,016 ) $ ( 11,300 ) (1) Amounts in parentheses indicate debits (2) See separate table below for details about these reclassifications Fiscal Year Ended December 31, 2022 (Loss) Gain on Loss on Total Beginning balance at January 1, 2022 $ ( 10,843 ) $ ( 7,761 ) $ ( 18,604 ) Other comprehensive income (loss) before reclassifications, net of tax 19,250 ( 8,432 ) 10,818 Amounts reclassified from accumulated other comprehensive loss, net of tax (2) 2,316 — 2,316 Net current period other comprehensive income (loss) $ 21,566 $ ( 8,432 ) $ 13,134 Ending balance at December 31, 2022 $ 10,723 $ ( 16,193 ) $ ( 5,470 ) (1) Amounts in parentheses indicate debits (2) See separate table below for details about these reclassifications Reclassifications out of Accumulated Other Comprehensive Loss (1) Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 Details about Other Comprehensive Amounts Reclassified from Affected Line Item in the Gain (Loss) on Qualifying Hedges Interest rate contracts $ 3,545 $ 12,980 $ ( 3,090 ) Interest expense 3,545 12,980 ( 3,090 ) Loss before income taxes ( 895 ) ( 3,242 ) 774 Provision for (benefit from) income taxes $ 2,650 $ 9,738 $ ( 2,316 ) Net loss (1) Amounts in parentheses indicate debits to profit/loss

Recently Issued Accounting Pron

Recently Issued Accounting Pronouncements	12 Months Ended
	Dec. 28, 2024
Accounting Changes and Error Corrections [Abstract]
Accounting Standards Adopted in Current Year and Recently Issued Accounting Pronouncements	3. Accounting Standards Adopted in Current Year In November 2023, the Financial Accounting Standards Board (the “FASB”) issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures” , to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, ASU 2023-07 enhances interim disclosure requirements, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment and contains other disclosure requirements. The effective date of the new guidance for public companies is for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. In the fourth quarter of fiscal 2024, the Company adopted ASU 2023-07 and applied the new guidance retrospectively to all prior periods presented in the financial statements. The adoption of this guidance did no t have a material impact on the Company’s consolidated financial statements. 21. Recently Issued Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” , to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. ASU 2023-09 also improves the effectiveness and comparability of income tax disclosures by (1) adding disclosures of pretax income (or loss) and income tax expense (or benefit) and (2) removing disclosures that no longer are considered cost beneficial or relevant. The effective date of the new guidance for public companies is for annual periods beginning after December 15, 2024. Early adoption is permitted. The new guidance should be applied prospectively, although retrospective application is permitted. The Company is currently evaluating the impact that ASU 2023-09 will have on its consolidated financial statements and related disclosures, including the adoption date and transition method. In November 2024, the FASB issued ASU 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures”, which requires the disaggregation of certain expenses in the notes to the financial statements to provide enhanced transparency into the expense captions presented on the face of the income statement. Additionally, in January 2025, the FASB issued ASU 2025-01 to clarify the effective date of ASU 2024-03. Under ASU 2024-03, a public entity would be required to disclose information about purchases of inventory, employee compensation, depreciation, intangible asset amortization, and depletion for each income statement line item that contains those expenses, as well as a qualitative description of amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. ASU 2024-03 also requires disclosure of the total amount of selling expenses and, in annual periods, an entity’s definition of selling expenses. This guidance is effective for fiscal years beginning after December 15, 2026 and interim periods within annual reporting periods beginning after December 15, 2027, and may be applied either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that ASU 2024-03 will have on its consolidated financial statements and related disclosures, including the adoption date and transition method. The Company has determined that other recently issued accounting pronouncements are not expected to have a material impact on its consolidated financial statements.

Related Party

Related Party	12 Months Ended
	Dec. 28, 2024
Related Party Transactions [Abstract]
Related Party	22. Related Party As previously disclosed, on October 18, 2015, the Company entered into the Strategic Collaboration Agreement with Oprah Winfrey, under which she consulted with the Company and participated in developing, planning, executing and enhancing the WW program and related initiatives, and provided it with services in her discretion to promote the Company and its programs, products and services for an initial term of five years (the “Initial Term”). As previously disclosed, on December 15, 2019, the Company entered into an amendment of the Strategic Collaboration Agreement with Ms. Winfrey, pursuant to which, among other things, the Initial Term of the Strategic Collaboration Agreement was extended until April 17, 2023 (with no additional successive renewal terms), after which a second term commenced that will continue through the earlier of the date of the Company’s 2025 annual meeting of shareholders or May 31, 2025. Ms. Winfrey will continue to provide certain consulting and other services to the Company during the second term. In addition to the Strategic Collaboration Agreement, Ms. Winfrey and her related entities provided services to the Company totaling $ 292 , $ 574 and $ 861 for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022, respectively, which services included advertising, production and related fees. The Company’s accounts payable to parties related to Ms. Winfrey at December 28, 2024 and December 30, 2023 was $ 13 and $ 0 , respectively.

Restructuring

Restructuring	12 Months Ended
	Dec. 28, 2024
Restructuring and Related Activities [Abstract]
Restructuring	23. Restructuring 2024 Plan As previously disclosed, in the third quarter of fiscal 2024, in connection with the strategic streamlining of its operational structure to optimize its clinical and behavioral product portfolio and its cost-savings initiative, the Company committed to a plan of reduction in force that has resulted and will further result in the elimination of certain positions and the termination of employment for certain employees worldwide (the “2024 Plan”). Refer to the tables below for the total restructuring charges under the 2024 Plan recorded for the fiscal year ended December 28, 2024. The cumulative amount incurred as of December 28, 2024 related to the aggregate 2024 Plan is $ 17,043 . The Company expects the 2024 Plan to be fully executed by the end of fiscal 2025. For the fiscal year ended December 28, 2024, the components of the Company’s restructuring charges for the 2024 Plan were as follows: Fiscal Year Ended December 28, 2024 Cash restructuring charges: Employee termination benefit costs $ 15,734 Lease termination costs 168 Other cash restructuring charges 1,141 Total restructuring charges $ 17,043 For the fiscal year ended December 28, 2024, restructuring charges for the 2024 Plan were recorded in the Company’s consolidated statements of operations as follows: Fiscal Year Ended December 28, 2024 Cost of revenues $ 2,497 Selling, general and administrative expenses 14,546 Total restructuring charges $ 17,043 All expenses were recorded to general corporate expenses. The following table presents a roll-forward of cash restructuring-related liabilities, which is included within accrued expenses in the Company’s consolidated balance sheets: Employee termination benefit costs Lease termination costs Other cash restructuring charges Total Balance as of December 30, 2023 $ — $ — $ — $ — Charges 15,520 168 1,141 16,829 Payments ( 8,590 ) — ( 1,141 ) ( 9,731 ) Change in estimate 214 — — 214 Balance as of December 28, 2024 $ 7,144 $ 168 $ — $ 7,312 As of December 28, 2024, the Company expects the remaining employee termination benefit liability to be paid in full by the end of fiscal 2027. 2023 Plan As previously disclosed, in the fourth quarter of fiscal 2022, management reviewed the then-current global business operations of the Company as well as the different functions and systems supporting those operations and contrasted them with the Company's strategic priorities and requirements for fiscal 2023 and beyond. Based on that review, in December 2022, the Company's management resolved to centralize its global management of certain functions and systems, deprioritize and in some cases cease operations for certain non-strategic business lines, and continue the rationalization of its real estate portfolio to align with its future needs. Throughout December 2022 and January 2023, management developed and continued refining a detailed plan to achieve these goals. The Company committed to a restructuring plan consisting of (i) an organizational restructuring and rationalization of certain functions and systems to centralize the Company’s management, align resources with strategic business lines and reduce costs associated with certain functions and systems (the “Organizational Restructuring”) and (ii) the continued rationalization of its real estate portfolio and resulting operating lease termination charges and the associated employment termination costs (the “Real Estate Restructuring,” and together with the Organizational Restructuring, the “2023 Plan”). Refer to the tables below for the total restructuring charges under the 2023 Plan recorded for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022. The cumulative amount incurred as of December 28, 2024 related to the aggregate 2023 Plan is $ 72,473 . The Organizational Restructuring has resulted and will further result in the elimination of certain positions and the termination of employment for certain employees worldwide. Refer to the tables below for the employee termination benefit costs related to the Organizational Restructuring under the 2023 Plan recorded for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022. The cumulative amount incurred as of December 28, 2024 for the aggregate employee termination benefit costs related to the Organizational Restructuring under the 2023 Plan is $ 40,950 . Refer to the tables below for the lease termination costs and employee termination benefit costs related to the Real Estate Restructuring under the 2023 Plan recorded for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022, as applicable. The cumulative amount incurred as of December 28, 2024 for the aggregate lease termination costs and employee termination benefit costs related to the Real Estate Restructuring under the 2023 Plan is $ 12,789 and $ 9,914 , respectively. Refer to the tables below for the other cash restructuring charges and other non-cash restructuring charges under the 2023 Plan recorded for the fiscal years ended December 28, 2024 and December 30, 2023. The cumulative amount incurred as of December 28, 2024 for the aggregate other cash restructuring charges and total non-cash restructuring charges under the 2023 Plan is $ 2,158 and $ 6,662 , respectively. For the fiscal year ended December 28, 2024, the components of the Company’s restructuring charges for the 2023 Plan were as follows: Fiscal Year Ended December 28, 2024 Cash restructuring charges: Real Estate Restructuring - Lease termination costs $ ( 135 ) Real Estate Restructuring - Employee termination benefit costs 2,438 Organizational Restructuring - Employee termination benefit costs 2,213 Other cash restructuring charges 581 Total cash restructuring charges $ 5,097 Non-cash restructuring charges 25 Total restructuring charges $ 5,122 For the fiscal year ended December 28, 2024, restructuring charges for the 2023 Plan were recorded in the Company’s consolidated statements of operations as follows: Fiscal Year Ended December 28, 2024 Cost of revenues $ 2,510 Selling, general and administrative expenses 2,612 Total restructuring charges $ 5,122 For the fiscal year ended December 30, 2023, the components of the Company’s restructuring charges for the 2023 Plan were as follows: Fiscal Year Ended December 30, 2023 Cash restructuring charges: Real Estate Restructuring - Lease termination costs $ 12,924 Real Estate Restructuring - Employee termination benefit costs 5,678 Organizational Restructuring - Employee termination benefit costs 26,927 Other cash restructuring charges 1,577 Total cash restructuring charges $ 47,106 Non-cash restructuring charges: Accelerated depreciation and amortization charges $ 6,831 Other non-cash restructuring charges ( 194 ) Total non-cash restructuring charges $ 6,637 Total restructuring charges $ 53,743 For the fiscal year ended December 30, 2023, restructuring charges for the 2023 Plan were recorded in the Company’s consolidated statements of operations as follows: Fiscal Year Ended December 30, 2023 Cost of revenues $ 21,116 Selling, general and administrative expenses 32,627 Total restructuring charges $ 53,743 For the fiscal year ended December 31, 2022, the components of the Company’s restructuring charges for the 2023 Plan were as follows: Fiscal Year Ended December 31, 2022 Cash restructuring charges: Real Estate Restructuring - Employee termination benefit costs $ 1,798 Organizational Restructuring - Employee termination benefit costs 11,810 Total restructuring charges $ 13,608 For the fiscal year ended December 31, 2022, restructuring charges for the 2023 Plan were recorded in the Company’s consolidated statements of operations as follows: Fiscal Year Ended December 31, 2022 Cost of revenues $ 1,798 Selling, general and administrative expenses 11,810 Total restructuring charges $ 13,608 All expenses were recorded to general corporate expenses. The following table presents a roll-forward of cash restructuring-related liabilities, which is included within accrued expenses in the Company’s consolidated balance sheets: Real Estate Restructuring - Real Estate Restructuring - Organizational Restructuring - Lease Employee Employee Other cash Total Balance as of December 31, 2022 $ — $ 1,798 $ 11,810 $ — $ 13,608 Charges 12,924 5,678 26,927 1,577 47,106 Payments ( 12,768 ) ( 4,813 ) ( 15,142 ) ( 1,233 ) ( 33,956 ) Balance as of December 30, 2023 $ 156 $ 2,663 $ 23,595 $ 344 $ 26,758 Charges — 2,363 2,547 581 5,491 Payments ( 21 ) ( 1,835 ) ( 19,342 ) ( 925 ) ( 22,123 ) Change in estimate ( 135 ) 75 ( 334 ) — ( 394 ) Balance as of December 28, 2024 $ — $ 3,266 $ 6,466 $ — $ 9,732 As of December 28, 2024, the Company expects the remaining employee termination benefit liability related to the Real Estate Restructuring and the remaining employee termination benefit liability related to the Organizational Restructuring to be paid in full by the end of fiscal 2026. 2022 Plan As previously disclosed, in the second quarter of fiscal 2022, the Company committed to a restructuring plan consisting of (i) an organizational realignment to simplify the Company’s corporate structure and reduce associated costs (the “Organizational Realignment”) and (ii) a continued rationalization of its real estate portfolio resulting in the termination of certain of the Company’s operating leases (together with the Organizational Realignment, the “2022 Plan”). The Organizational Realignment has resulted in the elimination of certain positions and termination of employment for certain employees worldwide. Refer to the tables below for the total restructuring charges under the 2022 Plan recorded for the fiscal year ended December 31, 2022. The cumulative amount incurred as of December 28, 2024 related to the aggregate 2022 Plan is $ 28,324 . For the fiscal year ended December 31, 2022, the components of the Company’s restructuring charges for the 2022 Plan were as follows: Fiscal Year Ended December 31, 2022 Cash restructuring charges: Lease termination costs $ 2,424 Employee termination benefit costs 19,170 Other cash restructuring charges 995 Total cash restructuring charges $ 22,589 Non-cash restructuring charges: Lease impairments $ 2,680 Accelerated depreciation and amortization charges 1,453 Other non-cash restructuring charges 459 Total non-cash restructuring charges $ 4,592 Total restructuring charges $ 27,181 See Note 4 for additional information in regard to the Company's lease impairments for the fiscal year ended December 31, 2022. For the fiscal year ended December 31, 2022, restructuring charges for the 2022 Plan were recorded in the Company’s consolidated statements of operations as follows: Fiscal Year Ended December 31, 2022 Cost of revenues $ 6,476 Selling, general and administrative expenses 20,705 Total restructuring charges $ 27,181 All expenses were recorded to general corporate expenses. The following table presents a roll-forward of cash restructuring-related liabilities, which is included within accrued expenses in the Company’s consolidated balance sheets: Lease termination costs Employee termination benefit costs Other cash restructuring charges Total Balance as of January 1, 2022 $ — $ — $ — $ — Charges 2,424 19,170 995 22,589 Payments ( 1,877 ) ( 10,909 ) — ( 12,786 ) Balance as of December 31, 2022 $ 547 $ 8,261 $ 995 $ 9,803 Payments ( 122 ) ( 8,880 ) ( 995 ) ( 9,997 ) Change in estimate ( 425 ) 1,560 — 1,135 Balance as of December 30, 2023 $ — $ 941 $ — $ 941 Payments — ( 949 ) — ( 949 ) Change in estimate — 8 — 8 Balance as of December 28, 2024 $ — $ — $ — $ —

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 28, 2024
Subsequent Events [Abstract]
Subsequent Event	24. Subsequent Event On January 2, 2 025 and January 31, 2025, the Company borrowed approximately $ 50,000 and $ 121,341 , respectively, under the Revolving Credit Facility. These borrowings under the Revolving Credit Facility were incurred to provide financial flexibility. As of February 28, 2025, the aggregate principal amount of borrowings under the Revolving Credit Facility was $ 175,000 , including approximately $ 3,659 of und rawn letters of credit under the Revolving Credit Facility, which represents the full amount available under the Revolving Credit Facility. On February 26, 2025, in connection with the Board’s appointment of Tara Comonte as permanent President and Chief Executive Officer of the Company, the Board approved entry into an employment agreement (the “Employment Agreement”) with Ms. Comonte. Pursuant to the Employment Agreement, Ms. Comonte will receive a cash award of $ 4,500 payable as soon as practicable following entry into the Employment Agreement. This award is in lieu of any annual cash bonus with respect to fiscal 2025 or any long-term incentive award in 2025. The award is subject to repayment by Ms. Comonte if prior to the earlier of (i) January 31, 2026 and (ii) 60 days following the consummation of a Change in Control, she is terminated by the Company for Cause, she resigns other than for Modified Good Reason prior to a Change in Control or she resigns other than for Good Reason following a Change in Control (as such terms are defined in the Employment Agreement). If, during the term of the Employment Agreement, Ms. Comonte’s employment is terminated (i) by the Company without Cause, (ii) due to a resignation for Modified Good Reason prior to a Change in Control or (iii) due to a resignation for Good Reason following a Change in Control, subject to her execution of a release and compliance with the restrictive covenants to which she is subject she will not be subject to repayment of the award described above.

VALUATION AND QUALIFYING ACCOUN

VALUATION AND QUALIFYING ACCOUNTS AND RESERVES	12 Months Ended
	Dec. 28, 2024
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
VALUATION AND QUALIFYING ACCOUNTS AND RESERVES	SCHEDULE II—VALUATION AND QUA LIFYING ACCOUNTS AND RESERVES (IN THOUSANDS) Additions Balance at Charged to Charged Balance at Beginning Costs and to Other Deductions End of Period Expenses Accounts (1) of Period FISCAL YEAR ENDED DECEMBER 28, 2024 Allowance for credit losses $ 1,041 $ 17,205 $ — $ ( 15,080 ) $ 3,166 Inventory and other reserves $ 8,888 $ 72 $ — $ ( 5,028 ) $ 3,932 Tax valuation allowance $ 89,801 $ 83,431 $ 6,068 $ ( 849 ) $ 178,451 FISCAL YEAR ENDED DECEMBER 30, 2023 Allowance for credit losses $ 976 $ 1,306 $ — $ ( 1,241 ) $ 1,041 Inventory and other reserves $ 6,468 $ 7,350 $ — $ ( 4,930 ) $ 8,888 Tax valuation allowance $ 35,818 $ 53,946 $ 110 $ ( 73 ) $ 89,801 FISCAL YEAR ENDED DECEMBER 31, 2022 Allowance for credit losses $ 1,726 $ ( 460 ) $ — $ ( 290 ) $ 976 Inventory and other reserves $ 7,141 $ 6,796 $ — $ ( 7,469 ) $ 6,468 Tax valuation allowance $ 10,083 $ 27,871 $ ( 143 ) $ ( 1,993 ) $ 35,818 (1) Primarily represents the utilization of established reserves, net of recoveries, where applicable.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 28, 2024
Accounting Policies [Abstract]
Fiscal Year	Fiscal Year The Company’s fiscal year ends on the Saturday closest to December 31st and consists of either 52 or 53-week periods. Fiscal 2024, fiscal 2023 and fiscal 2022 each contained 52 weeks.
Use of Estimates	Use of Estimates The preparation of financial statements, in conformity with GAAP, requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and judgments, including those related to the im pairment analyses for goodwill and other indefinite-lived intangible assets, revenue, share-based compensation, income taxes, tax contingencies and litigation. The Company bases its estimates on historical experience and on various other factors and assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. While all available information has been considered, actual amounts could differ from these estimates. These estimates and assumptions may change as new events occur and additional information is obtained, and such future changes may have an adverse impact on the Company's results of operations, financial position and liquidity.
Variable Interest Entity	Variable Interest Entity The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex and involve judgment and the use of estimates and assumptions based on available information. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, such entity is consolidated in the Company’s consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. The Company performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Through WeightWatchers Clinic, the Company operates certain clinical telehealth groups which are deemed to be Friendly-Physician Entities (“FPEs”) and due to legal requirements, the physician-owners must retain 100 % of the equity interest. The Company’s agreements with FPEs generally consist of both an Administrative Services Agreement, which provides for various administrative and management services to be provided by the Company to the FPE, and Share Transfer Agreement (“STA”) with the physician-owners of the FPEs, which provides for the transition of ownership interest of the FPEs under certain conditions. The Company has the right to receive income as an ongoing management fee, which effectively absorbs all of the residual interests, and can also provide financial support through loans to the FPEs. The Company has exclusive responsibility for the provision of all nonmedical services including technology and intellectual property required for the day-to-day operation and management of each of the FPEs. In addition, the STA provides that the Company has the right to designate a person(s) to purchase the equity interest of the FPE for a nominal amount in the event of a succession event at the Company’s discretion. Based on the provisions of these agreements, the Company determined that the FPEs are VIEs due to their equity holder having insufficient capital at risk, and the Company has a variable interest in the FPEs. The contractual arrangements described above allow the Company to direct the activities that most significantly affect the economic performance of the FPEs. Accordingly, the Company is the primary beneficiary of the FPEs and consolidates the FPEs under the VIE model. Furthermore, as a direct result of nominal initial equity contributions by the physicians, the financial support the Company can provide to the FPEs (e.g., loans) and the provisions of the contractual arrangements and nominee shareholder succession arrangements described above, the interests held by noncontrolling interest holders lack economic substance and do not provide them with the ability to participate in the residual profits or losses generated by the FPEs. Therefore, all income and expenses recognized by the FPEs are consolidated by the Company. The Company does not hold interests in any VIEs for which the Company is not deemed to be the primary beneficiary.
Translation of Foreign Currencies	Translation of Foreign Currencies For all foreign operations, the functional currency is the local currency. Assets and liabilities of these operations are translated into U.S. dollars using the exchange rate in effect at the end of each reporting period. Income statement accounts are translated at the average rate of exchange prevailing during each reporting period. Translation adjustments arising from the use of differing exchange rates from period to period are included in accumulated other comprehensive loss. Foreign currency gains and losses arising from the translation of intercompany receivables and intercompany payables with the Company’s international subsidiaries are recorded as a component of other expense , net, unless the receivable or payable is considered long-term in nature, in which case the foreign currency gains and losses are recorded as a component of accumulated other comprehensive loss.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents are defined as highly liquid investments with original maturities of three months or less. Cash balances may, at times, exceed insurable amounts. The Company believes it mitigates this risk by investing in or through major financial institutions. Cash includes balances due from third-party credit card companies.
Receivables	Receivables Receivables include amounts that are billed and currently due from customers. The amounts due are stated at their net estimated realizable value. The Company maintains an allowance for credit losses to provide for the estimated amount of receivables that will not be collected, including balances from customers under recur bill commitment plans. The assessment of the likelihood of customer defaults is based on various factors, including length of time the receivables are past due and historical experience, all of which are subject to change. The Company’ s credit write offs were $ 15,080 and $ 1,241 for the fiscal years ended December 28, 2024 and December 30, 2023 , respectively.
Inventories	Inventories Inventories, which consist of finished goods, are stated at the lower of cost or net realizable value on a first-in, first-out basis, net of reserves for obsolescence and shrinkage.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost. For financial reporting purposes, equipment is depreciated on the straight-line method over the estimated useful lives of the assets ( 3 to 10 years ). Leasehold improvements are amortized on the straight-line method over the shorter of the term of the lease o r the useful life of the related assets. Expenditures for new facilities and improvements that substantially extend the useful life of an asset are capitalized. Ordinary repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related depreciation are removed from the accounts and any related gains or losses are included in income.
Leases	Leases A lease is defined as an arrangement that contractually specifies the right to use and control an identified asset for a specific period of time in exchange for consideration. Operating leases are included in operating lease assets, portion of operating lease liabilities due within one year, and long-term operating lease liabilities in the Company’s consolidated balance sheets. Finance leases are included in property and equipment, net, other accrued liabilities, and other long-term liabilities in the Company’s consolidated balance sheets. Lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term, using the Company’s incremental borrowing rate commensurate with the lease term, since the Company’s lessors do not provide an implicit rate, nor is one readily available. The incremental borrowing rate is calculated based on the Company’s credit yield curve and adjusted for collateralization, credit quality and economic environment impact, all where applicable. The lease asset includes scheduled lease payments and excludes lease incentives, such as free rent periods and tenant improvement allowances. The Company has certain leases that may include an option to renew and when it is reasonably probable to exercise such option, the Company will include the renewal option terms in determining the lease asset and lease liability. The Company does not have any renewal options that would have a material impact on the terms of the leases and that are also reasonably expected to be exercised as of December 28, 2024. A lease may contain both fixed and variable payments. Variable lease payments that are linked to an index or rate are measured based on the current index or rate at the implementation of the lease accounting standard, or lease commencement date for new leases, with the impact of future changes in the index or rate being recorded as a period expense. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components and has elected not to separate non-lease components from lease components and instead to account for each separate lease component and non-lease component as a single lease component. The Company has elected the short-term lease exception accounting policy, whereby the recognition requirements of the updated guidance is not applied and lease expense is recorded on a straight-line basis with respect to leases with an initial term of 12 months or less.
Impairment of Long Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets, including amortizable intangible assets, for impairment whenever events or changes in business circumstances indicate that the carrying value of the assets may not be fully recoverable. In fiscal 2024, fiscal 2023 and fiscal 2022, the Company recorded impairment charg es of $ 142 , $ 900 and $ 714 , respectively, related to internal-use computer software and website development costs that were not expected to provide substantive service potential. In fiscal 2024, fiscal 2023 and fiscal 2022, the Company recorded impairment charges of $ 339 , $ 212 and $ 61 , respectively, related to property and equipment that were expected to be disposed of before the end of their estimated useful lives. In fiscal 2022, the Company recorded lease asset impairment charges of $ 2,680 in the aggregate. See No te 4 for further information on the Company’s leases.
Franchise Rights Acquired and Goodwill	Franchise Rights Acquired Finite-lived franchise rights acquired are amortized over the remaining contractual period, which is generally less than one year . Indefinite-lived franchise rights acquired are tested for potential impairment on at least an annual basis or more often if events so require. In performing the impairment analysis for indefinite-lived franchise rights acquired, the fair value for franchise rights acquired is estimated using a discounted cash flow approach referred to as the hypothetical start-up approach for franchise rights related to the Company’s Workshops + Digital business and a relief from royalty methodology for franchise rights related to the Company’s Digital business. The aggregate estimated fair value for these franchise rights is then compared to the carrying value of the unit of account for these rights. The Company has determined the appropriate unit of account for purposes of assessing impairment to be the combination of the rights in both the Workshops + Digital business and the Digital business in the country in which the applicable acquisition occurred. The net book value of franchise rights acquired for the United States unit of account as of the December 28, 2024 balance sheet date was $ 68,627 , which represented 100.0 % of total franchise rights acquired as of December 28, 2024 . The net book values of franchise rights acquired for the United States, Australia, United Kingdom and New Zealand units of account as of the December 30, 2023 balance sheet date were $ 374,353 , $ 4,232 , $ 2,806 and $ 2,420 , respectively, which represented 97.6 %, 1.1 %, 0.7 % and 0.6 %, respectively, of total franchise rights acquired as of December 30, 2023. In its hypothetical start-up approa ch analyses for fiscal 2024, the Company assumed that the year of maturity was reached after 7 years. Subsequent to the year of maturity, the Company estimated future cash flows for the Workshops + Digital business in each country based on assumptions regarding revenue growth and operating income margins. In the Company’s relief from royalty approach analyses for fiscal 2024, the cash flows associated with the Digital business in each country were based on the expected Digital re venue for such country and the application of a royalty rate based on current market terms. The cash flows for the Workshops + Digital and the Digital businesses were discounted utilizing rates which were calculated using the weighted average cost of capital, which included the cost of equity and the cost of debt. Goodwill In performing the impairment analysis for goodwill, the fair value for the Company’s reporting units is estimated using a discounted cash flow approach. This approach involves projecting future cash flows attributable to the reporting unit and discounting those estimated cash flows using an appropriate discount rate. The estimated fair value is then compared to the carrying value of the reporting unit. The Company has determined the appropriate reporting units for purposes of assessing goodwill impairment to be the Behavioral and Clinical business lines. See Note 7 for further information on the Company’s change in goodwill reporting units. The net book values of goodwill for the Behavioral and Clinical reporting units as of the December 28, 2024 balance sheet date were $ 149,841 and $ 89,742 , respectively, which represented 62.5 % and 37.5 %, respectively, of total goodwill as of December 28, 2024. In performing the impairment analysis for goodwill, for all of the Company’s reporting units, the Company estimated future cash flows by utilizing the historical debt-free cash flows (cash flows provided by operations less capital expenditures) attributable to each of the Behavioral and Clinical reporting units and then applied expected future operating income growth rates for the respective reporting unit. The Company utilized operating income as the basis for measuring its potential growth because it believes it is the best indicator of the performance of its business. The Company then discounted the estimated future cash flows utilizing a discount rate which was calculated using the weighted average cost of capital, which included the cost of equity and the cost of debt. Indefinite-Lived Franchise Rights Acquired and Goodwill Impairment Tests The Company reviews indefinite-lived franchise rights acquired and goodwill for potential impairment on at least an annual basis or more often if events so require. The Company performed its annual fair value impairment testing as of May 5, 2024 and May 7, 2023, each the first day of fiscal May, on its indefinite-lived franchise rights acquired and goodwill. In addition, based on triggering events, the Company performed interim impairment tests as of March 30, 2024 and September 28, 2024 on its indefinite-lived franchise rights acquired and goodwill for the first and third quarters of fiscal 2024, respectively. See Note 7 for further information regarding the results of the franchise rights acquired and goodwill annual impairment tests, and the franchise rights acquired and goodwill interim impairment tests for the first and third quarters of fiscal 2024.
Other Intangible Assets	Other Intangible Assets Other finite-lived intangible assets are amortized using the straight-line method over their estimated useful lives o f 3 to 20 years . The Company expenses all software costs incurred during the preliminary project stage and capitalizes all internal and external direct costs of materials and services consumed in developing software once the development has reached the application development stage. Application development stage costs generally include software configuration, coding, installation to hardware and testing. These costs are amortized over their estimated useful lives of 3 to 5 years for software and website development costs. All costs incurred for upgrades, maintenance and enhancements, including the cost of website content, which do not result in additional functionality, are expensed as incurred.
Revenue Recognition	Revenue Recognition Revenues are recognized when control of the promised services or goods is transferred to the Company’s customers in an amount that reflects the consideration it expects to be entitled to in exchange for those services or goods. The Company earns revenue from subscriptions for its Digital and Clinical products and by conducting workshops, for which it charges a fee, predominantly through commitment plans, as well as prepayment plans. The Company also earns revenue by collecting royalties related to licensing agreements, collecting royalties from franchisees, and publishing. Prior to fiscal 2024, the Company also earned revenue by selling consumer products. Commitment plan revenues and prepaid workshop fees are recorded to revenue on a straight-line basis as control is transferred since these performance obligations are satisfied over time. “Digital Subscription Revenues,” consisting of the fees associated with subscriptions for the Company’s Digital offerings, are recognized on a straight-line basis as control is transferred since these performance obligations are satisfied over time. One-time Digital sign-up fees are considered immaterial in the context of the contract and the related revenue is amortized into revenue over the commitment period. “Workshops + Digital Subscription Revenues”, consisting of the fees associated with subscriptions for the Company’s Workshops + Digital offerings, are recognized on a straight-line basis as control is transferred since these performance obligations are satisfied over time. In the Workshops + Digital business, the Company generally charges non-refundable registration and starter fees in exchange for access to the Company’s digital subscription products, an introductory information session and materials it provides to new members. Revenue from these registration and starter fees is considered immaterial in the context of the contract and is amortized into revenue over the commitment period. “Clinical Subscription Revenues” consist of revenues earned from initial consultations that are conducted to determine if a prospective member is eligible to be a Clinical subscriber and from fees associated with subscriptions for the Company’s Clinical offerings, predominantly through monthly commitment plans and prepayment plans. One-time initial consultation fees are recorded as revenue at the point in time control is transferred, which is when the initial consultation takes place. Commitment plan revenues and prepaid subscription fees are recognized on a straight-line basis as control is transferred since these performance obligations are satisfied over time. Revenue from royalties is recognized at the point in time control is transferred, which is when royalties are earned. Revenue from consumer product sales was recognized at the point in time control was transferred, which was when products were shipped to customers and partners and title and risk of loss passed to them. For revenue transactions that involve multiple performance obligations, the amount of revenue recognized is determined using the relative fair value approach, which is generally based on each performance obligation’s stand-alone selling price. Discounts to customers, including free registration offers, are recorded as a deduction from gross revenue in the period such revenue was recognized. The Company grants refunds in aggregate amounts that historically have not been material. Because the period of payment of the refund generally approximates the period revenue was originally recognized, refunds are recorded as a reduction of revenue over the same period. The Company does not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. The Company expenses sales commissions when incurred (amortization period would have been one year or less) and these expenses are recorded within selling, general and administrative expenses. The Company treats shipping and handling fees as fulfillment costs and not as a separate performance obligation, and as a result, any fees received from customers are included in the transaction price allocated to the performance obligation of providing goods with a corresponding amount accrued within cost of product sales and other for amounts paid to applicable carriers. Sales tax, value-added tax and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue.
Advertising Costs	Advertising Costs Advertising costs consist primarily of broadcast and digital media. All costs related to advertising are expensed in the period incurred, except for media production-related costs, which are expensed the first time the advertising takes place. Total advertising expenses for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 were $ 234,316 , $ 235,227 and $ 238,978 , respectively.
Income Taxes	Income Taxes Deferred income tax assets and liabilities result primarily from temporary differences between the financial statement and tax bases of assets and liabilities, using enacted tax rates in effect for the year in which differences are expected to reverse. If it is more-likely-than-not that some portion of a deferred tax asset will not be realized, a valuation allowance is recognized. The Company considers historic levels of income, estimates of future taxable income and feasible tax planning strategies in assessing the need for a tax valuation allowance. The Company recognizes a benefit for uncertain tax positions when a tax position taken or expected to be taken in a tax return is more-likely-than-not to be sustained upon examination by taxing authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company recognizes accrued interest and penalties associated with uncertain tax positions as part of the provision for income taxes on its consolidated statements of operations. In addition, assets and liabilities acquired in purchase business combinations are assigned their fair values and deferred taxes are provided for lower or higher tax bases.
Derivative Instruments and Hedging	Derivative Instruments and Hedging The Company is exposed to certain risks related to its ongoing business operations, primarily interest rate risk and foreign currency risk. Interest rate swaps were historically entered into to hedge a portion of the cash flow exposure associated with the Company’s variable-rate borrowings. At December 28, 2024, the Company did not have any interest rate swaps in effect. The Company does not use any derivative instruments for trading or speculative purposes. The Company recognized the fair value of all derivative instruments as either assets or liabilities on the balance sheet. The Company designated and accounted for interest rate swaps as cash flow hedges of its variable-rate borrowings. For derivative instruments that were designated and qualified as cash flow hedges, the effective portion of the gain or loss on the derivative was reported as a component of accumulated other comprehensive loss and reclassified into earnings in the periods during which the hedged transactions affected earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness were recognized in current earnings. The fair value of the Company’s interest rate swaps was reported as a component of accumulated other comprehensive loss on its balance sheet. See Note 18 for a further discussion regarding the fair value of the Company’s interest rate swaps. The net effect of the interest payable and receivable under the Company’s effective interest rate swap was included in interest expense on its consolidated statements of operations.
Deferred Financing Costs	Deferred Financing Costs Deferred financing costs consist of fees paid by the Company as part of the establishment, exchange and/or modification of the Company’s long-term debt. Amortization expense for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 was $ 5,018 , $ 5,018 and $ 5,018 , respectively.

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 28, 2024
Leases [Abstract]
Schedule of Lease Assets and Lease Liabilities	At December 28, 2024 and December 30, 2023, the Company’s lease assets and lease liabilities, primarily for its studios and corporate offices, were as follows: December 28, 2024 December 30, 2023 Assets: Operating leases $ 42,047 $ 52,272 Finance leases — 5 Total lease assets $ 42,047 $ 52,277 Liabilities: Current Operating leases $ 8,168 $ 9,613 Finance leases — 4 Noncurrent Operating leases 44,322 53,461 Finance leases — — Total lease liabilities $ 52,490 $ 63,078
Schedule of Components of Lease Expense	For the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022, the components of the Company’s lease expense were as follows: Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 Operating lease cost: Fixed lease cost $ 15,444 $ 21,259 $ 33,227 Lease termination cost 34 12,718 2,726 Variable lease cost 23 62 27 Total operating lease cost $ 15,501 $ 34,039 $ 35,980 Finance lease cost: Amortization of leased assets $ 4 $ 48 $ 112 Interest on lease liabilities 0 1 6 Total finance lease cost $ 4 $ 49 $ 118 Total lease cost $ 15,505 $ 34,088 $ 36,098
Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rates	At December 28, 2024 and December 30, 2023, the Company’s weighted average remaining lease term and weighted average discount rates were as follows: December 28, 2024 December 30, 2023 Weighted Average Remaining Lease Term (years) Operating leases 6.84 7.31 Finance leases — 0.48 Weighted Average Discount Rate Operating leases 7.68 7.54 Finance leases — 4.10
Schedule of Maturity of Operating Lease Liabilities	At December 28, 2024, the maturity of the Company’s operating lease liabilities in each of the next five fiscal years and thereafter are as follows: Operating Fiscal 2025 $ 11,977 Fiscal 2026 10,088 Fiscal 2027 9,307 Fiscal 2028 9,073 Fiscal 2029 8,963 Thereafter 17,852 Total lease payments $ 67,260 Less imputed interest 14,770 Present value of lease liabilities $ 52,490
Summary of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases for the fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 were as follows: Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 15,786 $ 22,013 $ 31,580 Operating cash flows from finance leases $ 0 $ 1 $ 6 Financing cash flows from finance leases $ 4 $ 48 $ 112 Lease assets obtained (modified) in exchange for new (modified) operating lease liabilities $ 968 $ ( 7,086 ) $ 13,297 Lease assets obtained in exchange for new finance lease liabilities $ — $ — $ 49

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Dec. 28, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Revenues Disaggregated by Revenue Source	The following table presents the Company’s revenues disaggregated by revenue source: Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 Digital Subscription Revenues $ 512,853 $ 571,074 $ 662,668 Workshops + Digital Subscription Revenues 186,139 221,139 256,387 Clinical Subscription Revenues 78,001 30,542 — Subscription Revenues, net $ 776,993 $ 822,755 $ 919,055 Other Revenues, net 8,928 66,796 120,780 Revenues, net $ 785,921 $ 889,551 $ 1,039,835
Schedule of Deferred Revenues	The opening and ending balances of the Company’s deferred revenues were as follows: Deferred Deferred Revenue Revenue-Long Term Balance as of December 31, 2022 $ 32,156 $ 360 Net increase (decrease) during the period 1,810 ( 195 ) Balance as of December 30, 2023 $ 33,966 $ 165 Net increase (decrease) during the period ( 2,311 ) ( 72 ) Balance as of December 28, 2024 $ 31,655 $ 93

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 28, 2024
Business Combinations [Abstract]
Summary of Purchase Price Allocation for Acquired Identifiable Assets, Liabilities Assumed and Goodwill	The following table show s the purchase price allocation for Sequence to the acquired identifiable assets, liabilities assumed and goodwill: Total consideration: Cash paid at closing $ 64,217 Cash paid on April 10, 2024 16,000 Cash to be paid on April 10, 2025 (1) 12,420 Total cash payments $ 92,637 Less stock-based compensation expense attributable to post combination vesting ( 3,882 ) Common shares issued 7,996 Stock price as of April 10, 2023 (2) $ 4.12 Total stock issuance purchase price (2) 32,943 Aggregated merger consideration $ 121,698 Assets acquired: Cash $ 25,776 Prepaid expenses and other current assets 2,220 Property, plant and equipment 34 Intangible assets 7,222 Total assets acquired 35,252 Liabilities assumed: Accounts payable $ 70 Accrued liabilities 14 Deferred revenue 1,300 Deferred tax liability 1,912 Total liabilities assumed 3,296 Net assets acquired 31,956 Total goodwill $ 89,742 (1) Reflects $ 16,000 of cash payable on April 10, 2025 as Merger Consideration discounted using the Company's weighted average cost of debt. (2) Represents the fair value of the shares transferred to the sellers as Merger Consideration, based on the number of shares to be issued, 7,996 , multiplied by the closing price of the Company's shares on April 10, 2023 of $ 4.12 per share.

Franchise Rights Acquired, Go_2

Franchise Rights Acquired, Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 28, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Change in Carrying Value of Goodwill	For the fiscal year ended December 28, 2024, the change in the carrying value of goodwill was due to the effect of exchange rate changes as follows: Balance as of December 31, 2022 $ 155,998 Goodwill acquired during the period 89,742 Goodwill impairment ( 3,586 ) Effect of exchange rate changes 1,287 Balance as of December 30, 2023 $ 243,441 Effect of exchange rate changes ( 3,858 ) Balance as of December 28, 2024 $ 239,583
Schedule of Carrying Values of Finite-lived Intangible Assets	The carrying values of finite-lived intangible assets as of December 28, 2024 and December 30, 2023 were as follows: December 28, 2024 December 30, 2023 Gross Gross Carrying Accumulated Carrying Accumulated Amount Amortization Amount Amortization Capitalized software and website development costs $ 255,822 $ 218,103 $ 251,410 $ 195,696 Trademarks 12,192 12,103 12,188 12,024 Other 13,537 6,714 13,991 6,661 Trademarks and other intangible assets $ 281,551 $ 236,920 $ 277,589 $ 214,381 Franchise rights acquired 7,820 5,316 8,029 5,314 Total finite-lived intangible assets $ 289,371 $ 242,236 $ 285,618 $ 219,695
Schedule of Estimated Amortization Expense of Finite-lived Intangible Assets	Estimated amortization expense of existing finite-lived intangible assets for the next five fiscal years and thereafter is as follows: Fiscal 2025 $ 22,025 Fiscal 2026 $ 13,143 Fiscal 2027 $ 4,776 Fiscal 2028 $ 727 Fiscal 2029 $ 704 Thereafter $ 5,760

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 28, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment	The carrying values of property and equipment as of December 28, 2024 and December 30, 2023 were as follows: December 28, 2024 December 30, 2023 Equipment $ 24,561 $ 31,264 Leasehold improvements 40,802 42,039 $ 65,363 $ 73,303 Less: Accumulated depreciation and amortization ( 49,565 ) ( 53,562 ) $ 15,798 $ 19,741

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 28, 2024
Debt Disclosure [Abstract]
Components of Long-Term Debt	The components of the Company’s long-term debt were as follows: December 28, 2024 December 30, 2023 Principal Unamortized Unamortized Effective (1) Principal Unamortized Unamortized Effective (1) Revolving Credit Facility due $ — $ — $ — 0.00 % $ — $ — $ — 0.00 % Term Loan Facility due 945,000 3,604 7,468 9.37 % 945,000 4,712 9,766 9.21 % Senior Secured Notes due 500,000 3,285 — 4.69 % 500,000 4,058 — 4.70 % Total $ 1,445,000 $ 6,889 $ 7,468 7.74 % $ 1,445,000 $ 8,770 $ 9,766 7.64 % Less: Current portion — — Unamortized deferred 6,889 8,770 Unamortized debt discount 7,468 9,766 Total long-term debt $ 1,430,643 $ 1,426,464 (1) Includes amortization of deferred financing costs and debt discount.
Schedule of Maturities of Long-term Debt	At December 28, 2024, the aggregate amounts of the Company’s existing long-term debt maturing in each of the next five fiscal years and thereafter are as follows: Fiscal 2025 — Fiscal 2026 — Fiscal 2027 10,000 Fiscal 2028 935,000 Fiscal 2029 500,000 Thereafter — $ 1,445,000

Per Share Data (Tables)

Per Share Data (Tables)	12 Months Ended
	Dec. 28, 2024
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and dilut ed net loss per share: Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 Numerator: Net loss $ ( 345,701 ) $ ( 112,255 ) $ ( 256,868 ) Denominator: Weighted average shares of common stock outstanding 79,578 76,677 70,321 Effect of dilutive common stock equivalents — — — Weighted average diluted common shares outstanding 79,578 76,677 70,321 Net loss per share Basic $ ( 4.34 ) $ ( 1.46 ) $ ( 3.65 ) Diluted $ ( 4.34 ) $ ( 1.46 ) $ ( 3.65 )

Stock Plans (Tables)

Stock Plans (Tables)	12 Months Ended
	Dec. 28, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The fair value of each of these option awards is estimated on the date of grant using the Black-Scholes option pricing model with the weighted average assumptions noted in the following table. Expected volatility is based on the historical volatility of the Company’s common stock. The expected term takes into consideration option exercise history. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of grant which most closely corresponds to the expected term of the Time-Vesting Options. The dividend yield is based on the Company’s historic average dividend yield. The Company did not grant any Time-Vesting Options for the fiscal years ended December 28, 2024 and December 30, 2023. December 31, 2022 Dividend yield 0.0 % Volatility 57.0 % - 57.1 % Risk-free interest rate 2.36 % - 2.86 % Expected term (years) 6.0 - 7.0
Schedule of Share-based Compensation, Stock Options Activity	A summary of all option activity for the fiscal year ended December 28, 2024 is presented below. Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Shares Price Life (Yrs.) Value Outstanding at December 30, 2023 6,951 $ 34.57 Granted — $ — Exercised — $ — Cancelled ( 1,919 ) $ 38.40 Outstanding at December 28, 2024 5,032 $ 33.12 1.9 $ — Exercisable at December 28, 2024 5,002 $ 33.27 1.9 $ —
Schedule of Share-based Compensation, Restricted Stock Unit Award Activity	A summary of RSU activity under t he Stock Plans for the fiscal year ended December 28, 2024 is presented below. Weighted Average Grant Date Fair Shares Value Outstanding at December 30, 2023 2,657 $ 7.75 Granted 4,810 $ 1.32 Vested ( 1,318 ) $ 6.59 Forfeited ( 2,061 ) $ 4.76 Outstanding at December 28, 2024 4,088 $ 2.06
Schedule of Share-based Compensation, Performance Stock Unit Award Activity	A summary of PSU activity for the fiscal year ended December 28, 2024 is presented below. Weighted Average Grant Date Fair Shares Value Outstanding at December 30, 2023 215 $ 13.80 Granted 598 $ 1.86 Vested — $ — Forfeited ( 655 ) $ 5.78 Outstanding at December 28, 2024 158 $ 1.86

Taxes (Tables)

Taxes (Tables)	12 Months Ended
	Dec. 28, 2024
Income Tax Disclosure [Abstract]
Schedule of Loss before Income Tax, Domestic and Foreign	The components of the Company’s consolidated loss before income taxes consist of the following: Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 Domestic $ ( 358,108 ) $ ( 222,260 ) $ ( 376,710 ) Foreign 12,933 148,628 9,907 $ ( 345,175 ) $ ( 73,632 ) $ ( 366,803 )
Schedule of Components of Income Tax Expense (Benefit)	The following table summarizes the Company’s consolidated provision for (benefit from) U.S. federal, state and foreign income taxes: Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 Current: U.S. federal $ 6,369 $ 1,330 $ 12,426 State 1,519 1,947 3,446 Foreign 19,216 15,525 20,022 $ 27,104 $ 18,802 $ 35,894 Deferred: U.S. federal $ ( 6,856 ) $ ( 12,419 ) $ ( 110,611 ) State ( 8,420 ) 4,263 ( 23,213 ) Foreign ( 11,302 ) 27,977 ( 12,005 ) $ ( 26,578 ) $ 19,821 $ ( 145,829 ) Total provision for (benefit from) income taxes $ 526 $ 38,623 $ ( 109,935 )
Schedule of Effective Income Tax Rate Reconciliation	Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 U.S. federal statutory tax rate 21.0 % 21.0 % 21.0 % State income taxes (net of federal benefit) 4.6 % 12.8 % 3.8 % Research and development credit 0.4 % 3.0 % 0.4 % Tax windfall/shortfall on share-based awards ( 1.5 %) ( 0.9 %) ( 0.5 %) Tax rate changes 0.0 % ( 0.1 %) 0.3 % Executive compensation limitation ( 0.4 %) ( 1.4 %) ( 0.2 %) FDII 1.2 % 3.6 % 1.2 % Change in valuation allowance ( 25.4 %) ( 72.8 %) ( 7.1 %) Impact of foreign operations ( 0.3 %) ( 16.5 %) ( 1.6 %) Reversal of certain deferred tax liabilities 0.0 % 0.0 % 12.5 % Nondeductible costs 0.0 % ( 1.3 %) 0.0 % Other 0.2 % 0.1 % 0.2 % Total effective tax rate ( 0.2 %) ( 52.5 %) 30.0 %
Schedule of Deferred Tax Assets and Liabilities	The deferred tax assets and liabilities recorded on the Company’s consolidated balance sheets are as follows: December 28, 2024 December 30, 2023 Interest expense disallowance $ 101,563 $ 76,350 Operating lease liabilities 13,672 16,174 Operating loss carryforwards 11,703 12,446 Provision for estimated expenses 2,916 3,657 Salaries and wages 8,904 13,489 Share-based compensation 9,553 14,920 Other comprehensive income 6,995 3,833 Capitalized research and development expenses 34,767 — Other 12,045 4,287 Less: valuation allowance ( 178,451 ) ( 89,801 ) Total deferred tax assets $ 23,667 $ 55,355 Goodwill and intangible assets $ ( 663 ) $ ( 47,323 ) Operating lease assets ( 10,941 ) ( 13,285 ) Depreciation ( 9,000 ) ( 12,749 ) Termination fee — ( 3,408 ) Prepaid expenses ( 1,289 ) ( 900 ) Total deferred tax liabilities $ ( 21,893 ) $ ( 77,665 ) Net deferred tax assets (liabilities) $ 1,774 $ ( 22,310 )
Schedule of Unrecognized Tax Benefits Roll Forward	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 Balance at beginning of year $ 613 $ 611 $ 1,055 Increases related to tax positions taken in current year — — 145 Increases related to tax positions taken in prior years — 9 8 Reductions related to tax positions taken in prior years — ( 9 ) ( 95 ) Reductions related to settlements with tax authorities — — ( 273 ) Reductions related to lapse of statutes of limitations ( 99 ) — ( 206 ) Effects of foreign currency translation ( 6 ) 2 ( 23 ) Balance at end of year $ 508 $ 613 $ 611

Cash Flow Information (Tables)

Cash Flow Information (Tables)	12 Months Ended
	Dec. 28, 2024
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures	Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 Net cash paid during the year for: Interest $ 96,844 $ 91,614 $ 76,216 Income taxes (1) $ 11,499 $ 30,908 $ 25,815 Noncash investing and financing activities were as follows: Fair value of net assets acquired in connection with acquisitions $ — $ 7,256 $ 240 Capital expenditures and capitalized software included in accounts payable and accrued expenses $ 75 $ 802 $ 1,466 Common stock issued in connection with acquisition of Sequence $ — $ 32,943 $ — (1) Fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 include tax refunds received of $ 15,421 , $ 7,054 and $ 5,109 , respectively.
Schedule of Cash and Cash Equivalents and Restricted Cash	The following table presents the Company’s cash and cash equivalents and restricted cash by balance sheet location at December 28, 2024 and December 30, 2023: December 28, 2024 December 30, 2023 Cash and cash equivalents $ 53,024 $ 109,366 Restricted cash included in “Prepaid expenses and other current assets” 3,003 — Restricted cash included in “Other noncurrent assets” 493 — Total cash and cash equivalents and restricted cash $ 56,520 $ 109,366

Segment and Geographic Data (Ta

Segment and Geographic Data (Tables)	12 Months Ended
	Dec. 28, 2024
Segment Reporting [Abstract]
Information About Sources of Revenue, Long-Lived Assets and Operating Lease Assets by Geographic Area	The following tables present information about the Company’s revenue and other information by geographic area. There were no material amounts of sales or transfers among geographic areas and no material amounts of U.S. export sales. Revenues, net for the Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 United States $ 541,973 $ 604,441 $ 682,428 Germany 82,649 97,085 116,452 Other 161,299 188,025 240,955 $ 785,921 $ 889,551 $ 1,039,835 Long-Lived Assets (1) December 28, 2024 December 30, 2023 United States $ 15,037 $ 18,171 Germany 257 418 Other 504 1,152 $ 15,798 $ 19,741 (1) Amounts include finance lease assets Operating Lease Assets December 28, 2024 December 30, 2023 United States $ 39,939 $ 48,870 Germany 130 446 Other 1,978 2,956 $ 42,047 $ 52,272

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 28, 2024
Fair Value Disclosures [Abstract]
Aggregate Fair Value of Derivative Financial Instruments	The following table presents the aggregate fair value of the Company’s derivative financial instruments: Fair Value Measurements Using: Total Quoted Prices in Significant Other Significant Interest rate swaps current asset at December 28, 2024 $ — $ — $ — $ — Interest rate swaps current asset at December 30, 2023 $ 3,555 $ — $ 3,555 $ —

Derivative Instruments and He_2

Derivative Instruments and Hedging (Tables)	12 Months Ended
	Dec. 28, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Aggregate Fair Value of Derivative Financial Instruments by Balance Sheet Classification and Location	The following table presents the aggregate fair value of the Company’s derivative financial instruments by balance sheet classification and location: Fair Value Balance Sheet Classification Balance Sheet December 28, 2024 December 30, 2023 Assets: Interest rate swaps Current asset Prepaid expenses and other current assets $ — $ 3,555 Total assets $ — $ 3,555

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	12 Months Ended
	Dec. 28, 2024
Equity [Abstract]
Changes in Accumulated Other Comprehensive Loss by Component	Amounts reclassified out of accumulated other comprehensive loss were as follows: Changes in Accumulated Other Comprehensive Loss by Component (1) Fiscal Year Ended December 28, 2024 Qualifying Loss on Total Beginning balance at December 30, 2023 $ 2,716 $ ( 14,016 ) $ ( 11,300 ) Other comprehensive loss before reclassifications, net of tax ( 66 ) ( 11,816 ) ( 11,882 ) Amounts reclassified from accumulated other comprehensive loss, net of tax (2) ( 2,650 ) — ( 2,650 ) Net current period other comprehensive loss $ ( 2,716 ) $ ( 11,816 ) $ ( 14,532 ) Ending balance at December 28, 2024 $ — $ ( 25,832 ) $ ( 25,832 ) (1) Amounts in parentheses indicate debits (2) See separate table below for details about these reclassifications Fiscal Year Ended December 30, 2023 Gain on Loss on Total Beginning balance at December 31, 2022 $ 10,723 $ ( 16,193 ) $ ( 5,470 ) Other comprehensive income before reclassifications, net of tax 1,731 2,177 3,908 Amounts reclassified from accumulated other comprehensive loss, net of tax (2) ( 9,738 ) — ( 9,738 ) Net current period other comprehensive (loss) income $ ( 8,007 ) $ 2,177 $ ( 5,830 ) Ending balance at December 30, 2023 $ 2,716 $ ( 14,016 ) $ ( 11,300 ) (1) Amounts in parentheses indicate debits (2) See separate table below for details about these reclassifications Fiscal Year Ended December 31, 2022 (Loss) Gain on Loss on Total Beginning balance at January 1, 2022 $ ( 10,843 ) $ ( 7,761 ) $ ( 18,604 ) Other comprehensive income (loss) before reclassifications, net of tax 19,250 ( 8,432 ) 10,818 Amounts reclassified from accumulated other comprehensive loss, net of tax (2) 2,316 — 2,316 Net current period other comprehensive income (loss) $ 21,566 $ ( 8,432 ) $ 13,134 Ending balance at December 31, 2022 $ 10,723 $ ( 16,193 ) $ ( 5,470 ) (1) Amounts in parentheses indicate debits (2) See separate table below for details about these reclassifications
Reclassifications out of Accumulated Other Comprehensive Loss	Reclassifications out of Accumulated Other Comprehensive Loss (1) Fiscal Year Ended December 28, December 30, December 31, 2024 2023 2022 Details about Other Comprehensive Amounts Reclassified from Affected Line Item in the Gain (Loss) on Qualifying Hedges Interest rate contracts $ 3,545 $ 12,980 $ ( 3,090 ) Interest expense 3,545 12,980 ( 3,090 ) Loss before income taxes ( 895 ) ( 3,242 ) 774 Provision for (benefit from) income taxes $ 2,650 $ 9,738 $ ( 2,316 ) Net loss (1) Amounts in parentheses indicate debits to profit/loss

Restructuring (Tables)

Restructuring (Tables)	12 Months Ended
	Dec. 28, 2024
Restructuring and Related Activities [Abstract]
Schedule of Components of Restructuring Expenses	For the fiscal year ended December 28, 2024, the components of the Company’s restructuring charges for the 2024 Plan were as follows: Fiscal Year Ended December 28, 2024 Cash restructuring charges: Employee termination benefit costs $ 15,734 Lease termination costs 168 Other cash restructuring charges 1,141 Total restructuring charges $ 17,043 For the fiscal year ended December 28, 2024, restructuring charges for the 2024 Plan were recorded in the Company’s consolidated statements of operations as follows: Fiscal Year Ended December 28, 2024 Cost of revenues $ 2,497 Selling, general and administrative expenses 14,546 Total restructuring charges $ 17,043 For the fiscal year ended December 28, 2024, the components of the Company’s restructuring charges for the 2023 Plan were as follows: Fiscal Year Ended December 28, 2024 Cash restructuring charges: Real Estate Restructuring - Lease termination costs $ ( 135 ) Real Estate Restructuring - Employee termination benefit costs 2,438 Organizational Restructuring - Employee termination benefit costs 2,213 Other cash restructuring charges 581 Total cash restructuring charges $ 5,097 Non-cash restructuring charges 25 Total restructuring charges $ 5,122 For the fiscal year ended December 28, 2024, restructuring charges for the 2023 Plan were recorded in the Company’s consolidated statements of operations as follows: Fiscal Year Ended December 28, 2024 Cost of revenues $ 2,510 Selling, general and administrative expenses 2,612 Total restructuring charges $ 5,122 For the fiscal year ended December 30, 2023, the components of the Company’s restructuring charges for the 2023 Plan were as follows: Fiscal Year Ended December 30, 2023 Cash restructuring charges: Real Estate Restructuring - Lease termination costs $ 12,924 Real Estate Restructuring - Employee termination benefit costs 5,678 Organizational Restructuring - Employee termination benefit costs 26,927 Other cash restructuring charges 1,577 Total cash restructuring charges $ 47,106 Non-cash restructuring charges: Accelerated depreciation and amortization charges $ 6,831 Other non-cash restructuring charges ( 194 ) Total non-cash restructuring charges $ 6,637 Total restructuring charges $ 53,743 For the fiscal year ended December 30, 2023, restructuring charges for the 2023 Plan were recorded in the Company’s consolidated statements of operations as follows: Fiscal Year Ended December 30, 2023 Cost of revenues $ 21,116 Selling, general and administrative expenses 32,627 Total restructuring charges $ 53,743 For the fiscal year ended December 31, 2022, the components of the Company’s restructuring charges for the 2023 Plan were as follows: Fiscal Year Ended December 31, 2022 Cash restructuring charges: Real Estate Restructuring - Employee termination benefit costs $ 1,798 Organizational Restructuring - Employee termination benefit costs 11,810 Total restructuring charges $ 13,608 For the fiscal year ended December 31, 2022, restructuring charges for the 2023 Plan were recorded in the Company’s consolidated statements of operations as follows: Fiscal Year Ended December 31, 2022 Cost of revenues $ 1,798 Selling, general and administrative expenses 11,810 Total restructuring charges $ 13,608 For the fiscal year ended December 31, 2022, the components of the Company’s restructuring charges for the 2022 Plan were as follows: Fiscal Year Ended December 31, 2022 Cash restructuring charges: Lease termination costs $ 2,424 Employee termination benefit costs 19,170 Other cash restructuring charges 995 Total cash restructuring charges $ 22,589 Non-cash restructuring charges: Lease impairments $ 2,680 Accelerated depreciation and amortization charges 1,453 Other non-cash restructuring charges 459 Total non-cash restructuring charges $ 4,592 Total restructuring charges $ 27,181 For the fiscal year ended December 31, 2022, restructuring charges for the 2022 Plan were recorded in the Company’s consolidated statements of operations as follows: Fiscal Year Ended December 31, 2022 Cost of revenues $ 6,476 Selling, general and administrative expenses 20,705 Total restructuring charges $ 27,181
Schedule of Restructuring-related Liabilities	The following table presents a roll-forward of cash restructuring-related liabilities, which is included within accrued expenses in the Company’s consolidated balance sheets: Employee termination benefit costs Lease termination costs Other cash restructuring charges Total Balance as of December 30, 2023 $ — $ — $ — $ — Charges 15,520 168 1,141 16,829 Payments ( 8,590 ) — ( 1,141 ) ( 9,731 ) Change in estimate 214 — — 214 Balance as of December 28, 2024 $ 7,144 $ 168 $ — $ 7,312 The following table presents a roll-forward of cash restructuring-related liabilities, which is included within accrued expenses in the Company’s consolidated balance sheets: Real Estate Restructuring - Real Estate Restructuring - Organizational Restructuring - Lease Employee Employee Other cash Total Balance as of December 31, 2022 $ — $ 1,798 $ 11,810 $ — $ 13,608 Charges 12,924 5,678 26,927 1,577 47,106 Payments ( 12,768 ) ( 4,813 ) ( 15,142 ) ( 1,233 ) ( 33,956 ) Balance as of December 30, 2023 $ 156 $ 2,663 $ 23,595 $ 344 $ 26,758 Charges — 2,363 2,547 581 5,491 Payments ( 21 ) ( 1,835 ) ( 19,342 ) ( 925 ) ( 22,123 ) Change in estimate ( 135 ) 75 ( 334 ) — ( 394 ) Balance as of December 28, 2024 $ — $ 3,266 $ 6,466 $ — $ 9,732 The following table presents a roll-forward of cash restructuring-related liabilities, which is included within accrued expenses in the Company’s consolidated balance sheets: Lease termination costs Employee termination benefit costs Other cash restructuring charges Total Balance as of January 1, 2022 $ — $ — $ — $ — Charges 2,424 19,170 995 22,589 Payments ( 1,877 ) ( 10,909 ) — ( 12,786 ) Balance as of December 31, 2022 $ 547 $ 8,261 $ 995 $ 9,803 Payments ( 122 ) ( 8,880 ) ( 995 ) ( 9,997 ) Change in estimate ( 425 ) 1,560 — 1,135 Balance as of December 30, 2023 $ — $ 941 $ — $ 941 Payments — ( 949 ) — ( 949 ) Change in estimate — 8 — 8 Balance as of December 28, 2024 $ — $ — $ — $ —

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail) $ in Thousands		12 Months Ended
	Mar. 30, 2025	Mar. 29, 2025	Dec. 28, 2024 USD ($)	Dec. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Feb. 01, 2025	Jan. 31, 2025 USD ($)	Jan. 02, 2025 USD ($)	Jan. 01, 2022 USD ($)
Basis of Presentation [Line Items]
Operating loss			$ (236,222)	$ 22,333	$ (283,971)
Net loss			(345,701)	(112,255)	(256,868)
Franchise rights acquired and goodwill impairments			315,033	3,633	396,727
Cash used for operating activities			(16,840)	6,686	76,646
Interest payments			96,844	91,614	76,216
Revenues			785,921	889,551	1,039,835
Revenue decline by closure of consumer products business			54,968
Total Deficit			(1,114,372)	(761,094)	(685,780)				$ (452,904)
Long-term debt			1,430,643	1,426,464
Interest expense			108,954	95,893	$ 81,141
Cash and cash equivalents			53,024	109,366
Cash maintained at foreign subsidiaries			22,024
Loan outstanding amount			1,445,000	1,445,000
Error Corrected in Second Quarter of Fiscal 2024
Basis of Presentation [Line Items]
Income tax expense (benefit) out-of-period adjustment			2,748
Error Corrected in Fourth Quarter of Fiscal 2024
Basis of Presentation [Line Items]
Income tax expense (benefit) out-of-period adjustment			(1,963)
Employee Termination Benefit Costs
Basis of Presentation [Line Items]
Severance payments			30,716
Term Loan Facility due April 13, 2028
Basis of Presentation [Line Items]
Loan outstanding amount			945,000	945,000
Senior Secured Notes due April 15, 2029
Basis of Presentation [Line Items]
Loan outstanding amount			$ 500,000	$ 500,000
Interest Rate			4.50%
Revolving Credit Facility
Basis of Presentation [Line Items]
Loan outstanding amount			$ 0
Minimum outstanding amount to compliance springing maintenance covenant			35%
Credit Facility, maximum borrowing capacity			$ 61,250
Consolidated first lien leverage ratio			8.36
Revolving Credit Facility | Forecast
Basis of Presentation [Line Items]
Consolidated first lien leverage ratio compliance	5	5.25
Revolving Credit Facility | Subsequent Event
Basis of Presentation [Line Items]
Loan outstanding amount							$ 121,341	$ 50,000
Interest Rate						7.30%

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]
Leases, Practical Expedient, Description	The Company has elected the short-term lease exception accounting policy, whereby the recognition requirements of the updated guidance is not applied and lease expense is recorded on a straight-line basis with respect to leases with an initial term of 12 months or less.
Lease asset impairment charge			$ 2,680
Franchise rights maturity period	7 years
Net book value of goodwill	$ 239,583	$ 243,441	155,998
Revenue, practical expedient, remaining performance obligation, description	contracts with an original expected length of one year or less.
Revenue, remaining performance obligation, optional exemption, performance obligation	true
Advertising expenses	$ 234,316	235,227	238,978
Deferred financing costs, amortization expense	5,018	5,018	5,018
Allowance for credit write offs	$ 15,080	1,241
Minimum
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]
Equipment, estimated useful life (in years)	3 years
Finite-lived intangible assets, estimated useful life (in years)	3 years
Maximum
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]
Equipment, estimated useful life (in years)	10 years
Finite-lived intangible assets, estimated useful life (in years)	20 years
Property and Equipment
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]
Long-lived assets, impairment charges	$ 339	212	61
Friendly-Physician Entities
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]
Percentage of equity interest of physician-owners	100%
Behavioral Reporting Unit
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]
Net book value of goodwill	$ 149,841
Percentage of goodwill held	62.50%
Clinical Reporting Unit
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]
Net book value of goodwill	$ 89,742
Percentage of goodwill held	37.50%
Internal Use Computer Software and Website Development Costs
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]
Long-lived assets, impairment charges	$ 142	900	$ 714
Franchise Rights Acquired | Maximum
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]
Finite-lived intangible assets, estimated useful life (in years)	1 year
Internal Use Computer Software and Website Development Costs | Minimum
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]
Finite-lived intangible assets, estimated useful life (in years)	3 years
Internal Use Computer Software and Website Development Costs | Maximum
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]
Finite-lived intangible assets, estimated useful life (in years)	5 years
United States | Franchise Rights Acquired
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]
Net book value of franchise rights acquired	$ 68,627	$ 374,353
Percentage of franchise rights acquired held	100%	97.60%
United Kingdom | Franchise Rights Acquired
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]
Net book value of franchise rights acquired		$ 2,806
Percentage of franchise rights acquired held		0.70%
Australia | Franchise Rights Acquired
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]
Net book value of franchise rights acquired		$ 4,232
Percentage of franchise rights acquired held		1.10%
New Zealand | Franchise Rights Acquired
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]
Net book value of franchise rights acquired		$ 2,420
Percentage of franchise rights acquired held		0.60%

Accounting Standards Adopted _2

Accounting Standards Adopted in Current Year - Additional Information (Detail)	12 Months Ended
	Dec. 28, 2024
Accounting Changes and Error Corrections [Abstract]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true
Accounting Standards Update [Extensible Enumeration]	us-gaap:AccountingStandardsUpdate202307Member

Leases - Schedule of Lease Asse

Leases - Schedule of Lease Assets and Lease Liabilities (Detail) - USD ($) $ in Thousands	Dec. 28, 2024	Dec. 30, 2023
Assets:
Operating leases	$ 42,047	$ 52,272
Finance leases		$ 5
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]		Property and equipment, net
Total lease assets	42,047	$ 52,277
Current
Operating leases	8,168	9,613
Finance leases		$ 4
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]		Other accrued liabilities
Noncurrent
Operating leases	44,322	$ 53,461
Total lease liabilities	$ 52,490	$ 63,078

Leases - Schedule of Components

Leases - Schedule of Components of Lease Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Operating lease cost:
Fixed lease cost	$ 15,444	$ 21,259	$ 33,227
Lease termination cost	34	12,718	2,726
Variable lease cost	23	62	27
Total operating lease cost	15,501	34,039	35,980
Finance lease cost:
Amortization of leased assets	4	48	112
Interest on lease liabilities	0	1	6
Total finance lease cost	4	49	118
Total lease cost	$ 15,505	$ 34,088	$ 36,098

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Lessee Lease Description [Line Items]
Lease weighted average remaining lease term	6 years 10 months 2 days
Lease asset impairment charge			$ 2,680
Sublease income	$ 4,217	$ 3,375
Selling, General and Administrative Expenses
Lessee Lease Description [Line Items]
Lease asset impairment charge			$ 2,680
Minimum
Lessee Lease Description [Line Items]
Leases, remaining lease term	0 years
Maximum
Lessee Lease Description [Line Items]
Leases, remaining lease term	8 years

Leases - Summary of Weighted Av

Leases - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rates (Detail)	Dec. 28, 2024	Dec. 30, 2023
Weighted Average Remaining Lease Term (years)
Operating leases	6 years 10 months 2 days	7 years 3 months 21 days
Finance leases		5 months 23 days
Weighted Average Discount Rate
Operating leases	7.68%	7.54%
Finance leases		4.10%

Leases - Schedule of Maturity o

Leases - Schedule of Maturity of Operating Lease Liabilities (Detail) $ in Thousands	Dec. 28, 2024 USD ($)
Operating Leases
Fiscal 2025	$ 11,977
Fiscal 2026	10,088
Fiscal 2027	9,307
Fiscal 2028	9,073
Fiscal 2029	8,963
Thereafter	17,852
Total lease payments	67,260
Less imputed interest	14,770
Present value of lease liabilities	$ 52,490

Leases - Summary of Supplementa

Leases - Summary of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$ 15,786	$ 22,013	$ 31,580
Operating cash flows from finance leases	0	1	6
Financing cash flows from finance leases	4	48	112
Lease assets obtained (modified) in exchange for new (modified) operating lease liabilities	$ 968	$ (7,086)	13,297
Lease assets obtained in exchange for new finance lease liabilities			$ 49

Revenue - Schedule of Revenues

Revenue - Schedule of Revenues Disaggregated by Revenue Source (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Disaggregation Of Revenue [Line Items]
Revenues, net	$ 785,921	$ 889,551	$ 1,039,835
Digital Subscription Revenues
Disaggregation Of Revenue [Line Items]
Revenues, net	512,853	571,074	662,668
Workshops + Digital Subscription Revenues
Disaggregation Of Revenue [Line Items]
Revenues, net	186,139	221,139	256,387
Clinical Subscription Revenues
Disaggregation Of Revenue [Line Items]
Revenues, net	78,001	30,542
Subscription Revenues, net
Disaggregation Of Revenue [Line Items]
Revenues, net	776,993	822,755	919,055
Other Revenues, net
Disaggregation Of Revenue [Line Items]
Revenues, net	$ 8,928	$ 66,796	$ 120,780

Revenue - Schedule of Deferred

Revenue - Schedule of Deferred Revenues (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Deferred Revenue - Short Term
Contract With Customer Asset And Liability [Line Items]
Deferred Revenue, Beginning balance	$ 33,966	$ 32,156
Net increase (decrease) during the period	(2,311)	1,810
Deferred Revenue, Ending balance	31,655	33,966
Deferred Revenue - Long Term
Contract With Customer Asset And Liability [Line Items]
Deferred Revenue, Beginning balance	165	360
Net increase (decrease) during the period	(72)	(195)
Deferred Revenue, Ending balance	$ 93	$ 165

Revenue - Additional Informatio

Revenue - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Revenues [Abstract]
Deferred revenue recognized	$ 33,753	$ 32,156

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands						12 Months Ended
	Feb. 20, 2024	Apr. 10, 2023	Feb. 17, 2023	Feb. 18, 2022	Dec. 21, 2021	Dec. 30, 2023	Apr. 10, 2025	Dec. 28, 2024	Apr. 10, 2024	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill						$ 243,441		$ 239,583		$ 155,998
Business acquisition, purchase price allocation, tax asset valuation allowance						89,801		$ 178,451
Denross Limited
Business Acquisition [Line Items]
Business acquisition, aggregate purchase price				$ 4,500
Business acquisition, cash payment	$ 375		$ 375	3,100	$ 650
Business acquisition, cash in reserves				750
Business acquisition, purchase price allocation, assumed liabilities				166
Business acquisition, purchase price allocation, cash				4
Goodwill				4,645
Business acquisition, purchase price allocation, deferred tax asset				496
Business acquisition, purchase price allocation, tax asset valuation allowance				496
Business acquisition, purchase price allocation, other receivables				3
Denross Limited | Customer Relationship
Business Acquisition [Line Items]
Business acquisition, purchase price allocation, finite lived intangible assets				14
Checkweight Limited
Business Acquisition [Line Items]
Business acquisition, aggregate purchase price				1,500
Business acquisition, cash payment	$ 125		$ 125	1,250
Business acquisition, cash in reserves				250
Business acquisition, purchase price allocation, assumed liabilities				56
Business acquisition, purchase price allocation, cash				4
Goodwill				1,291
Business acquisition, purchase price allocation, deferred tax asset				5
Business acquisition, purchase price allocation, tax asset valuation allowance				5
Business acquisition, purchase price allocation, other receivables				4
Checkweight Limited | Franchise Rights Acquired
Business Acquisition [Line Items]
Business acquisition, purchase price allocation, finite lived intangible assets				240
Checkweight Limited | Customer Relationship
Business Acquisition [Line Items]
Business acquisition, purchase price allocation, finite lived intangible assets				$ 17
Weekend Health, Inc. d/b/a Sequence
Business Acquisition [Line Items]
Business acquisition effective date		Apr. 10, 2023
Business acquisition, aggregate purchase price		$ 132,000
Business acquisition, cash payment		64,217
Business acquisition, purchase price allocation, cash		25,800
Business acquisition, amount paid one year from closing date									$ 16,000
Transaction related costs						$ 8,605
Weekend Health, Inc. d/b/a Sequence | Scenario Forecast
Business Acquisition [Line Items]
Business acquisition, amount to be paid two years from closing date							$ 16,000
Weekend Health, Inc. d/b/a Sequence | Common Stock
Business Acquisition [Line Items]
Business acquisition, equity interest issued as consideration for acquisition, value		$ 34,702
Business acquisition, equity interest issued as consideration for acquisition, shares		7,996
Business acquisition, common stock price per share		$ 4.34

Acquisitions - Summary of Purch

Acquisitions - Summary of Purchase Price Allocation for Acquired Identifiable Assets, Liabilities Assumed and Goodwill (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		Apr. 10, 2023	Apr. 10, 2025	Dec. 28, 2024	Apr. 10, 2024	Dec. 30, 2023	Dec. 31, 2022
Liabilities assumed:
Total goodwill				$ 239,583		$ 243,441	$ 155,998
Weekend Health, Inc. d/b/a Sequence
Total consideration:
Cash paid at closing		$ 64,217
Cash paid on April 10, 2024					$ 16,000
Aggregated merger consideration		132,000
Assets acquired:
Cash		$ 25,800
Weekend Health, Inc. d/b/a Sequence | Common Stock
Total consideration:
Common shares issued		7,996
Stock price as of April 10, 2023		$ 4.34
Weekend Health, Inc. d/b/a Sequence | Purchase Price Allocation
Total consideration:
Cash paid at closing		$ 64,217
Cash paid on April 10, 2024					$ 16,000
Total cash payments		92,637
Less stock-based compensation expense attributable to post combination vesting		(3,882)
Aggregated merger consideration		121,698
Assets acquired:
Cash		25,776
Prepaid expenses and other current assets		2,220
Property, plant and equipment		34
Intangible assets		7,222
Total assets acquired		35,252
Liabilities assumed:
Accounts payable		70
Accrued liabilities		14
Deferred revenue		1,300
Deferred tax liability		1,912
Total liabilities assumed		3,296
Net assets acquired		31,956
Total goodwill		$ 89,742
Weekend Health, Inc. d/b/a Sequence | Purchase Price Allocation | Common Stock
Total consideration:
Common shares issued		7,996
Stock price as of April 10, 2023	[1]	$ 4.12
Total stock issuance purchase price	[1]	$ 32,943
Weekend Health, Inc. d/b/a Sequence | Scenario Forecast
Total consideration:
Cash to be paid on April 10, 2025			$ 16,000
Weekend Health, Inc. d/b/a Sequence | Scenario Forecast | Purchase Price Allocation
Total consideration:
Cash to be paid on April 10, 2025	[2]		$ 12,420
[1] Represents the fair value of the shares transferred to the sellers as Merger Consideration, based on the number of shares to be issued, 7,996 , multiplied by the closing price of the Company's shares on April 10, 2023 of $ 4.12 per share. Reflects $ 16,000 of cash payable on April 10, 2025 as Merger Consideration discounted using the Company's weighted average cost of debt.

Acquisitions - Summary of Pur_2

Acquisitions - Summary of Purchase Price Allocation for Acquired Identifiable Assets, Liabilities Assumed and Goodwill (Parenthetical) (Detail) - Weekend Health, Inc. d/b/a Sequence - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		Apr. 10, 2023	Apr. 10, 2025
Scenario Forecast
Business Acquisition [Line Items]
Cash to be paid on April 10, 2025			$ 16,000
Common Stock
Business Acquisition [Line Items]
Common shares issued		7,996
Stock price		$ 4.34
Purchase Price Allocation | Scenario Forecast
Business Acquisition [Line Items]
Cash to be paid on April 10, 2025	[1]		$ 12,420
Purchase Price Allocation | Common Stock
Business Acquisition [Line Items]
Common shares issued		7,996
Stock price	[2]	$ 4.12
[1] Reflects $ 16,000 of cash payable on April 10, 2025 as Merger Consideration discounted using the Company's weighted average cost of debt. Represents the fair value of the shares transferred to the sellers as Merger Consideration, based on the number of shares to be issued, 7,996 , multiplied by the closing price of the Company's shares on April 10, 2023 of $ 4.12 per share.

Franchise Rights Acquired, Go_3

Franchise Rights Acquired, Goodwill and Other Intangible Assets - Additional Information (Detail)

3 Months Ended

12 Months Ended

May 05, 2024 USD ($)

May 07, 2023 USD ($)

May 08, 2022 USD ($)

Aug. 10, 2018 USD ($)

Sep. 28, 2024 USD ($)

Mar. 30, 2024 USD ($)

Dec. 30, 2023 USD ($)

Dec. 31, 2022 USD ($)

Oct. 01, 2022 USD ($)

Jul. 02, 2022 USD ($)

Dec. 28, 2024 USD ($) Segment

Dec. 30, 2023 USD ($)

Dec. 31, 2022 USD ($)

Goodwill And Intangible Assets Disclosure [Line Items]

Accumulated goodwill impairment loss

$ 25,111,000

$ 25,111,000

$ 25,111,000

Number of reportable segments | Segment

1

Number of operating segments | Segment

1

Net book value of goodwill

243,441,000

$ 155,998,000

$ 239,583,000

243,441,000

$ 155,998,000

Goodwill impairment

$ 0

$ 0

$ 0

$ 0

$ 0

3,586,000

Finite-lived intangible assets, aggregate amortization expense

$ 33,596,000

$ 42,449,000

$ 33,676,000

Kurbo, Inc

Goodwill And Intangible Assets Disclosure [Line Items]

Goodwill impairment

$ 1,101,000

Kurbo Health, Inc

Goodwill And Intangible Assets Disclosure [Line Items]

Net purchase price

$ 3,063,000

Net book value of goodwill

$ 1,101,000

Behavioral Reporting Unit

Goodwill And Intangible Assets Disclosure [Line Items]

Percentage of goodwill held

62.50%

Net book value of goodwill

$ 149,841,000

Goodwill impairment

$ 0

Behavioral Reporting Unit | Minimum

Goodwill And Intangible Assets Disclosure [Line Items]

Percentage of estimated fair value in excess of carrying amount

100%

Clinical Reporting Unit

Goodwill And Intangible Assets Disclosure [Line Items]

Percentage of goodwill held

37.50%

Net book value of goodwill

$ 89,742,000

Goodwill impairment

$ 0

Clinical Reporting Unit | Minimum

Goodwill And Intangible Assets Disclosure [Line Items]

Percentage of estimated fair value in excess of carrying amount

20%

All Reporting Units | Minimum

Goodwill And Intangible Assets Disclosure [Line Items]

Percentage of estimated fair value in excess of carrying amount

30%

25%

Republic of Ireland

Goodwill And Intangible Assets Disclosure [Line Items]

Goodwill impairment

2,383,000

2,023,000

Northern Ireland

Goodwill And Intangible Assets Disclosure [Line Items]

Goodwill impairment

1,203,000

Franchise Rights Acquired | Northern Ireland

Goodwill And Intangible Assets Disclosure [Line Items]

Finite-lived intangible assets, impairment charges

$ 47,000

Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]

Franchise rights acquired and goodwill impairments

Franchise Rights Acquired

Goodwill And Intangible Assets Disclosure [Line Items]

Indefinite-lived intangible assets, impairment charges

$ 0

$ 0

Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]

Franchise rights acquired and goodwill impairments

Franchise rights acquired and goodwill impairments

Franchise Rights Acquired | Other Units of Account

Goodwill And Intangible Assets Disclosure [Line Items]

Indefinite-lived intangible assets, impairment charges

$ 0

Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]

Franchise rights acquired and goodwill impairments

Franchise Rights Acquired | Australia

Goodwill And Intangible Assets Disclosure [Line Items]

Indefinite-lived intangible assets, impairment charges

$ 4,074,000

$ 1,872,000

Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]

Franchise rights acquired and goodwill impairments

Franchise rights acquired and goodwill impairments

Percentage of franchise rights acquired held

1.10%

1.10%

Net book value of franchise rights acquired

$ 4,232,000

$ 4,232,000

Franchise Rights Acquired | United States

Goodwill And Intangible Assets Disclosure [Line Items]

Indefinite-lived intangible assets, impairment charges

$ 0

$ 54,295,000

$ 251,431,000

$ 25,739,000

$ 298,291,000

Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]

Franchise rights acquired and goodwill impairments

Franchise rights acquired and goodwill impairments

Franchise rights acquired and goodwill impairments

Franchise rights acquired and goodwill impairments

Franchise rights acquired and goodwill impairments

Percentage of franchise rights acquired held

97.60%

100%

97.60%

Net book value of franchise rights acquired

$ 374,353,000

$ 68,627,000

$ 374,353,000

Franchise Rights Acquired | United States | Minimum

Goodwill And Intangible Assets Disclosure [Line Items]

Percentage of estimated fair value in excess of carrying amount

5%

Franchise Rights Acquired | United Kingdom

Goodwill And Intangible Assets Disclosure [Line Items]

Indefinite-lived intangible assets, impairment charges

$ 0

$ 2,750,000

$ 155,000

$ 8,275,000

Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]

Franchise rights acquired and goodwill impairments

Franchise rights acquired and goodwill impairments

Franchise rights acquired and goodwill impairments

Franchise rights acquired and goodwill impairments

Percentage of franchise rights acquired held

0.70%

0.70%

Net book value of franchise rights acquired

$ 2,806,000

$ 2,806,000

Franchise Rights Acquired | United Kingdom | Minimum

Goodwill And Intangible Assets Disclosure [Line Items]

Percentage of estimated fair value in excess of carrying amount

5%

Franchise Rights Acquired | Canada

Goodwill And Intangible Assets Disclosure [Line Items]

Indefinite-lived intangible assets, impairment charges

$ 19,657,000

$ 13,312,000

$ 24,485,000

Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]

Franchise rights acquired and goodwill impairments

Franchise rights acquired and goodwill impairments

Franchise rights acquired and goodwill impairments

Franchise Rights Acquired | New Zealand

Goodwill And Intangible Assets Disclosure [Line Items]

Indefinite-lived intangible assets, impairment charges

$ 2,328,000

$ 0

$ 1,138,000

$ 834,000

Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]

Franchise rights acquired and goodwill impairments

Franchise rights acquired and goodwill impairments

Franchise rights acquired and goodwill impairments

Franchise rights acquired and goodwill impairments

Percentage of franchise rights acquired held

0.60%

0.60%

Net book value of franchise rights acquired

$ 2,420,000

$ 2,420,000

Franchise Rights Acquired, Go_4

Franchise Rights Acquired, Goodwill and Other Intangible Assets - Change in Carrying Value of Goodwill (Detail) - USD ($)				3 Months Ended		12 Months Ended
	May 05, 2024	May 07, 2023	May 08, 2022	Sep. 28, 2024	Mar. 30, 2024	Dec. 28, 2024	Dec. 30, 2023
Goodwill [Line Items]
Beginning balance					$ 243,441,000	$ 243,441,000	$ 155,998,000
Goodwill acquired during the period							89,742,000
Goodwill impairment	$ 0	$ 0	$ 0	$ 0	$ 0		(3,586,000)
Effect of exchange rate changes						(3,858,000)	1,287,000
Ending balance						$ 239,583,000	$ 243,441,000

Franchise Rights Acquired, Go_5

Franchise Rights Acquired, Goodwill and Other Intangible Assets - Schedule of Carrying Values of Finite-lived Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 28, 2024	Dec. 30, 2023
Finite-Lived Intangible Assets
Gross Carrying Amount	$ 289,371	$ 285,618
Accumulated Amortization	242,236	219,695
Capitalized software and website development costs
Finite-Lived Intangible Assets
Gross Carrying Amount	255,822	251,410
Accumulated Amortization	218,103	195,696
Trademarks
Finite-Lived Intangible Assets
Gross Carrying Amount	12,192	12,188
Accumulated Amortization	12,103	12,024
Other
Finite-Lived Intangible Assets
Gross Carrying Amount	13,537	13,991
Accumulated Amortization	6,714	6,661
Trademarks and other intangible assets
Finite-Lived Intangible Assets
Gross Carrying Amount	281,551	277,589
Accumulated Amortization	236,920	214,381
Franchise rights acquired
Finite-Lived Intangible Assets
Gross Carrying Amount	7,820	8,029
Accumulated Amortization	$ 5,316	$ 5,314

Franchise Rights Acquired, Go_6

Franchise Rights Acquired, Goodwill and Other Intangible Assets - Schedule of Estimated Amortization Expense of Finite-lived Intangible Assets (Detail) $ in Thousands	Dec. 28, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Fiscal 2025	$ 22,025
Fiscal 2026	13,143
Fiscal 2027	4,776
Fiscal 2028	727
Fiscal 2029	704
Thereafter	$ 5,760

Property and Equipment (Detail)

Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 28, 2024	Dec. 30, 2023
Property, Plant and Equipment [Abstract]
Equipment	$ 24,561	$ 31,264
Leasehold improvements	40,802	42,039
Property and equipment, gross	65,363	73,303
Less: Accumulated depreciation and amortization	(49,565)	(53,562)
Property and equipment, net	$ 15,798	$ 19,741

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense, property and equipment	$ 4,188	$ 10,022	$ 10,125

Long-Term Debt - Components of

Long-Term Debt - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands		Dec. 28, 2024	Dec. 30, 2023
Debt Instrument
Total debt		$ 1,445,000	$ 1,445,000
Unamortized deferred financing costs		6,889	8,770
Unamortized debt discount		7,468	9,766
Total long term debt		$ 1,430,643	$ 1,426,464
Effective rate	[1]	7.74%	7.64%
Revolving Credit Facility due April 13, 2026
Debt Instrument
Total debt		$ 0
Effective rate	[1]	0%	0%
Term Loan Facility due April 13, 2028
Debt Instrument
Total debt		$ 945,000	$ 945,000
Unamortized deferred financing costs		3,604	4,712
Unamortized debt discount		$ 7,468	$ 9,766
Effective rate	[1]	9.37%	9.21%
Senior Secured Notes due April 15, 2029
Debt Instrument
Total debt		$ 500,000	$ 500,000
Unamortized deferred financing costs		$ 3,285	$ 4,058
Effective rate	[1]	4.69%	4.70%
[1] Includes amortization of deferred financing costs and debt discount.

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail)						12 Months Ended
		Mar. 30, 2025	Jul. 01, 2023	Jul. 03, 2021 USD ($)	Apr. 13, 2021 USD ($)	Mar. 29, 2025	Dec. 28, 2024 USD ($)	Dec. 30, 2023 USD ($)
Debt Instrument
Loan outstanding amount							$ 1,445,000,000	$ 1,445,000,000
Aggregate principal amount							$ 1,430,643,000	$ 1,426,464,000
Percentage of equity interests pledged							100%
Percentage of annual excess cash flow							50%
Percentage of annual excess cash flow after attaining first lien secured net leverage ratio one							25%
Percentage of annual excess cash flow after attaining first lien secured net leverage ratio two							0%
Percentage of net cash proceeds of certain non ordinary course asset sales by company and its restricted subsidiaries							100%
Percentage of right to invest of net cash proceeds of certain non ordinary course asset sales by company and its restricted subsidiaries subject to certain qualifications							100%
Percentage of net proceeds of any issuance or incurrence of debt by the Company or any of its restricted subsidiaries							100%
Effective Interest Rate	[1]						7.74%	7.64%
Average interest rate on outstanding debt, exclusive the impact of swap							7.75%	7.64%
Average interest rate on outstanding debt, including the impact of swap							7.47%	6.53%
One-Month Term Secured Overnight Financing Rate (SOFR)
Debt Instrument
Credit facility, interest rate			0.11448%
Three-Month Term Secured Overnight Financing Rate (SOFR)
Debt Instrument
Credit facility, interest rate			0.26161%
Six-Month Term Secured Overnight Financing Rate (SOFR)
Debt Instrument
Credit facility, interest rate			0.42826%
Twelve-Month Term Secured Overnight Financing Rate (SOFR)
Debt Instrument
Credit facility, interest rate			0.71513%
Maximum
Debt Instrument
Pledge percentage of first tier foreign subsidiaries directly owned by company or wholly owned subsidiaries							65%
4.500% Senior Secured Notes due 2029
Debt Instrument
Debt Instrument, maturity year				2029
Debt Instrument Interest Rate Stated Percentage				4.50%
Aggregate principal amount				$ 500,000,000
Credit Facilities
Debt Instrument
Credit Facility, maximum borrowing capacity				$ 1,000,000,000
Loan outstanding amount							$ 945,000,000
Term Loan Facility due April 13, 2028
Debt Instrument
Loan outstanding amount							$ 945,000,000	$ 945,000,000
Effective Interest Rate	[1]						9.37%	9.21%
Term Loan Facility due April 13, 2028 | Federal Funds Effective Rate
Debt Instrument
Credit facility, interest rate							0.50%
Term Loan Facility due April 13, 2028 | Secured Overnight Financing Rate (SOFR)
Debt Instrument
Credit facility, interest rate							1%
Debt instrument variable rate floor percent determined option one							0.50%
Effective Interest Rate							3.50%
Term Loan Facility due April 13, 2028 | Maximum | Secured Overnight Financing Rate (SOFR)
Debt Instrument
Debt instrument variable rate floor percent determined option one							1.50%
Senior Secured Notes due April 15, 2029
Debt Instrument
Debt Instrument Interest Rate Stated Percentage							4.50%
Loan outstanding amount							$ 500,000,000	$ 500,000,000
Effective Interest Rate	[1]						4.69%	4.70%
Debt instrument issued date							Apr. 13, 2021
Debt instrument, mature date							Apr. 15, 2029
Debt instrument interest payment term							Interest on the Senior Secured Notes is payable semi-annually on April 15 and October 15 of each year.
Debt Instrument, redemption, description							April 15, 2024, the Company may on any one or more occasions redeem some or all of the Senior Secured Notes at a purchase price equal to 102.250% of the principal amount of the Senior Secured Notes, plus accrued and unpaid interest, if any, to, but not including, the redemption date, such optional redemption price decreasing to 101.125% on or after April 15, 2025 and to 100.000% on or after April 15, 2026.
Senior Secured Notes due April 15, 2029 | Change of Control
Debt Instrument
Debt instrument, percentage of aggregate principal amount that may be redeemed (up to)							101%
Senior Secured Notes due April 15, 2029 | Sale of Assets
Debt Instrument
Debt instrument, percentage of aggregate principal amount that may be redeemed (up to)							100%
Senior Secured Notes due April 15, 2029 | Debt Instrument Redemption Date, April 15, 2024
Debt Instrument
Debt Instrument, percentage of principal can be redeemed							102.25%
Debt Instrument, redemption date							Apr. 15, 2024
Senior Secured Notes due April 15, 2029 | Debt Instrument Redemption Date, April 15, 2025
Debt Instrument
Debt Instrument, percentage of principal can be redeemed							101.125%
Debt Instrument, redemption date							Apr. 15, 2025
Senior Secured Notes due April 15, 2029 | Debt Instrument Redemption Date, April 15, 2026
Debt Instrument
Debt Instrument, percentage of principal can be redeemed							100%
Debt Instrument, redemption date							Apr. 15, 2026
Credit Facilities and Senior Secured Notes
Debt Instrument
Loan outstanding amount							$ 1,445,000,000
Revolving Credit Facility
Debt Instrument
Credit Facility, maximum borrowing capacity							61,250,000
Loan outstanding amount							0
Aggregate principal amount							0	$ 0
Credit facility available amount							173,841,000
Line of credit facility, issued but undrawn letters of credit							$ 1,159,000
Effective Interest Rate	[1]						0%	0%
Minimum outstanding amount to compliance springing maintenance covenant							35%
Consolidated first lien leverage ratio							8.36
Revolving Credit Facility | Forecast
Debt Instrument
Consolidated first lien leverage ratio compliance		5				5.25
Revolving Credit Facility | Federal Funds Effective Rate
Debt Instrument
Credit facility, interest rate							0.50%
Revolving Credit Facility | Secured Overnight Financing Rate (SOFR)
Debt Instrument
Credit facility, interest rate							1%
Debt instrument variable rate floor percent determined option one							0%
Effective Interest Rate							2.75%
Revolving Credit Facility | Maximum | Secured Overnight Financing Rate (SOFR)
Debt Instrument
Debt instrument variable rate floor percent determined option one							1%
Revolving Credit Facility | Senior Secured Revolving Credit Facility
Debt Instrument
Debt Instrument, maturity year					2026
Credit Facility, maximum borrowing capacity					$ 175,000,000
Term Loan Facility | Senior Secured Tranche B Term Loan
Debt Instrument
Debt Instrument, maturity year					2028
Credit Facility, maximum borrowing capacity					$ 1,000,000,000
[1] Includes amortization of deferred financing costs and debt discount.

Long-Term Debt - Long-Term Debt

Long-Term Debt - Long-Term Debt Maturities (Detail) - USD ($) $ in Thousands	Dec. 28, 2024	Dec. 30, 2023
Debt Disclosure [Abstract]
Fiscal 2027	$ 10,000
Fiscal 2028	935,000
Fiscal 2029	500,000
Total Debt	$ 1,445,000	$ 1,445,000

Treasury Stock - Additional Inf

Treasury Stock - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022	Oct. 21, 2010	May 25, 2006	Jun. 13, 2005	Oct. 09, 2003
Class of Stock Disclosures [Abstract]
Treasury Stock, value of common stock shares authorized for repurchase				$ 250,000,000	$ 250,000,000	$ 250,000,000	$ 250,000,000
Treasury Stock, common stock shares repurchased	0	0	0
Amount remained available to purchase shares under repurchase program	$ 208,933,000

Per Share Data - Computation of

Per Share Data - Computation of Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Numerator:
Net Income (Loss)	$ (345,701)	$ (112,255)	$ (256,868)
Denominator:
Weighted average shares of common stock outstanding	79,578	76,677	70,321
Weighted average diluted common shares outstanding	79,578	76,677	70,321
Net loss per share
Basic	$ (4.34)	$ (1.46)	$ (3.65)
Diluted	$ (4.34)	$ (1.46)	$ (3.65)

Per Share Data - Additional Inf

Per Share Data - Additional Information (Detail) - shares	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Earnings Per Share [Abstract]
Anti-dilutive common stock equivalents excluded from the calculation of diluted net loss per share	9,572	9,113	8,540

Stock Plans - Additional Inform

Stock Plans - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022	Dec. 28, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 7,764	$ 15,185	$ 12,957
Total income tax benefit recognized for all share-based compensation awards	1,197	1,850	2,603
Tax benefits realized from options exercised and RSUs and PSUs vested	658	1,287	1,017
Compensation costs capitalized	0	$ 0	$ 0
Total unrecognized compensation cost related to stock options and RSUs granted	$ 6,569
Compensation expense recognition period (years)	1 year 2 months 12 days
Options outstanding, exercise price, lower range	$ 5.25	$ 5.25	$ 5.25
Options outstanding, exercise price, upper range	$ 50	$ 50	50
Weighted-average grant-date fair value of all options granted			$ 3.96
Total intrinsic value of all options exercised	$ 0	$ 248	$ 0
Cash received from options exercised	$ 0	$ 718	$ 0
Dividend yield			0%
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average grant-date fair value granted	$ 1.32	$ 7.43	$ 6.69
Total fair value vested	$ 8,692	$ 7,943	$ 14,576
Granted	4,810
Vested	1,318
Incremental shares vested	$ 6.59
Performance-based Stock Unit
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (years)	3 years	3 years
Weighted-average grant-date fair value granted	$ 1.86	$ 13.8
Granted	598	239	0	280
Vested	0	0	0
Estimated fair value, per share	$ 1.86	$ 13.8
Volatility rate	97.80%	86.20%
Risk-free interest rate	4.59%	3.79%
Dividend yield	0%	0%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (years)			6 years
Minimum | Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period (years)	3 years	3 years	3 years
Expiration term (years)	7 years	7 years	7 years
Minimum | Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period (years)	1 year	1 year	1 year
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (years)			7 years
Maximum | Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period (years)	4 years	4 years	4 years
Expiration term (years)	10 years	10 years	10 years
Maximum | Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period (years)	3 years	3 years	3 years
Employees and Third Parties, Excluding Directors | Selling, General and Administrative Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 7,583	$ 10,715	$ 12,333
Share-based compensation expense attributable to post combination vesting		$ 3,882
2014 Stock Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of shares of common stock available for grant	12,500
2014 Stock Incentive Plan | Board of Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, fully-vested shares granted	53	70	77
Share based compensation, value of fully-vested shares granted	$ 181	$ 404	$ 624
2014 Stock Incentive Plan | Deferred Stock Units | Board of Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, fully-vested shares granted	89	54	27
Share based compensation, fully-vested shares settled	0	23
Share based compensation, value of fully-vested shares granted	$ 809	$ 373	$ 174

Stock Plans - Weighted Average

Stock Plans - Weighted Average Assumptions Used to Estimate Fair Value of Option Award on Grant Date (Detail)	12 Months Ended
	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0%
Volatility, minimum	57%
Volatility, maximum	57.10%
Risk-free interest rate, minimum	2.36%
Risk-free interest rate, maximum	2.86%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (years)	6 years
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (years)	7 years

Stock Plans - Summary of Option

Stock Plans - Summary of Option Activity (Detail) shares in Thousands	12 Months Ended
	Dec. 28, 2024 $ / shares shares
Shares
Beginning Balance | shares	6,951
Cancelled | shares	(1,919)
Ending Balance | shares	5,032
Exercisable at December 28, 2024 | shares	5,002
Weighted-Average Exercise Price
Beginning Balance | $ / shares	$ 34.57
Cancelled | $ / shares	38.4
Ending Balance | $ / shares	33.12
Exercisable at December 28, 2024 | $ / shares	$ 33.27
Weighted-Average Remaining Contractual Life, Outstanding at December 28, 2024	1 year 10 months 24 days
Weighted-Average Remaining Contractual Life, Exercisable at December 28, 2024	1 year 10 months 24 days

Stock Plans - Summary of RSU Ac

Stock Plans - Summary of RSU Activity Under Stock Plans (Detail) - Restricted Stock Units - $ / shares shares in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Shares
Beginning Balance	2,657
Granted	4,810
Vested	(1,318)
Forfeited	(2,061)
Ending Balance	4,088	2,657
Weighted-Average Grant-Date Fair Value
Beginning Balance	$ 7.75
Granted	1.32	$ 7.43	$ 6.69
Vested	6.59
Forfeited	4.76
Ending Balance	$ 2.06	$ 7.75

Stock Plans - Summary of PSU Ac

Stock Plans - Summary of PSU Activity Under Stock Plans (Detail) - Performance-Based Stock Units - $ / shares	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Shares
Beginning Balance	215
Granted	598
Vested	0	0	0
Forfeited	(655)
Ending Balance	158	215
Weighted-Average Grant-Date Fair Value
Beginning Balance	$ 13.8
Granted	1.86	$ 13.8
Forfeited	5.78
Ending Balance	$ 1.86	$ 13.8

Taxes - Components of Consolida

Taxes - Components of Consolidated Income Before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Domestic	$ (358,108)	$ (222,260)	$ (376,710)
Foreign	12,933	148,628	9,907
Loss before income taxes	$ (345,175)	$ (73,632)	$ (366,803)

Taxes - Summary of Consolidated

Taxes - Summary of Consolidated Provision for (Benefit from) U.S. Federal, State and Foreign Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Current:
U.S. federal	$ 6,369	$ 1,330	$ 12,426
State	1,519	1,947	3,446
Foreign	19,216	15,525	20,022
Current tax provision (benefit)	27,104	18,802	35,894
Deferred:
U.S. federal	(6,856)	(12,419)	(110,611)
State	(8,420)	4,263	(23,213)
Foreign	(11,302)	27,977	(12,005)
Deferred tax provision (benefit)	(26,578)	19,821	(145,829)
Total provision for (benefit from) income taxes	$ 526	$ 38,623	$ (109,935)

Taxes - Additional Information

Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Income Taxes [Line Items]
Effective income tax rate	(0.20%)	(52.50%)	30%
Tax benefit from legal entity restructuring			$ 45,748
Tax expense related to share-based awards	$ 5,342		1,732
Tax expense related to income earned in foreign jurisdictions		$ 12,172	2,245
Tax benefit related to state tax	15,689	9,441
Tax benefit related to foreign-derived intangible income	3,976	2,637	4,450
Tax expense from change in valuation allowance	87,624	53,626	27,108
Deferred tax assets, valuation allowance	178,451	89,801
Valuation allowance on remaining U.S. deferred tax assets		30,331
Additional valuation allowance on U.S. deferred tax assets	88,650
Net operating loss carry forwards	110,471	107,415
Undistributed foreign earnings	114,545
Total amount of unrecognized tax benefits, if recognized, would affect effective tax rate	424
Unrecognized tax benefits, accrued interest and penalties	33	83
Unrecognized tax benefits, interest and penalties recognized	(50)	0	(60)
Unrecognized tax benefits would reduce due to resolution of open tax matters	$ 120
Business Interest Expense Carryforwards
Income Taxes [Line Items]
Deferred tax assets, valuation allowance			$ 27,108
Increase in valuation allowance		$ 20,268

Taxes - Schedule of Effective I

Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
U.S. federal statutory tax rate	21%	21%	21%
State income taxes (net of federal benefit)	4.60%	12.80%	3.80%
Research and development credit	0.40%	3%	0.40%
Tax windfall/shortfall on share-based awards	(1.50%)	(0.90%)	(0.50%)
Tax rate changes	0%	(0.10%)	0.30%
Executive compensation limitation	(0.40%)	(1.40%)	(0.20%)
FDII	1.20%	3.60%	1.20%
Change in valuation allowance	(25.40%)	(72.80%)	(7.10%)
Impact of foreign operations	(0.30%)	(16.50%)	(1.60%)
Reversal of certain deferred tax liabilities	0%	0%	12.50%
Nondeductible costs	0%	(1.30%)	0%
Other	0.20%	0.10%	0.20%
Total effective tax rate	(0.20%)	(52.50%)	30%

Taxes - Deferred Tax Assets and

Taxes - Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 28, 2024	Dec. 30, 2023
Income Tax Disclosure [Abstract]
Interest expense disallowance	$ 101,563	$ 76,350
Operating lease liabilities	13,672	16,174
Operating loss carryforwards	11,703	12,446
Provision for estimated expenses	2,916	3,657
Salaries and wages	8,904	13,489
Share-based compensation	9,553	14,920
Other comprehensive income	6,995	3,833
Capitalized research and development expenses	34,767
Other	12,045	4,287
Less: valuation allowance	(178,451)	(89,801)
Total deferred tax assets	23,667	55,355
Goodwill and intangible assets	(663)	(47,323)
Operating lease assets	(10,941)	(13,285)
Depreciation	(9,000)	(12,749)
Termination fee		(3,408)
Prepaid expenses	(1,289)	(900)
Total deferred tax liabilities	(21,893)	(77,665)
Net deferred tax assets	$ 1,774
Net deferred tax liabilities		$ (22,310)

Taxes - Schedule of Unrecognize

Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Balance at beginning of year	$ 613	$ 611	$ 1,055
Increases related to tax positions taken in current year			145
Increases related to tax positions taken in prior years		9	8
Reductions related to tax positions taken in prior years		(9)	(95)
Reductions related to settlements with tax authorities			(273)
Reductions related to lapse of statutes of limitations	(99)		(206)
Effects of foreign currency translation	(6)	2	(23)
Balance at end of year	$ 508	$ 613	$ 611

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Profit Sharing Plan
Defined Contribution Plan Disclosure [Line Items]
Employee benefit plans, contribution cost	$ 0	$ 0	$ 179
Executive Profit Sharing Plan
Defined Contribution Plan Disclosure [Line Items]
Employee benefit plans, contribution cost	$ 631	$ 1,005	$ 929
EPSP annualized interest rate, added percentage above prime rate	2%
Maximum | Executive Profit Sharing Plan
Defined Contribution Plan Disclosure [Line Items]
EPSP annualized interest rate cap	15%
Savings Plan
Defined Contribution Plan Disclosure [Line Items]
Employee benefit plans, employer contribution percentage	6%	6%	6%
Employee benefit plans, contribution cost	$ 2,462	$ 3,227	$ 2,564
Savings Plan | Maximum
Defined Contribution Plan Disclosure [Line Items]
Employee benefit plans, employer matching contribution percentage	50%	50%	50%

Cash Flow Information - Schedul

Cash Flow Information - Schedule of Cash Flow, Supplemental Disclosures (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Net cash paid during the year for:
Interest		$ 96,844	$ 91,614	$ 76,216
Income taxes	[1]	11,499	30,908	25,815
Noncash investing and financing activities were as follows:
Fair value of net assets acquired in connection with acquisitions			7,256	240
Capital expenditures and capitalized software included in accounts payable and accrued expenses		$ 75	802	$ 1,466
Common stock issued in connection with acquisition of Sequence			$ 32,943
[1] Fiscal years ended December 28, 2024, December 30, 2023 and December 31, 2022 include tax refunds received of $ 15,421 , $ 7,054 and $ 5,109 , respectively.

Cash Flow Information - Sched_2

Cash Flow Information - Schedule of Cash Flow, Supplemental Disclosures (Parenthetical) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Tax refunds received	$ 15,421	$ 7,054	$ 5,109

Cash Flow Information - Sched_3

Cash Flow Information - Schedule of Cash and Cash Equivalents And Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 28, 2024	Dec. 30, 2023
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 53,024	$ 109,366
Restricted cash included in "Prepaid expenses and other current assets"	3,003
Restricted cash included in "Other noncurrent assets"	493
Total cash and cash equivalents and restricted cash	$ 56,520	$ 109,366

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	Dec. 28, 2024 USD ($)
Commitments and Contingencies [Line Items]
Minimum commitments under non-cancelable purchase obligations	$ 13,726
Minimum commitments under non-cancelable purchase obligations, due in 2025	9,483
Minimum commitments under non-cancelable purchase obligations, due in 2026	1,981
Minimum commitments under non-cancelable purchase obligations, due in 2027	1,696
Minimum commitments under non-cancelable purchase obligations, due in 2028	$ 566

Segment and Geographic Data - A

Segment and Geographic Data - Additional Information (Detail)	12 Months Ended
	Dec. 28, 2024 Segment
Segment Reporting [Abstract]
Number of reportable segments	1
Number of operating segments	1

Segment and Geographic Data - S

Segment and Geographic Data - Sources of Revenue and Other Information by Geographic Area (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, net		$ 785,921	$ 889,551	$ 1,039,835
Long-lived assets	[1]	15,798	19,741
Operating lease assets		42,047	52,272
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, net		541,973	604,441	682,428
Long-lived assets	[1]	15,037	18,171
Operating lease assets		39,939	48,870
Germany
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, net		82,649	97,085	116,452
Long-lived assets	[1]	257	418
Operating lease assets		130	446
Other
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, net		161,299	188,025	$ 240,955
Long-lived assets	[1]	504	1,152
Operating lease assets		$ 1,978	$ 2,956
[1] Amounts include finance lease assets

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	Dec. 28, 2024	Dec. 30, 2023
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt outstanding amount	$ 1,430,643,000	$ 1,426,464,000
Fair value of long-term debt	320,174,000	996,429,000
Fair value assets, transfer between level 1 to level 2	0	0
Fair value liabilities, transfer between level 1 to level 2	0	0
Fair value assets, transfer between level 2 to level 1	0	0
Fair value liabilities, transfer between level 2 to level 1	0	0
Revolving Credit Facility
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value of long-term debt	0	0
Debt outstanding amount	$ 0	$ 0

Fair Value Measurements - Aggre

Fair Value Measurements - Aggregate Fair Value of Derivative Financial Instruments (Detail) - Fair Value, Measurements, Recurring - Interest Rate Swaps $ in Thousands	Dec. 30, 2023 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Interest rate swaps current asset	$ 3,555
Fair Value Measurements Using Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Interest rate swaps current asset	$ 3,555

Derivative Instruments and He_3

Derivative Instruments and Hedging - Additional Information (Detail) - Interest Rate Swaps - USD ($)	Mar. 31, 2021	Apr. 02, 2020	Jun. 07, 2019	Jun. 11, 2018	Dec. 28, 2024	Dec. 30, 2023
Derivative
Cumulative gain for qualifying hedges reported as a component of accumulated other comprehensive loss net of tax					$ 0	$ 2,716,000
Cumulative gain for qualifying hedges reported as a component of accumulated other comprehensive loss before tax						3,474,000
2018 Swap
Derivative
Forward-starting interest rate swap, effective date				Apr. 02, 2020
Forward starting interest rate swap, termination date				Mar. 31, 2024
Derivative interest rate swap percentage				3.1513%
2019 Swap
Derivative
Forward-starting interest rate swap, effective date			Apr. 02, 2020
Forward starting interest rate swap, termination date			Mar. 31, 2024
Derivative interest rate swap percentage			1.9645%
Cash Flow Hedging
Derivative
Notional amount					$ 0	$ 500,000,000
Cash Flow Hedging | 2018 Swap
Derivative
Notional amount	$ 250,000,000	$ 500,000,000		$ 500,000,000
Forward-starting interest rate swap, effective date	Mar. 31, 2021	Apr. 02, 2020
Cash Flow Hedging | 2019 Swap
Derivative
Notional amount			$ 250,000,000

Derivative Instruments and He_4

Derivative Instruments and Hedging - Aggregate Fair Value of Derivative Financial Instruments by Balance Sheet Classification and Location (Detail) $ in Thousands	Dec. 30, 2023 USD ($)
Derivative [Line Items]
Derivative assets	$ 3,555
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Assets
Interest Rate Swaps
Derivative [Line Items]
Derivative assets, current	$ 3,555
Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration]	Prepaid Expense and Other Assets, Current

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Changes in Accumulated Other Comprehensive Loss by Component (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	[1]	Dec. 30, 2023		Dec. 31, 2022
Accumulated Other Comprehensive Income Loss [Line Items]
Other comprehensive income (loss) before reclassifications, net of tax	$ (11,882)		$ 3,908	[2]	$ 10,818	[3]
Amounts reclassified from accumulated other comprehensive loss, net of tax	(2,650)	[4]	(9,738)	[2],[5]	2,316	[3],[6]
Net current period other comprehensive income (loss)	(14,532)		(5,830)	[2]	13,134	[3]
Gain (Loss) on Qualifying Hedges
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	2,716		10,723	[2]	(10,843)	[3]
Other comprehensive income (loss) before reclassifications, net of tax	(66)		1,731	[2]	19,250	[3]
Amounts reclassified from accumulated other comprehensive loss, net of tax	(2,650)	[4]	(9,738)	[2],[5]	2,316	[3],[6]
Net current period other comprehensive income (loss)	(2,716)		(8,007)	[2]	21,566	[3]
Ending balance			2,716	[1]	10,723	[2]
Loss on Foreign Currency Translation
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	(14,016)		(16,193)	[2]	(7,761)	[3]
Other comprehensive income (loss) before reclassifications, net of tax	(11,816)		2,177	[2]	(8,432)	[3]
Net current period other comprehensive income (loss)	(11,816)		2,177	[2]	(8,432)	[3]
Ending balance	(25,832)		(14,016)	[1]	(16,193)	[2]
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	(11,300)		(5,470)	[2]	(18,604)	[3]
Ending balance	$ (25,832)		$ (11,300)	[1]	$ (5,470)	[2]
[1] Amounts in parentheses indicate debits Amounts in parentheses indicate debits Amounts in parentheses indicate debits See separate table below for details about these reclassifications See separate table below for details about these reclassifications See separate table below for details about these reclassifications

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Loss - Reclassifications out of Accumulated Other Comprehensive Loss (Detail) - Interest Rate Contracts - USD ($) $ in Thousands		12 Months Ended
		Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Interest Expense
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Gain (Loss) on Qualifying Hedges	[1]	$ 3,545	$ 12,980	$ (3,090)
Loss Before Income Taxes
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Gain (Loss) on Qualifying Hedges	[1]	3,545	12,980	(3,090)
Provision for (benefit from) income taxes
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Gain (Loss) on Qualifying Hedges	[1]	(895)	(3,242)	774
Net loss
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Gain (Loss) on Qualifying Hedges	[1]	$ 2,650	$ 9,738	$ (2,316)
[1] Amounts in parentheses indicate debits to profit/loss

Related Party - Additional Info

Related Party - Additional Information (Detail) - USD ($)		12 Months Ended
	Oct. 18, 2015	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Initial agreement term	5 years
Services provided by related party		$ 217,825,000	$ 264,950,000	$ 263,840,000
Ms. Winfrey And Her Related Entities | Related Party
Related Party Transaction [Line Items]
Services provided by related party		292,000	574,000	$ 861,000
Accounts payable to related party		$ 13,000	$ 0

Restructuring - Additional Info

Restructuring - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended			24 Months Ended	27 Months Ended	33 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022	Dec. 28, 2024	Dec. 28, 2024	Dec. 28, 2024
2024 Plan
Restructuring Cost And Reserve [Line Items]
Restructuring charges	$ 17,043
2024 Plan | Cumulative Amount Incurred
Restructuring Cost And Reserve [Line Items]
Restructuring charges	17,043
2023 Plan
Restructuring Cost And Reserve [Line Items]
Restructuring charges	$ 5,122	$ 53,743	$ 13,608
2023 Plan | Cumulative Amount Incurred
Restructuring Cost And Reserve [Line Items]
Restructuring charges					$ 72,473
2023 Plan | Other Cash Restructuring Charges | Cumulative Amount Incurred
Restructuring Cost And Reserve [Line Items]
Restructuring charges				$ 2,158
2023 Plan | Non-cash Restructuring Charges | Cumulative Amount Incurred
Restructuring Cost And Reserve [Line Items]
Restructuring charges				6,662
2023 Plan | Real Estate Restructuring | Lease Termination Costs | Cumulative Amount Incurred
Restructuring Cost And Reserve [Line Items]
Restructuring charges				$ 12,789
2023 Plan | Real Estate Restructuring | Employee Termination Benefit Costs | Cumulative Amount Incurred
Restructuring Cost And Reserve [Line Items]
Restructuring charges					9,914
2023 Plan | Organizational Restructuring | Employee Termination Benefit Costs | Cumulative Amount Incurred
Restructuring Cost And Reserve [Line Items]
Restructuring charges					$ 40,950
2022 Plan
Restructuring Cost And Reserve [Line Items]
Restructuring charges			$ 27,181
2022 Plan | Cumulative Amount Incurred
Restructuring Cost And Reserve [Line Items]
Restructuring charges						$ 28,324

Restructuring - Components of R

Restructuring - Components of Restructuring Charges (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
2024 Plan
Restructuring Cost And Reserve [Line Items]
Total restructuring charges	$ 17,043
2024 Plan | Lease Termination Costs
Restructuring Cost And Reserve [Line Items]
Cash restructuring charges	168
2024 Plan | Employee Termination Benefit Costs
Restructuring Cost And Reserve [Line Items]
Cash restructuring charges	15,734
2024 Plan | Other Cash Restructuring Charges
Restructuring Cost And Reserve [Line Items]
Cash restructuring charges	1,141
2023 Plan
Restructuring Cost And Reserve [Line Items]
Cash restructuring charges	5,097	$ 47,106	$ 13,608
Non-cash restructuring charges	25	6,637
Total restructuring charges	5,122	53,743	13,608
2023 Plan | Other Cash Restructuring Charges
Restructuring Cost And Reserve [Line Items]
Cash restructuring charges	581	1,577
2023 Plan | Accelerated Depreciation And Amortization Charges
Restructuring Cost And Reserve [Line Items]
Non-cash restructuring charges		6,831
2023 Plan | Other Non-cash Restructuring Charges
Restructuring Cost And Reserve [Line Items]
Non-cash restructuring charges		(194)
2023 Plan | Real Estate Restructuring | Lease Termination Costs
Restructuring Cost And Reserve [Line Items]
Cash restructuring charges	(135)	12,924
2023 Plan | Real Estate Restructuring | Employee Termination Benefit Costs
Restructuring Cost And Reserve [Line Items]
Cash restructuring charges	2,438	5,678	1,798
2023 Plan | Organizational Restructuring | Employee Termination Benefit Costs
Restructuring Cost And Reserve [Line Items]
Cash restructuring charges	$ 2,213	$ 26,927	11,810
2022 Plan
Restructuring Cost And Reserve [Line Items]
Cash restructuring charges			22,589
Non-cash restructuring charges			4,592
Total restructuring charges			27,181
2022 Plan | Lease Termination Costs
Restructuring Cost And Reserve [Line Items]
Cash restructuring charges			2,424
2022 Plan | Employee Termination Benefit Costs
Restructuring Cost And Reserve [Line Items]
Cash restructuring charges			19,170
2022 Plan | Other Cash Restructuring Charges
Restructuring Cost And Reserve [Line Items]
Cash restructuring charges			995
2022 Plan | Lease Impairments
Restructuring Cost And Reserve [Line Items]
Non-cash restructuring charges			2,680
2022 Plan | Accelerated Depreciation And Amortization Charges
Restructuring Cost And Reserve [Line Items]
Non-cash restructuring charges			1,453
2022 Plan | Other Non-cash Restructuring Charges
Restructuring Cost And Reserve [Line Items]
Non-cash restructuring charges			$ 459

Restructuring - Schedule of Res

Restructuring - Schedule of Restructuring Charges (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
2024 Plan
Restructuring Cost And Reserve [Line Items]
Total restructuring charges	$ 17,043
2024 Plan Cost of Revenues
Restructuring Cost And Reserve [Line Items]
Total restructuring charges	$ 2,497
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of Goods and Services Sold
2024 Plan Selling, General and Administrative Expenses
Restructuring Cost And Reserve [Line Items]
Total restructuring charges	$ 14,546
Restructuring, Name of Segment [Extensible Enumeration]	Selling, General and Administrative Expense
2023 Plan
Restructuring Cost And Reserve [Line Items]
Total restructuring charges	$ 5,122	$ 53,743	$ 13,608
2023 Plan Cost of Revenues
Restructuring Cost And Reserve [Line Items]
Total restructuring charges	$ 2,510	$ 21,116	$ 1,798
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of Goods and Services Sold	Cost of Goods and Services Sold	Cost of Goods and Services Sold
2023 Plan Selling, General and Administrative Expenses
Restructuring Cost And Reserve [Line Items]
Total restructuring charges	$ 2,612	$ 32,627	$ 11,810
Restructuring, Name of Segment [Extensible Enumeration]	Selling, General and Administrative Expense	Selling, General and Administrative Expense	Selling, General and Administrative Expense
2022 Plan
Restructuring Cost And Reserve [Line Items]
Total restructuring charges			$ 27,181
2022 Plan Cost of Revenues
Restructuring Cost And Reserve [Line Items]
Total restructuring charges			$ 6,476
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]			Cost of Goods and Services Sold
2022 Plan Selling, General and Administrative Expenses
Restructuring Cost And Reserve [Line Items]
Total restructuring charges			$ 20,705
Restructuring, Name of Segment [Extensible Enumeration]			Selling, General and Administrative Expense

Restructuring - Schedule of R_2

Restructuring - Schedule of Restructuring-related Liabilities (Detail) - USD ($) $ in Thousands	12 Months Ended			24 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022	Dec. 28, 2024
Employee Termination Benefit Costs
Restructuring Cost and Reserve [Line Items]
Payments	$ (30,716)
2024 Plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	17,043
2024 Plan | Cash Restructuring-Related Liabilities Roll-Forward
Restructuring Cost and Reserve [Line Items]
Restructuring charges	16,829
Payments	(9,731)
Change in estimate	214
Ending Balance	7,312			$ 7,312
2024 Plan | Lease Termination Costs | Cash Restructuring-Related Liabilities Roll-Forward
Restructuring Cost and Reserve [Line Items]
Restructuring charges	168
Ending Balance	168			168
2024 Plan | Employee Termination Benefit Costs | Cash Restructuring-Related Liabilities Roll-Forward
Restructuring Cost and Reserve [Line Items]
Restructuring charges	15,520
Payments	(8,590)
Change in estimate	214
Ending Balance	7,144			7,144
2024 Plan | Other Cash Restructuring Charges | Cash Restructuring-Related Liabilities Roll-Forward
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,141
Payments	(1,141)
2023 Plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	5,122	$ 53,743	$ 13,608
2023 Plan | Cash Restructuring-Related Liabilities Roll-Forward
Restructuring Cost and Reserve [Line Items]
Beginning Balance	26,758	13,608		13,608
Restructuring charges	5,491	47,106
Payments	(22,123)	(33,956)
Change in estimate	(394)
Ending Balance	9,732	26,758	13,608	9,732
2023 Plan | Other Cash Restructuring Charges | Cash Restructuring-Related Liabilities Roll-Forward
Restructuring Cost and Reserve [Line Items]
Beginning Balance	344
Restructuring charges	581	1,577
Payments	(925)	(1,233)
Ending Balance		344
2023 Plan | Real Estate Restructuring | Lease Termination Costs | Cash Restructuring-Related Liabilities Roll-Forward
Restructuring Cost and Reserve [Line Items]
Beginning Balance	156
Restructuring charges		12,924
Payments	(21)	(12,768)
Change in estimate	(135)
Ending Balance		156
2023 Plan | Real Estate Restructuring | Employee Termination Benefit Costs | Cash Restructuring-Related Liabilities Roll-Forward
Restructuring Cost and Reserve [Line Items]
Beginning Balance	2,663	1,798		1,798
Restructuring charges	2,363	5,678
Payments	(1,835)	(4,813)
Change in estimate	75
Ending Balance	3,266	2,663	1,798	3,266
2023 Plan | Organizational Restructuring | Employee Termination Benefit Costs | Cash Restructuring-Related Liabilities Roll-Forward
Restructuring Cost and Reserve [Line Items]
Beginning Balance	23,595	11,810		11,810
Restructuring charges	2,547	26,927
Payments	(19,342)	(15,142)
Change in estimate	(334)
Ending Balance	6,466	23,595	11,810	6,466
2022 Plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges			27,181
2022 Plan | Cash Restructuring-Related Liabilities Roll-Forward
Restructuring Cost and Reserve [Line Items]
Beginning Balance	941	9,803		9,803
Restructuring charges			22,589
Payments	(949)	(9,997)	(12,786)
Change in estimate	8	1,135
Ending Balance		941	9,803
2022 Plan | Lease Termination Costs | Cash Restructuring-Related Liabilities Roll-Forward
Restructuring Cost and Reserve [Line Items]
Beginning Balance		547		547
Restructuring charges			2,424
Payments		(122)	(1,877)
Change in estimate		(425)
Ending Balance			547
2022 Plan | Employee Termination Benefit Costs | Cash Restructuring-Related Liabilities Roll-Forward
Restructuring Cost and Reserve [Line Items]
Beginning Balance	941	8,261		8,261
Restructuring charges			19,170
Payments	(949)	(8,880)	(10,909)
Change in estimate	$ 8	1,560
Ending Balance		941	8,261
2022 Plan | Other Cash Restructuring Charges | Cash Restructuring-Related Liabilities Roll-Forward
Restructuring Cost and Reserve [Line Items]
Beginning Balance		995		$ 995
Restructuring charges			995
Payments		$ (995)
Ending Balance			$ 995

Subsequent Event - Additional I

Subsequent Event - Additional Information (Details) - USD ($) $ in Thousands	Feb. 28, 2025	Feb. 26, 2025	Jan. 31, 2025	Jan. 02, 2025	Dec. 28, 2024	Dec. 30, 2023
Subsequent Event [Line Items]
Loan outstanding amount					$ 1,445,000	$ 1,445,000
Revolving Credit Facility
Subsequent Event [Line Items]
Loan outstanding amount					0
Line of credit facility, issued but undrawn letters of credit					$ 1,159
Subsequent Event | Ms. Tara Comonte | Employment Agreement
Subsequent Event [Line Items]
Cash award payable		$ 4,500
Subsequent Event | Revolving Credit Facility
Subsequent Event [Line Items]
Loan outstanding amount			$ 121,341	$ 50,000
Aggregate principal amount of borrowings	$ 175,000
Line of credit facility, issued but undrawn letters of credit	$ 3,659

Valuation and Qualifying Acco_2

Valuation and Qualifying Accounts and Reserves (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Allowance for credit losses
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period		$ 1,041	$ 976	$ 1,726
Additions charged to Costs and Expenses		17,205	1,306	(460)
Deductions	[1]	(15,080)	(1,241)	(290)
Balance at End of Period		3,166	1,041	976
Inventory and other reserves
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period		8,888	6,468	7,141
Additions charged to Costs and Expenses		72	7,350	6,796
Deductions	[1]	(5,028)	(4,930)	(7,469)
Balance at End of Period		3,932	8,888	6,468
Tax valuation allowance
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period		89,801	35,818	10,083
Additions charged to Costs and Expenses		83,431	53,946	27,871
Additions charged to Other Accounts		6,068	110	(143)
Deductions	[1]	(849)	(73)	(1,993)
Balance at End of Period		$ 178,451	$ 89,801	$ 35,818
[1] Primarily represents the utilization of established reserves, net of recoveries, where applicable.